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Cognitive dysfunction is evident in a wide variety of neurological disorders from
schizophrenia to Alzheimer's disease (AD). Impaired attention has been recorded in
each of these patient groups and has been hypothesised to directly impact on their
general cognitive ability and symptomatology. To date there is a paucity of
treatment options for this impairment. Administration of nicotine, the prototypical
agonist of the nicotinic class of acetylcholine receptors (nAChR), improves attention
and the overall symptomatology of various CNS disorders. Its use as a possible
therapeutic agent is limited by its adverse side-effects profile which includes
addictiveness and nausea. Identification of the receptors/pathways through which
nicotine produces these beneficial effects is a prerequisite to the discovery of more
selective agonists with minimal side-effects. Current interest has focussed on the
homopentameric alpha 7 (a7) receptor (nAChR) due to its proposed role in attention
and memory, and neuroprotection in AD and other neurodegenerative disorders. In
the thesis, the role of the a7 nAChR in modulating nicotine-induced cognitive
improvement has been studied using both pharmacological and genetic means.
Assessment of sustained attention in rodents can be performed using the 5-choice
serial reaction-time (5-CSR) task; analogous to the continuous performance test used
in man. A protocol was established which allowed the demonstration of nicotine-
induced improvements in sustained attention in mice. In this task a7 nAChR
knockout (KO) mice exhibited impaired acquisition and performance, providing
additional evidence that this receptor may be a valid therapeutic target for cognitive
enhancement. In order to investigate the role of nAChR manipulation on working
memory, the odour span task, a test of olfactory working memory capacity, was
established in mice. Nicotine administration did not improve performance of
C57B1/6J mice probably as a consequence of ceiling effects. Transgenic mice over-
expressing human caspase-3 (hc-3) displayed a robust impairment in the task that
was attenuated by nicotine administration. Moreover a7 nAChR KO mice exhibited
impaired acquisition and performance in the task but in a different pattern to that of
the hc-3 mice. This pattern may reflect an impaired ability to attend to the task as
opposed to a working memory deficit. These demonstrations provide further support
for a role of the a7 nAChR in cognition. Tg2576 mice represent the best well
characterised transgenic mouse model of AD, however there remains a dearth of
information on their attentional and olfactory capabilities. The mice exhibited a
deficit in sustained attention as measured by the 5-CSR task as well as an age-related
impairment in the odour span task.
In conclusion the development of the 5-CSR task for mice was used to identify a
nicotine-induced improvement in normal mice and impaired performance in a7 KO
and Tg2576 mice. The establishment of the odour span task in mice allowed the
demonstration of impaired working memory performance in hc-3 mice (attenuated
by nicotine administration), a7 KO mice and Tg2576 mice (age-related). In
summary these data provide some evidence for a role of the a7 nAChR in nicotine-
induced improvement in cognition, and the tasks developed provide new tools for the
assessment of putative cognitive enhancing compounds.
Est. word count = 50,000
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"It's been said that the quest for truth is the noblest occupation of man, but there be
dragons lurking in the dark forests of ignorance"
From 'The Hidden City' by David Eddings
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Chapter 1 General Introduction
Chapter 1
1.1 Frontal Lobe Syndrome
Levin and colleagues (1991) described the history of the frontal lobes, citing Varolio
as the first to discuss the frontal lobes in 1573. By 1807, Chaussier had proposed the
names frontal, temporal and occipital for these three areas (cited in Levin et al.,
1991). The consequences of damage to the frontal lobes were not documented until
the end of the 18th century when several groups detailed the increased awkwardness
and irritability, plus reduced levels of socialisation, attention and intelligence,
following bilateral lesions of the frontal lobes in a variety of species including dogs,
monkeys and humans (Ferrier, 1876, cited in Levin et al., 1991; Welt, 1888, cited in
Niedermeyer, 1998). However, the group of symptoms that subsequently became
known as the frontal lobe syndrome was first described by Harlow (1968), when
describing the effect of an iron bar passing through the frontal lobes of one of his
patients (cited in Andres, 2003).
Welt (1888, cited in Niedermeyer, 1998) identified that it was specific damage to the
orbitofrontal cortex that that resulted in the irritability and personality changes that
partially characterised frontal syndrome. Feuchteanger's (1923, cited in Pantelis and
Brewer, 1995) later demonstrated that lesions to other brain areas led to symptoms
akin to those observed in frontal syndrome patients, making the simplistic view of a
single frontal lobe syndrome untenable. However many researchers still used it as an
umbrella term to categorise a variety of disorders that had similar behavioural
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manifestations and which appeared to relate to levels of frontal lobe damage in the
patients. More recent research supplementing the work detailed by Feuchtwanger
(1923) has led to the term being referred to less often within the literature (Pantelis
and Brewer, 1995).
The term now used to encompass these disorders is 'dysexecutive syndrome'
(Baddeley, 1986; Pantelis and Brewer, 1995; Baddeley and Delia Sala, 1996;
Godefroy, 2003), with executive functions defined as the cognitive processing
involved in planning, initiating and regulating behaviour (Lezak, 1983; cited in
Parkin, 1999). This syndrome covers a broad spectrum of disorders, with
Alzheimer's disease (Sultzer et al., 1995; Chen et al., 1998; Tekin et al., 2001), and
schizophrenia (Franzen et al., 1975; Levin, 1984; Elliot and Sahakian, 1995) at
opposite poles, and includes ADHD (Benson, 1991; Barkley et al., 1992;
Neidermeyer, 1998), autism (Gedye, 1991a; Hill, 2004), Tourette's syndrome
(Gedye, 1991b) and traumatic brain damage patients (Mattson and Levin, 1990). A
decline in frontal lobe function has also been reported in subjects with age-associated
memory impairments (Hanninen, 1997), also known as mild cognitive impairments
(MCI).
1.1.1 Schizophrenia and Dysexecutive syndrome
Kraepelin (1896) first described as dementia praecox the disorder now known as
schizophrenia (cited in Hirsch and Weinberger, 1985). It carries a lifetime risk of
1% (Cannon and Jones, 1996), and has both a genetic and environmental aetiology
2
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(lifetime risk for a dizygotic twin of a schizophrenic is -40%, Klaning, 1999; van Os
and McGuffin, 2003). Diagnosis for schizophrenia is based on a set of characterised
positive and negative symptoms (Andreason, 1997; Pearlson, 2000). In 1996, the
NHS spent a greater proportion ofmoney treating schizophrenic patients (24%) than
it did on any other mental disorders, except the treatment of dementia (26%), which
includes Alzheimer's disease (NHS executive, 1996). In 1992/1993, the NHS spent
£809 million on treating patients with schizophrenia (Patel and Knapp, 1998).
Whilst the behavioural phenotype of schizophrenic patients suggested that they
suffer from dysexecutive syndrome, it was reports by Franzen and colleagues (1975)
of reduced functional activity in their frontal lobes that provided confirmation. This
diagnosis soon achieved general acceptance; with Shallice and colleagues (1991)
even writing that "All schizophrenics have problems with processes tapped by
'frontal' tests". Support came from post-mortem (Shapiro, 1993) and imaging
studies of the frontal lobes (Chua and McKenna, 1995; Hazlett and Buchsbaum,
2001; Weinberger et al., 2001). Hypofrontality was also observed in neuroleptic
naive schizophrenics (Biver et al., 1995; Taylor, 1996; Andreasen et al., 1997), and
those with childhood onset (Jacobsen et al., 1997). The dysexecutive syndrome
classification of schizophrenic patients also stems from neurodevelopmental model
theories (Lillrank et al., 1995; Chambers et al., 1996; Laplante et al., 2004), and
neuropsychological evidence (Shallice et al., 1991). Whilst both Kraepelin (1896)
and Bleuler (1911; cited in Hirsch and Weinberger, 1985) characterised the primary
symptom of schizophrenia to be that of impaired cognition, that viewpoint became
neglected after the development of antipsychotics that treated positive symptoms
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(Harrison, 1999). However there has recently been renewed interest in the cognitive
deficits exhibited by schizophrenic patients.
1.1.2 Alzheimer's Disease and Dysexecutive Syndrome
Alois Alzheimer (1907) first described a patient with the disease that bears his name.
Not only did he note the cognitive symptoms (memory loss and disorientation), but
even then he identified a curious clumping and distortion of the cortical neurofibrils.
Today it is a common form of dementia and although our knowledge of the disease is
now far greater, no truly effective treatment has been developed (Nordberg, 2001).
With an ever increasing elderly population, this problem will inevitably worsen with
time, with 4.5 million sufferers in the U.S.A. in 2000 and with the expectation
numbers rising to 13.2 million by 2050 (Hebert et al., 2003). The percentage of the
population with Alzheimer's disease is approximately 1% of those > 60 years, but
30% of those > 85 years (Yorm, 1991). The huge cost in treating these patients will
progressively increase with the concomitant increase in the elderly population.
Whilst £3,312 million was spent caring for English patients with Alzheimer's disease
in 1998, this figure was expected to rise to £7,920 million by 2031 (Rnapp et al.,
1998). Identifying sufferers remains challenging, with non-invasive tests being only
between 65-90% accurate (Kukull et al., 1990). Once diagnosed, life expectancy of
the patient is estimated to be between 8-10 years (Walsh et al., 1990)
Alzheimer's disease patients exhibit a range of behavioural abnormalities that have
long led researches to suspect that it was also frontally mediated. These include
4
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memory loss, impaired attention, personality changes and agitation. Sultzer and
colleagues (2003), identified hypometabolism in the areas of the frontal lobes in the
brains of Alzheimer's disease patients as measured by positron emission tomography
(PET) scans. These findings were supported by Chen and colleagues (1998), and
Tekin and colleagues (2001) who suggested that the agitation experienced by
Alzheimer's disease patients may actually be a surrogate marker for dysexecutive
syndrome. Pathology in orbitofrontal cortex has been observed in patients with
Alzheimer's disease and, similarly to Welt's observations in 1888, has been linked to
the irritability, agitation and personality changes exhibited by these patients (Chu et




An understanding of the neural mechanisms underlying the cognitive impairments in
schizophrenia and Alzheimer's disease patients may prove to be essential in
developing treatment therapies. Despite both Alzheimer's disease and schizophrenia
falling within the concept of dysexecutive syndrome, the pathologies that underlie
each are quite disparate. Precisely identifying the sequence of pathogenic events
underlying the aetiology of neurological disorders is difficult as once diagnosed, any
developmental sequence is likely to be altered by pharmacotherapy (Selkoe, 2001).
The recent advent of in vivo imaging techniques such as functional Magnetic
Resonance Imaging (fMRI) and PET, has greatly increased our knowledge of the
pathology of these two disorders.
1.2.1 Schizophrenia
As discussed above, schizophrenia was originally thought of as a 'brain disease'
(Kraepelin, 1986). However, trying to identify consistencies in the autopsies of
schizophrenic patients proved difficult with pharmacotherapy confounding disease
pathology (Chakos et al., 1994). With the recent advent of in vivo imaging
techniques, greater consistency has been found, though ideally first-episode non-
medicated patients should be studied where possible (Copolov et al., 2000). There is
now a consensus that patients with schizophrenia have enlarged ventricles (Johnstone
et al., 1976; Spence et al., 1998), with loss of cortical brain tissue (Lawrie and
Abukmeil, 1998) with no correlation between the two (Harrison, 1999).
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Monozygotic twin and familial studies suggest that enlarged ventricle size may be a
marker for a genetic liability to the disorder (Noga et al., 1996; Sharma et al., 1998).
This is supported by the findings that subjects at high risk of developing
schizophrenia also exhibit enlarged ventricles in addition to reduced medial temporal
lobes. These findings therefore support a neurodevelopmental model for the disorder
(Walker, 1994; Bunney et al., 1995; Lawrie et al., 1999). However, whether these
pathologies remain static or progressively worsen is controversial. It is also difficult
to come to any conclusion as after the first episode, medication, age, severity and
symptomatology confounds are present (Vita et al., 1997; Gur et al., 1998).
Reduction in size of the superior temporal gyrus size appears to consistently correlate
with severity of thought disorder and auditory hallucinations (Shenton et al., 1992;
Marsh et al., 1997). The contradictions within the literature on the macroscopic
features of schizophrenic brains viewed ante-or post-mortem, makes a meta-analysis
of the existing data unrealistic (Harrison, 1999; Powers, 1999). Another challenge
when analysing schizophrenic brain pathology is the high proportion of non-specific
focal degenerative abnormalities present in the tissue (Harrison, et al., 1999).
Bogerts (1999) suggested that the limbic dysfunction in schizophrenia patients may
lead to a dissociation between cognitive activities and basic emotional reactions.
Hazlett and Buchsbaum (2001) identified hypofrontality in schizophrenic patients
when compared to controls, when assessed using a simple attention to prepulse task.
Moreover these authors identified that attending to the prepusle in a prepulse
inhibition paradigm (where a non-startling stimulus, the prepulse, reduces the startle
response to the subsequent startle stimulus) lead to an increase in frontal activation in
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controls but not schizophrenics. They suggested that this reflects an impaired
response of the frontal lobes to environmental stimuli.
Copolov and colleagues, (2000) suggest that the diverse neuropathologies observed
for schizophrenic patients may reflect altered structural and functional connectivity
between regions, with particular emphasis being placed on the functional relationship
between the medial temporal lobe and the prefrontal cortex (Heckers et al., 1998).
Aberrant pathology of the medial temporal lobe has been suggested as a link to the
positive symptoms of schizophrenia, suggesting aberrant memory functioning can
cause inappropriate 'memory replays', such that the differences between external
events and perceptual thought cannot be distinguished (Copolov and McKinnon,
1998 in Copolov et al., 2000).
On measuring functional related changes in local cerebral blood flow, Heckers and
colleagues (1998), suggested that reduced hippocampal activation in schizophrenic
patients when compared to controls correlated with poor performance in a memory
task. Nelson and colleagues (1998) performed a meta-analytic study of hippocampal
volume (bilaterally) in schizophrenic patients, and suggested there was a consistent
reduction in size, though they were not specific as to the phase of the illness.
Velakoulis and colleagues (1999) assessed the hippocampal volumes in first episode
patients and observed an even greater reduction, with left hippocampal volume being
smaller than right, though they admit to there being confounding variables. For
example marijuana use was prevalent amongst the patients they assessed and the
main psychoactive component 9-tetrahydrocannabinol has been shown to be
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neurotoxic to hippocampal neurones in low concentrations (Chan et al., 1998;
Velakoulis et al., 1999).
The alterations in neurotransmitter systems that occur in the brains of schizophrenic
patients may provide greater insight and potentially more viable therapeutic targets to
treat the cognitive dysfunction observed in schizophrenia. The dopamine hypothesis
of schizophrenia has been the most prominent hypothesis of schizophrenia in recent
years and suggests that the symptoms of schizophrenia are a result of dopaminergic
hyperactivity of the mesolimbic cortical system (Kapur and Mamo, 2003). This
hypothesis originated from the findings that effective antipsychotics, such as
haloperidol, were dopamine (D2) antagonists. Further evidence arose from the
discovery that psychomimmetic drugs, drugs that produce schizophrenia-like
symptoms such as amphetamine, cocaine or phencyclidine, released dopamine.
However, new studies assessing dopamine neurotransmitter abnormalities in
schizophrenic patients are confounded by antipsychotic treatment. This was
demonstrated when D2 receptor densities were reported to be reduced in the brains of
schizophrenic patients (Zakanis and Hansen, 1998), yet PET studies in drug naive
patients reported no differences to their control subjects (Nordstrom et al., 1995).
Perhaps the most compelling evidence for dopamine dysregulation is the increased
sensitivity of schizophrenic patients to stimulation of dopaminergic neurons
exacerbating the symptoms these patients exhibit (Breier et al., 1997). However,
such drugs also act on the serotonergic system, as do many atypical antipsychotics
(Meltzer, 1989). Serotonergic receptor abnormalities have been identified in the
brains of treatment naive schizophrenic patients suggesting they may be as a result of
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the disease progression (Burnet et al., 1997; Harrison et al., 1999; Roth et al., 2004).
Phencyclidine is principally however, a non-competitive antagonist to the NMDA
subtype of glutamate receptor (Coyle, 1996), suggesting a possible link to the
glutamatergic neurotransmitter system in the symptoms of schizophrenia. This has
been supported with genetic linkage, post-mortem and psychopharmacological
studies (Krystal et al., 2003; Moghaddam, 2003).
However, increasing interest has beer placed on the cholinergic system in
schizophrenia. Similarities between the cognitive deficits observed in schizophrenic
to those in Alzheimer's disease patients (discussed below, section 1.3, pp. 20) have
fuelled such speculation (Friedman, 2004). A correlation between the degree of
cognitive functioning and the cortical levels of choline acetyltransferase activity
(marker for cholinergic innervation) of schizophrenic patients has been observed
(Powchik et al., 1998). Conversely it has been hypothesised that the putative
cognitive-enhancing effects of atypical antipsychotics are linked to their ability to
increase acetylcholine levels in the medial prefrontal cortex (Ichikawa et al., 2002).
Thus, whilst the obvious neuropathology of the cholinergic system observed in
Alzheimer's disease patients is absent in schizophrenic patients (el-Mallakh et al.,
1991), the latter do exhibit several cholinergic neurotransmitter abnormalities.
Acetylcholine predominantly acts via two classes of cholinergic receptors,
muscarinic or nicotinic. Altered expression of muscarinic acetylcholine receptors
(mAChR) have been observed in the brains of schizophrenic patients (Crook et al.,
2000; Dean et al., 2002). Also scopolamine, the non-selective mAChR antagonist,
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impairs cognitive performance of a variety of species including mice (Bontempi et
al., 2003), rats (Stolerman et al., 2000; van Kampen et al., 2004), monkeys (Terry et
al., 1993) and man (Wesnes and Warburton, 1984; Koller et al., 2003). These
impairments are reversible by the administration of nicotinic acetylcholine receptor
(nAChR) agonists (discussed in greater detail below, sections 1.3.6, pp. 26 and 1.3.7,
pp. 28).
Abnormalities in nAChR expression have been identified in the post-mortem brains
of schizophrenic patients. Whilst reduced protein levels ofal nAChR were reported
in the frontal cortex of schizophrenic patients, no differences were observed for the
a4 nAChR (Guan et al., 1999). However reduced expression of a4p2 nAChRs was
noted in the hippocampus, cortex, striatum and thalamus in schizophrenic patients by
Breese and colleagues (2000). The identification of such nAChR specific changes
may assist in identifying therapeutic targets for the disease. Both schizophrenic
patients and their relatives suffer from abnormal sensory gating, suggestive of an
underlying genetic cause (Adler et al., 1992; 1993; see section 1.3.3, pp. 23). Further
investigation has localised this genetic abnormality to chromosome 15, proximal to
the al nAChR locus (Freedman et al., 1997). It has been hypothesised that their
inability to gate sensory information may cause and/or exacerbate many of a
schizophrenic patients symptoms (Venables, 1992), thus treatments targeted at the al
nAChR may prove efficacious at treating these patients. This has been postulated as
a possible reason why such a high percentage of the schizophrenic population (80 -
90 %) smoke compared to the general population (25 - 30%; Dalack et al., 1998;
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Rippoll et al., 2004). This hypothesis is supported by the discovery that nicotine
enhances cognitive performance in these patients (discussed in section 1.3.6, pp. 26).
1.2.2 Alzheimer's Disease
As discussed previously (see section 1.1.2, pp. 4) Alois Alzheimer (1907) first
described several of the neuropatholigical features of the disease that bears his name.
He observed what are now referred to as [i-amyloid (A(3) plaque deposits and
neurofibrillary tangles (NFTs) of abnormally phosphorylated tau protein. Other
hallmark feature have now been recognised and include inflammation and
cholinergic degeneration. The exact cause of the cognitive decline observed in
Alzheimer's disease has been the subject of much debate, being dominated for years
by the 'cholinergic hypothesis'. This hypothesis stemmed from work in a variety of
fields. Drachman and Leavitt (1974) first showed that administration of an
acetylcholine receptor antagonist (scopolamine) impaired cognitive performance in
young humans. This finding was repeated with other acetylcholine receptor
antagonists, including the non-selective nAChR antagonist mecamylamine, with
comparisons made to the pattern of cognitive deficits observed in Alzheimer's
disease patients (Bartus and Johnson, 1976; Smith and Swash, 1978; Newhouse et
al., 1992; 1994). Compounds increasing levels of acetylcholine, such as nAChR
agonists (e.g. nicotine or ABT-418) or anticholinesterase inhibitors (e.g.
physostigmine, tacrine and galantamine), reversed these antagonist induced deficits
in cognition (Drachman, 1977; Potter et al., 1999). Finally several groups
discovered reduced cortical cholinergic activity in the post mortem brains of patients
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with Alzheimer's disease, which correlated with the cognitive decline observed in
these patients, latterly supported by PET scans (Bowen et al., 1976; Davies and
Maloney, 1976; Perry et al., 1978a,b; Davies, 1979; Shinotoh et al., 2000).
It has been advocated that cholinergic cell loss in the basal forebrain with consequent
cholinergic dysfunction in other brain regions, correlates more consistently and
strongly with the cognitive decline of Alzheimer's disease patients than the other two
pathological hallmarks of Alzheimer's disease - (AP) plaques or NFTs (Perry et al.,
1978a; McGeer et al., 1984; Roberson and Harrell, 1997). More specifically,
following post mortems, the loss of nAChR in the cortex of patients with
Alzheimer's disease correlates with the cognitive impairments observed during life
(Perry et al., 1987; Nordberg et al., 1988; 1991; 1997; Marutle et al., 1999; Sihver et
al., 1999; Nordberg, 2001). A reduction in al nAChRs density are also observed in
the brains of traumatic brain injury patients, a known risk factor for Alzheimer's
disease (Verbois et al., 2000). This decrease in a7 nAChRs has also been linked
with the cognitive impairments observed in traumatic brain injury patients, and can
also be ameliorated by chronic nicotine treatment (Verbois et al., 2000; 2003).
Current symptomatic treatments for Alzheimer's include acetylcholinesterase
inhibitors, and to date four have been approved for use in this clinical population.
These are donepezil (E2020, Aricept, Pfizer Inc.), rivastigmine (SDZ ENA 713,
Exelon, Novartis Pharmaceuticals), galantamine (Reminyl, Jansen-Cigal) and tacrine
(9-amino-l,2,3,4-tetrahydroacridine, Cognex, Parke-Davis), although the latter was
rarely used due to its hepatoxic effects in nearly half of those treated (Watkins et al.,
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1994; Kelly, 1999). These inhibitors were developed to counter the reduced
cholinergic activity observed in Alzheimer's disease patients, though it is recognised
that they may work via a variety of additional mechanisms.
One such mechanism is the direct or indirect activation of nAChRs, and this is
proposed to enhance the efficacy of galantamine (Maelicke et al., 2000; Raskind et
al., 2000; Wilcock et al., 2000). The potential benefits of stimulating nAChRs
include modulating several neurotransmitter systems, enhancing neuronal survival
and possibly antagonising the toxicity of A(3 (Wonnacott, 1997; Kaiser et al., 2000;
Allain et al., 2003). Direct activation of the nAChRs via nicotine administration has
been shown to improve cognitive function in Alzheimer's disease patients and
healthy controls even after chronic treatment (Newhouse et al., 1988; Sahakian et al.,
1989; Jones et al., 1992; Levin et al., 1999; White and Levin, 1999; Mumenthaler et
al., 2003; see chapters 1.3.6, pp. 26; 3.3.3, pp. 86; 3.3.4, pp. 88 and 4.3.5, pp. 142).
In fact the direct activation of the nAChRs by nicotine administration has been
shown to be more efficacious at enhancing performance of experienced pilots in a
flight simulator task than donepezil (Mumenthaler et al., 2003).
Another mechanism by which nicotine is potentially therapeutically beneficial in
Alzheimer's disease is because of its reported neuroprotective effect. These
observations were initially based on reports that smokers had a lower risk for
Alzheimer's disease (van Duijn and Hofman, 1991; Brenner et al., 1993).
Subsequent studies have however failed to replicate these findings. Indeed some
show an increased risk of Alzheimer's disease in smokers (Prince et al., 1994; Ott et
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al, 1998; Doll et al., 2000). These contradictory findings could stem from the fact
that tobacco smoking is clearly not equivalent to direct nicotine administration, and
tobacco product ingredients vary from brand to brand (Sabbagh et al., 2002). Whilst
the clinical effects of smoking in human subjects appear inconsistent, there is a
wealth of evidence supporting a neuroprotective action of nicotine in vivo and in
vitro. Nicotine administration has been shown in vitro to inhibit Ap aggregation and
neurotoxicity and protect against NMDA-induced neurotoxicity, (Marin et al., 1994;
Zamani et al., 1997; Kihara et al., 1999). In vivo studies using the Tg2576
transgenic mouse model of Alzheimer's disease (see chapter 5, pp. 156) have
demonstrated both long- (5.5 months) and short-term (10 days) nicotine
administration can significantly reduce the levels ofAp plaque burden in a variety of
brain regions, though most predominantly in the olfactory system (Hsiao et al., 1996;
Norberg et al., 2002; Hellstrom-Lindhal et al., 2004). The mechanism of Ap
induced neurotoxicity and potential cholinergic blockade has yet to be definitively
explained, however the evidence gathered to date has given extra credence to the
amyloid hypothesis, which suggests that Alzheimer's disease progression is a result
of abnormal amyloid precursor protein (APP) processing (Blessed et al., 1968).
Cummings (2004) recently discussed a possible pathway (Fig. 1.1) explaining the
histopathological and clinical observations observed in Alzheimer's disease, and
placed abnormal APP processing as the primary cause of Alzheimer's disease, which
eventually leads to the development of NFTs and neurotransmitter abnormalities
including cholinergic loss (Roberson and Harrell, 1997; Newhouse et al., 2001;
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Fig. 1.1: Putative model of Amyloid cascade (from Cummings, 2004)
Hypothesis of the amyloid cascade charting its progression from the initial
generation of the P-amyloid (AP) peptide via amyloid precursor protein (APP)




APP exists in a variety of isoforms that vary from 651 to 770 amino acids long,
including APP695, APP765 and APP770 (Oltersdorf et al, 1989). Abnormal
processing of these APPs can underlie Ap deposition in the brains of patients with
Alzheimer's disease (Goate et al., 1991; Mullan et al., 1992). The term amyloid
describes a heterogenous class ofprotein aggregates with a P-pleated sheet secondary
structure that confers affinity to the histochemical dye congo red (Gotz et al., 2004).
In normal processing APP is proteolytically cleaved either by a-sectretase or P-
secretase (Fig. 1.1). Cleavage by a-secretase is non-amyloidogenic as it creates a
fragment, a-APP, that is released from the cell surface leaving a C-terminal fragment
of 83 amino acids (C83) still embedded to the membrane which when cleaved by y-
secretase produces the latter two thirds of Ap (designated p3). However, when APP
is cleaved by P-secretase the surface terminal fragment is 99 amino acids long (C99),
which when cleaved by y-secretase, produces Ap. The C99 cleavage site by y-
secretase is critical as it determines the peptide length, producing either AP(mo)
(more common) or APp-42) (less common but the neurotoxic form.
Blessed and colleagues (1968) first proposed what is now referred to as the amyloid
hypothesis when they suggested a correlation (+0.770) between the intensity of Ap
plaque formation and the degree of cognitive decline. Whilst some studies support
these findings, others have found this correlation difficult to reproduce (Dekosky et
al., 1990; 1992; Terry et al., 1991; Samuel et al., 1994b; Cummings et al., 1996).
The presence of diffuse Ap deposits could account for some of the inconsistencies
observed (Hardy and Selkoe, 2002). Whilst it has been suggested that there is a
better correlation between NFTs and cognitive decline, this link is confounded by the
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presence of dementia in some Alzheimer's disease patients without NFTs (Samuel et
al., 1994b). There is increasing consensus in the proposition that the formation of
NFTs in Alzheimer's disease represents a cytological response by neurons to the
accumulation of Ap and associated proteins (Gotz et al., 2001; Hardy and Selkoe,
2002; Oddo et al., 2003; Selkoe et al., 2004; Fig. 1.1).
Evidence supporting the amyloid hypothesis comes from numerous sources. For
example, whenever Ap pathology was identified tau pathology was also detected
whereas the opposite is not true (Arriagada et al., 1992; Delacourte et al., 2002).
Also to date no mutations in the tau gene have been discovered in patients with
Alzheimer's disease, whereas they are present in other patients with other
neurodegenerative disorders such as frontotemporal dementia, in which Ap
deposition does not occur (Spillantini and Goedert 1998; Hutton et al., 1998; Gotz et
al., 2004; Selkoe, 2004). Numerous mutations in genes that contribute to Ap plaque
formation have been identified (see table 1.1).
The first mutation of the APP gene identified was in a British family (Goate et al.,
1991), where a valine was replaced by an isoleucine at codon 717 (V717I; the
'London mutation'). Mutations at codons 670 and 671 were also discovered in two
Swedish families (Mullan et al., 1992), whereby lysine and methionine were
replaced by aspartic acid and leucine (K670D/M671L; 'Swedish mutation' APPswe).
Presenilin 1 and presenilin 2 mutations, linking to chromosomes 14 and 1
respectively, were later discovered and have since been identified in most cases of
familial Alzheimer's disease (Van Broeckhoven et al., 1992; Levy-Lahad et al.,
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1995; Sherrington et al., 1995; Gotz et al., 2004). However, the only definitive risk
factor gene for sporadic Alzheimer's disease identified to date is the apolipoprotein
E4 (ApoE4) gene that promotes A(3 deposition (see review by Rocchi et al., 2003).
Chromosome Gene Defect Phenotype
21 AP precursor
protein mutations




Increased density of AP plaques





Increased production of Ap(i_42)




Increased production of AP(1.42)
+ very early onset
Table 1.1: Genetic Factors Predisposing to Alzheimer's disease: Relationships to the
AB phenotype
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1.3 Cognitive Consequences of the Syndrome
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Some of the most common behavioural consequences of dysexecutive syndrome
include attentional impairments, with increased distractibility, poor memory,
perseveration, and agitation (Levin, 1984; Trimble, 1990; Godefroy et al., 1996;
Baddeley et al., 1997; Adler et al., 1998). Naturally there are also impairments of
executive function. Unlike other cognitive domains such as attention and memory,
there is no intuitive lay concept of executive function. Funahashi, (2001) defined it
as 'a product of the co-ordinated operation of various processes to accomplish a
particular goal in a flexible manner'. Greater importance is being placed on
neuropsychological assessment of clinical patients, where identification of the exact
cognitive impairments may be more relevant in the search for therapeutics (Evans et
al., 1997).
1.3.1 Impairments ofExecutive Function
The Wisconsin Card Sort Task (WCST; Grant and Berg, 1948) is the most widely
used test for executive dysfunction. In this test, subjects are required to sort cards
according to three perceptual dimensions (e.g. shape, colour and number). The cards
change constantly, yet a correct choice is required each time. To do this task the
subject learns to formulate a rule, such as always select the card with the red
colouring. The rule is gauged to have been learned when six consecutively correct
choices are made. The rule can then be altered, for example to select green colouring
only, equating to an intra-dimensional shift as the new rule is within the same
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dimension - colour. Six consecutively correct responses are required once again.
This intra-dimensional shift forces the subject to abandon a learned rule in light of
new evidence. An extra-dimensional shift occurs when a previously irrelevant
dimension (shape) becomes the new sorting rule. It generally takes more attempts to
shift attention to this new dimension, and patients with executive dysfunction take
even longer. This is known as perseverative responding, and is interpreted as an
impaired ability to shift an attentional set (Owen et al., 1993).
Patients with schizophrenia perform poorly in the WCST (reviewed in Wienberger
and Lipska, 1995) as they perseverate and do not readily shift attentional set, even in
comparison to their monozygotic twins (Berman et al., 1992). This has been linked
to hypofrontality of the dorsolateral prefrontal cortex (Weinberger et al., 1986; 1988;
Taylor, 1996; Bunney and Bunney, 2000). However, it has recently been recognised
that impaired performance in the WCST may be confounded by impairments in
attention and working memory, reducing its suitability as a test solely selective for
executive dysfunction (see Reitan and Wolfson, 1994 for a critical review of the
WCST; Demakis, 2003). Similar confounds of attentional and working memory
deficits may also mar the poor WCST performance in Alzheimer's disease patients
(Michon et al., 1994; Paolo et al., 1996).
1.3.2 Attentional Impairment
One of the most consistent cognitive deficits in schizophrenia is attention (Cornblatt
and Kelip, 1994). This attentional impairment has been proposed to underlie the
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positive, negative and other cognitive symptoms of the disorder (Venables, 1992;
Cullum et al., 1993; Cornblatt and Kelip, 1994). Alzheimer's disease patients also
exhibit attentional impairments that are suggested to be a core feature of the disease,
contributing to the reduction in cognitive performance observed in these patients
(Lawrence and Sahakian, 1995; Perry and Hodges, 1999, Rizzo et al., 2000).
Attention can be split into separate yet inter-related subsystems, such as selective
attention (ignoring irrelevant stimuli in the environment in order to attend to the
relevant), divided attention (attending to two sets of stimuli simultaneously) and
sustained attention (maintaining focus on a specific stimulus over a period of time).
Whilst impairments in both selective and divided attention have been noted in
schizophrenic patients (Jacobsen et al., 2004), greater focus has been placed on
sustained attention. One of the most widely used tests of sustained attention is the
Continuous Performance Test (CPT; Rosvold et al., 1956) which requires a subject
to attend to visual stimuli over a sustained period of time, making a specific response
when the target stimuli appear. Though there are many forms of this test, the
performance of schizophrenic patients is consistently low (Katz et al., 1996; Chen et
al., 1998; Cornblatt et al., 1998; Liu et al., 2000; Cornblatt and Malhorta, 2001).
Hazlett and colleagues (2000) used PET to show that whereas normal subjects had
increased cerebral blood flow in the frontal cortex during task performance,
schizophrenics did not. Barch and colleagues (2001) more specifically claimed a
dysfunction in the dorso-lateral prefrontal cortex in medication-free first-episode
patients mediates this impaired attentional functioning.
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Alzheimer's disease patients also exhibit impaired sustained attention (White and
Levin, 1999). Uncertainty still abounds as to whether this impairment occurs prior to
impaired episodic memory (Becker, 1988; Baddeley et al., 1991; Becker et al., 1992)
or whether episodic memory impairments occur first, followed by
attentional/executive, then visuo-spatial and language impairments (Binetti et al.,
1996; Reid et al., 1996; Perry and Hodges, 2000). Though not all components of
attention are affected at the same stages in Alzheimer's disease patients (Perry and
Hodges, 1999), Simone and colleagues (1997) suggest that early attentional deficits
in Alzheimer's disease patients may contribute to the performance reductions in
other cognitive domains such as memory and executive functions. Indeed Lawrence
and Sahakian (1995) suggest it may be a core feature of Alzheimer's disease. These
proposals are supported by the findings that visual sustained attention and processing
speed impairments in patients with mild Alzheimer's disease correlate with specific
cognitive deficits such as memory and decision-making, and with overall cognitive
ability (Rizzo et al., 2000).
1.3.3 Memory Deficits
Schizophrenic patients exhibit a consistent impairment in working memory (Castner
et al., 2004). This is commonly assessed by the digit span task, whereby subjects are
required to remember a list of random numbers and the poor performance of
schizophrenic patients in this task suggests a reduced capacity of their 'online'
memory (Baddeley, 1986; Byrne et al., 1999; Appels et al., 2003). The consistency
of this impairment has recently been confirmed by a meta-analysis by Sitskoorn and
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colleagues (2004). The first memory impairment to manifest in Alzheimer's disease
is episodic memory, particularly the formation of new memory traces. Episodic
memory is the long-term memories of events in your life, and an episodic buffer
(Baddeley, 2000) has recently been incorporated into Baddeley's (1986) seminal
construct ofworking memory. Unfortunately this area of cognition has proven to be
especially difficult to model in rodents, and thus the development of drugs to
alleviate this symptom has been hampered. However shorter-term memory trace
impairments are also apparent in Alzheimer's disease. This has been assessed using
a variety of methods such as the repetition test (Bayles, 2003) and spatial working
memory task (Rahman et al., 1999), the latter being a test based on the radial arm
maze (RAM) test of spatial working memory for animals. Both tasks assess visuo-
spatial working memory span capacity, which is severely reduced in patients with
Alzheimer's disease. Reduced working memory capacity in Alzheimer's disease
patients have also been identified using the digit span task (Jones et al., 1992;
Pasquier et al., 2001).
1.3.4 Impaired Pre-attentional Processing
The sensory gating (pre-attentive) impairments exhibited by schizophrenic patients
have also been well documented (Adler et al., 1982; Freedman et al., 1997; Kumari
et al., 2000; Freedman et al., 2003). It has been suggested that these deficits might
indirectly be the cause of impaired sustained attention (Nieoullon, 2002). Sensory
gating refers to pre-attentive information processing at a subconscious level
(Ellenbroek, 2004). This processing can be assessed in a variety of ways, but two of
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the most widely used is Pre-Pulse Inhibition (PPI), the reducing effect of a weak,
non-startling stimulus on a subsequent startle stimulus (Graham, 1975), and P50
gating, the reducing effect a pre-stimulus has on a subsequent stimulus. The former
is measured by the startle amplitude of the subject, whilst the latter is assessed using
electroencephalograph. Whilst results using the two techniques share similarities,
there are differences that should be taken into consideration (see Ellenbroek, 2004).
However, as no response is required of the subject, confounds that hamper other
neuropsychological tests such as background and education level are absent.
Venables (1992) theorised that this sensory gating impairment in schizophrenic
patients leads to information overload, irrelevant stimuli are not filtered out, and their
symptoms (cognitive and positive) exacerbated. The reproducibility of this
impairment has led it to be a focus of animal models of schizophrenia (Ellenbroek
and Cools 1990; Swerdlow-Geyer, 1998; Sams-Dod, 1999; Geyer et al., 2002).
Uncertainty exists as to whether patients with Alzheimer's disease impaired sensory
gating (Jessen, 2001; Hejl et al., 2004), though this may reflect the stage in the
progression of the disease at which the patients were tested.
1.3.5 Impairments ofOlfactory Functioning
Interestingly olfactory capabilities (acuity, threshold and working memory) are
impaired in patients with Alzheimer's disease and schizophrenia (Kopala et al.,
1993; Wu et al., 1993; Moberg et al., 1997; Larsson et al., 1999; Devanand et al.,
2000; Kohler, 2001). These impairments appear to be related to disease progression,
may be present prior to diagnosis, with no apparent relation to other cognitive
25
Chapter 1
deficits (Moberg et al., 1997; Devanand et al., 2000). As such they have been
proposed as possible early markers for neurological diseases and psychosis (Kwapil
et al., 1996; Martzke et al., 1997). In support of these findings is the observation that
MCI patients also have poor olfactory capabilities (Devanand et al., 2000).
1.3.6 Nicotine therapy
In comparison to the general population, patients with schizophrenia exhibit higher
rates of smoking (Dalack et al., 1998) smoke more heavily (Leonard et al., 2001) and
extract more nicotine from cigarettes (Olincy et al., 1997). This is thought to be a
form of self-medication, whereby indirectly, nicotine ameliorates some of the
cognitive impairments associated with the disease (George et al., 2002), or
antipsychotic medication (Levin et al., 1996). Nicotine-induced cognitive
enhancement has also been observed in patients with Alzheimer's disease (Sahakian
et al., 1989; Jones et al., 1992; White and Levin, 1999) and even in normal control
subjects (Levin et al., 1998; Mumenthaler et al., 2003). The use of smokers si
known to confound the interpretation of studies and therefore not all studies have
identified improved working memory post nicotine administration (Sahakian et al.,
1989; Heishman and Henningfield, 2000; Harris et al., 2004).
It has also been proposed that nicotine-induced improvement in cognitive
performance may only occur in tasks of high attentional demand or in subjects with
impaired performance (Robbins et al., 1988; Warburton and Rusted, 1993;
Warburton and Arnall, 1994; Levin and Simon, 1998; White and Levin, 1999; Harris
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et al., 2004; Newhouse et al., 2004). Therefore the lack of effect of nicotine in some
cognitive tasks could be due to a lack of attentional demand in the task. This was
elegantly demonstrated by Bernard and colleagues (1991) who developed a memory
task with a variable attentive load, and found that nicotine only improved
performance in the task with the high attentional load. The attention-enhancing
efficacy of nicotine was further demonstrated by Mumenthaler and colleagues
(2003). These authors administered nicotine or the acetylcholinesterase inhibitor
donepezil to experienced pilots performing on a flight simulator, a task requiring
continuously high levels of sustained attention, and found that both improved
performance to a similar degree. Of specific therapeutic interest was that this effect
was observed in an acute, single dose of nicotine, whilst donepezil was administered
over a month. Newhouse and colleagues (2004) explained the observed effects of
nicotine in relation to the Yerkes-Dodson principal. That is to say, a person
operating at near-optimal levels in a cognitive task, would exhibit a ceiling effect,
making drug administration ineffective, or deleterious to performance as occurred
consistently in normal healthy volunteers administered nicotine (Heishman and
Heningfield, 2000; Sakurai and Kanazawa, 2002). Conversely, in patient groups
where a cognitive deficit is present and performance sub-optimal, a window for
improvement is present and nicotine administration could normalise their
performance, (Newhouse et al, 1988; White and Levin, 1999; Davranche and
Audifffen, 2002). However, improvements in cognition observed when nicotine is
administered to normal subjects could also be explained in terms of the Yerkes-
Dobson principal. Tasks of extreme difficulty could force sub-optimal performance
in subjects, thus proffering an opportunity for drug-induced improvement.
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Confirmation of this concept is provided when nicotine-induced improvements in
attention were observed in healthy controls performing the CPT (Levin et al., 1998),
and pilots in a flight simulator (Mumenthaler et al., 2003). The side-effects profile
of nicotine is extensive and includes addiction, nausea, cardiovascular stress and
weight loss, the costsof which are deemed to outweigh nicotine's potential benefits
(Waldum et al., 1996; Levin, 2002; White and Levin, 2004; Yildiz, 2004). Therefore
the identification of the receptors/pathways through which nicotine produces its
beneficial cognitive effects is a prerequisite to facilitate the discovery of more
selective ligands with minimal side-effects (Levin, 2002).
1.3.7 Nicotinic Acetylcholine Receptors
Nicotine is the prototypical ligand to the nAChRs. The nAChRs are transmembrane
proteins composed of distinct subunits (Arias et al., 2000). To date twelve genes
have been described that encode neuronal nAChRs subunits (a2-al0, p2-|34),
forming both heteromeric and homomeric ligand gated ion channels. Heteromeric
nAChRs are composed of both a (a2-a6) and p (P2-P4) subunits, whilst homomeric
nAChRs consist of only a (a.7-10) subunits. Every neuronal nAChR subunit has
four transmembrane spanning domains (Fig. 1.2a) with the second (M2)
transmembrane domain hypothesised to line the pore of the nAChR ion channel
(Unwin, 1995, 1998; Arias, 2000; Fig. 1.2b). Several conserved amino acids in the
M2 domain are critical for pore function, and such is the specificity that in humans, a
missense mutation of a conserved serine ring to phenylalinine (S248F), or another
conserved serine to leucine (S252L) in the a4 subunit has been identified in families
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with a form of frontal lobe epilepsy (Steinlein et al., 1995; 1997; Hirose et al., 1999).
The interface between an a subunit and its neighbouring subunit has been identified
as being the agonist-binding domain of the nAChRs (Czajkowski & Karlin, 1995;
Chiara & Cohen, 1997; Arias, 2000; Fig. 1.2c). Specific nAChRs are preferentially
expressed in certain brain regions although the a.7 and a4p2 nAChRs are highly
expressed in the hippocampus, providing a hypothetical link to learning and memory
(Levin, 2002). These receptors can modulate a variety of neurotransmitter systems
in the brain by both pre-and post-synaptic mechanisms (Bednar et al., 1998; Levin
and Simon, 1998; Keiser et al., 2000).
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Fig. 1.2: Schematic representation of the nAChR.
Each nAChR consists of four transmembrane spanning domains (a). The M2 domain
has been hypothesised to line the pore of the nAChR ion channel, with mutations in
this domain capable of altering pore function. Finally the interface between an a





























































































































































Table 1.2: Summary of tasks discussed within this thesis.
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Focus shall be placed on assessing attention, not only as deficits in attention are
purported to being central to the cognitive deficits suffered by schizophrenic and
Alzheimer's disease patients, but also due to the central role of attention in animal
learning theories. Mackintosh (1975a) suggested that animals attend to stimuli in
their environment that are more salient or provide greater validity for predicting an
event, and that the saliency of some stimuli is innate. This theory therefore allows
for selective association, whereby some stimulus/event associations are more readily
learned than others. This is observed in Garcia and Koelling's (1966) classic
experiment showing that rats associate a novel flavour cue with subsequent illness
far more readily than an auditory or visual cue, whilst the opposite is true if the
aversive event is an electric shock. This also offers an explanation as to why
learning is faster when mice are required to dig to retrieve a food reward (the odour
span task, see section 1.4.3, pp. 37), than when they are required to nose poke into a
brightly lit hole for a reward that is presented in a separate area (5-choice serial
reaction-time task, see section 1.4.1, pp. 34). Mackintosh (1975b) also claimed that
more salient/valid stimuli in the environment will have greater associative strength
(strength by which a stimulus is associated with an event) than other stimuli within
that environment, and that when this is reinforced, its associative strength increases
with a concomitant decrease in the associative strengths of other environmental
stimuli, a phenomenon he termed as the inverse hypothesis. However, whilst the
associative strengths of a stimuli may be great (e.g. 80% of attentional resources),
attention is also given to other stimuli in the environment. The ability of rats to shift
their attentional set from one dimension to another (Birrell and Brown, 2000)
provides support for this theory (see section 1.4.2, pp. 36).
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The theory of Pearce and Hall (1980) also places attention as core to their animal
learning theory. However, whilst Mackintosh (1975a) proposed that greater attention
would be given to stimuli that predict an event, Pearce and Hall (1980), claim the
opposite. They suggested that the more predictable a stimulus is to an event, the
more it will be processed automatically and thus less attention is paid to it. Only
surprising stimuli or unexpected events will receive attention as they are yet to be
learned about. Whilst this theory receives some experimental support (Hall and
Pearce, 1982), it also has its shortcomings. For example, this theory cannot explain
learned irrelevance, whereby the pairing of a particular stimulus to an event takes
longer if said stimulus was previously randomly paired with said event (thus did not
reliably predict that event), than if the stimuli and event were novel.
1.4.1 Sustained Attention
The 5-choice serial reaction-time (5-CSR) task is a very good example of an animal
task with a high degree of face validity. The 5-CSR task is a rodent test of sustained
attention, originally developed by Carli and colleagues over twenty years ago in
1983. The 5-CSR task was based on Leonard's 5 choice test of serial reaction,
devised to assess the attentional performance of enlisted men (cited in Wilkinson,
1963), and has latterly became accepted as being analogous to the CPT (Jones and
Higgins, 1995). Though it was primarily designed to assess sustained attention, it




The 5-CSR task is the most widely used test of attention in rodents, and though a
variety of protocols and apparatus have been utilised (Muir et al., 1996; Humby et
al., 1999; Grottick and Higgins, 2000; Hahn and Stolerman, 2000; Marston et al.,
2001) the task largely remains unchanged (Carli et al, 1983). The rodent is placed in
an operant box with 9 apertures located at the rear of the box, with 4 occluded by
metal caps (see Fig. 2.1, pp. 54). A magazine for trial initiation and reward delivery
is located at the front of the box, with trials initiated by a nose-poke in the magazine,
after which a predetermined delay begins (inter-trial interval; ITI). At the end of
each ITI one of the 5 apertures at the rear of the box is illuminated for a brief time,
and within that time the rodent must nose poke into that aperture to gain a reward.
Thus during the ITI the rodent must vigilantly attend to the apertures (array) at the
rear of the box, and divide its attention between the 5 apertures. This behaviour must
be maintained for a predetermined number of trials (100-120), or session length (25-
30 min). See chapter 2.2 (pp. 52) for a more detailed description of the task and the
modifications available. Although the design is simple, training rodents to perform
the task is time-consuming and labour intensive, taking 3-4 months, and producing
approximately 5000 bits of data per animal for acquisition alone. However, the high
degree of face validity between this task and the CPT makes it an invaluable test of
attention in rodents.
In fact the predictive validity between the 5-CSR task and the CPT has recently been
reinforced. As described previously nicotine improves sustained attention in man,
including schizophrenic and Alzheimer's disease patients (Levin et al 1998; White
and Levin, 1999; Yong et al., 2002; Mumenthaler et al., 2003, see chapter 1.3.6, pp.
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26). More recently nicotine has been shown to improve rat performance of the 5-
CSR task (Grottick and Higgins, 2000, Hahn and Stolerman, 2002; Grottick et al.,
2003), following considerable effort invested in attempts to consistently produce this
effect (Mirza and Stolerman, 1998; Blondel et al., 1999; Grottick and Higgins, 2000;
Stolerman et al., 2000; Mirza and Bright, 2001; Hahn et al., 2002; Terry et al., 2002;
Grottick et al., 2003; Hahn et al., 2003a,b).
1.4.2 Executive Function
Birrell and Brown (2000) recently described a rodent analogue to the WCST, which
they named the attention set-shifting task. In this test, instead of using colours and
shapes to assess attentional set-shifting, the authors utilised different odours and
digging mediums. This is appropriate as rodents exhibit preferential attendance to
olfactory as opposed to visual cues (Jennings and Keefer, 1969). Hence an intra-
dimensional shift in this task is represented by shifting the rule for a correct response
to a different stimulus within the same dimension (e.g. for odour, shifting from
parsley to sage). An extra-dimensional shift represented shifting the rule from one
dimension to the other (e.g. from odour to digging medium). As with the WCST, 6
consecutively correct responses are required prior to 'shifting' the rule.
With this task Birrell and Brown (2000) showed that although the rodent medial
prefrontal cortex is not anatomically analogous to the primate (including man)
dorsolateral prefrontal cortex, it does appear functionally homologous. Evidence in
support of this notion already existed with impaired performance ofmedial prefrontal
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cortex lesioned rats in the 5-CSR task in response to altering the task protocol (Muir
et al., 1996; Granon et al., 1998). This attention set-shifting task has recently been
adapted for use in mice (Colacicco et al., 2002), and so provides a valuable tool for
modelling executive functioning in transgenic animals. More recently, rats
administered chronic phencyclidine, an animal model of schizophrenia (Cochran et
al., 2003), exhibited impaired performance in attention set-shifting task akin to that
observed in schizophrenic patients (Reid et al., 2004).
Thus the high degree of face (using intra- and extra-dimensional shifts) and
predictive (lesions and animal models producing similar results to those observed in
humans) validity between the attentional set-shifting task and the WCST gives
credence to its continued use in modelling executive functioning in animals.
However, this is a novel task and requires further validation. Moreover, the lack of
studies examining the effects of nicotine in schizophrenic or Alzheimer's disease
patients using the WCST, and the confounds of the WCST discussed above (see
section 1.3.1, pp. 20), may limit the use of this task to identify cognitive enhancing
compounds.
1.4.3 Sensory Gating
Schizophrenic, and more recently Alzheimer's disease patients, exhibit impairments
in pre-pulse inhibition (PPI) and P50 suppression of the event related potential (ERP;
Adler et al., 1982; Freedman et al., 1987; Kumari et al., 2000; lessen, 2001), two
measures of sensory gating (pre-attentional processing; Braff and Light, 2004).
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These two tasks have been modelled in animals, with PPI being a direct comparison,
whilst the P50 suppression of ERP has been modelled using the P20-N40
hippocampal waveform in mice (Stevens et al., 1996; Simosky et al., 2001; Simosky
et al., 2003). PPI is measured by the ability of a subject (man or rodent) to inhibit
their startle response to an auditory (or tactile - puff of air) stimulus when it is
preceded by a similar but sub-startle threshold stimulus. The P50 suppression of the
ERP test is conducted in a similar fashion, with a startle and pre-startle stimuli.
However, its effects are measured directly as hippocampal waveforms of electric
current.
The greater inhibition of startle response of schizophrenic patients in these tasks
following nicotinic administration (Adler et al., 1992) has also been modelled in rats
(Acri et al., 1994; Suemaru et al., 2004) and mice (Semenova et al., 2003). In fact
work conducted on the P20-N40 waveform in different lab mouse strains found a
positive correlation between impaired sensory gating performance and reduced levels
of the a7 nAChR in the hippocampus (Stevens et al., 1996). The following year the
sensory gating impairment observed in schizophrenics was linked to SNIp or
mutation in chromosome 15, proximal to the a7 locus (Freedman et al., 1997), with
P50 suppression being regulated by neural circuitry with a prominent role for
hippocampal circuitry (Waldo et al., 1994). Using the P20-N40 waverform and PPI
tasks to model attentional processing in rodents has various benefits, the main being
the high throughput that can be achieved when compared with the 5-CSR task, as no
training is required. Both acoustic and tactile startle stimuli can be employed to for
reliability. However, these tests do not involve conscious attentional processing,
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therefore do not reflect the 'real world' attentional problems schizophrenic patients
face. In fact PPI and P50 suppression can be altered by the level of effortful
attention placed on detecting the startle stimulus (Heekeren et al., 2004). Also, the
incidental nature of performance in these tasks is reflected in the involvement of the
hippocampus in mediating the response (Stevens et al., 1996; Freedman et al., 1997;
Le Pen, et al., 2003), whilst hippocampal ablation has no effect on the attentional
performance of rats in the 5-CSR task (Kirkby and Higgins, 1998). The high
throughput availability in the task still makes it a valuable tool for the
psychopharmacologist, using it as a possible screen for attentional enhancing agents
prior to testing them on the more laborious 5-CSR task.
1.4.4 Working Memory
1.4.4.1 Morris Water Maze
One of the most commonly used tool in behavioural neuroscience is the Morris
Water Maze (MWM), which is in part due to its simple and elegant design. The
MWM was first developed by Morris and colleagues (1981) to assess spatial learning
and memory in rats, and involved placing the test animals in a pool of opaque water,
in which traditionally they used spatial cues to locate a platform situated just under
the water's surface (Fig. 1.3a). Their ability to learn the location of the platform was
originally measured by their escape latency (length of time they took to reach the
platform). Whilst many researchers still report this measure alone, increasingly more
complex measures have been incorporated. Temporal working memory can also be
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assessed by retesting the animal after a delay period. However, researchers are
becoming increasingly aware of the influence of apparatus, training procedure,
species, strain, gender and even bodyweight, on performance of the animals tested
(D'Hooge and Deyn, 2001). Whilst both rats and mice have been tested using this
apparatus, many innate differences exist between these two species affect
performance. For example, floating and thigmotaxis (tendency to swim close to the
pool wall) is more common in mice. Hence the recommendation that path length
taken by the animal to reach the platform is the most appropriate measure of the task,
as opposed to reporting escape latencies alone (Lindner, 1997). Lipp and Wolfer
(1998) found that spatial working memory of C57B1/6 to be comparable to that of
Long-Evans hooded rats when assessed on a dry-land task, but was worse when























Fig. 1.3: Schematics of the various tasks discussed.
The Morris Water Maze apparatus (a) is a circular pool filled with opaque water, plus
an escape platform located just under the water's surface in a predetermined position.
The top panel gives an example of the path length taken to reach the platform on the
first day of acquisition, with performance greatly improved after several sessions of
training (bottom panel). The Delayed Non-Match To Place apparatus (b) is a two-
lever operant box. Within each trial, the rodent will progress through the sequence
shown, depressing the extended lever (left) in the sample phase, nose-poking in the
magazine continuously during the choice phase, and being required to depress the
opposite lever (right) in the choice phase. The T-maze (c) requires the rodent to
leave the start arm and turn left or right. The rodent is then returned (or returns on
own accord in continuous format) to start arm, and then must enter the alternate arm,
either spontaneously or reinforced. Each new trial requires alternation to the
opposite arm previously visited. The Radial Arm Maze apparatus (d) has 8 arms
(though 16 is possible) and the rodent begins the task in the hub. Each arm is baited,
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and the rodent visits each arm to retrieve the reward. Performance is measured on
the number of arms entered prior to re-entry.
Even the temperature of the water has been shown to differentially affect
performance (Seldon et al., 1990). One of the major disadvantages of the task is that
it requires the animal to escape from an aversive environment that is apparently
devoid of escape routes (Block, 1999), therefore causing considerable stress in the
test animal. Thus animals with greater anxiogenic reactivity perform worse in the
task (Holscher, 1999). In fact anxiolytic drugs treatment alters the response of the
animal being tested, as do other drug and lesions, by altering their search strategy
(see Hodges, 1996 for a review). This may complicate the interpretation of results
obtained during drug treatment by altering anxiety levels as opposed to spatial
working memory. The innate behaviour of the test animals could also confound
performance, even within a species. Galea and colleagues (1994) found that the
performance of deer mice from an island population was significantly better than
those from a mainland population.
Despite reports of the task being solved utilising spatial cues, rats may also use non-
spatial cues, such as odour-trails, which can also confound the interpretation of the
results (Lindner et al., 1997). However, the MWM still remains a popular tool for
assessing genetically modified mice and drug administration. The behavioural
assessment of some of the first transgenic models of Alzheimer's disease was
assessed in the MWM (Hsiao et al., 1996; Chen et al., 2000). It is quick to establish,
easy to use, and does not require food deprivation, thus the MWM remains a popular
and well characterised test of learning and memory in rodents.
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1.4.4.2 Delayed Non-Match to Place
Another task capable of assessing temporal working memory is the delayed non-
match/match to position (DNMTP/DMTP) task. This has traditionally been assessed
in a two-lever operant conditioning box (Fig. 1,3b), and is predominantly performed
by rats (Dunnett, 1985; Dunnett and Martel, 1990; Chudasama and Muir, 1997;
Marston et ai, 1999), although other species have been tested including pigeons and
monkeys (Kelly and Soetch, 2000; Sawaguchi and Yamane, 1999; Terry et al.,
2002). During the task, one lever is presented and remains extended until it is
depressed by the animal (sample phase). A randomly selected delay period then
ensues (traditionally between 0 and 30 s), after which the animal is required to nose-
poke into the lit magazine. Thus, the animal is required to repeatedly nose-poke in
the magazine until the magazine light is extinguished. After the light is extinguished,
both levers are extended (choice phase) and the animal is required to depress the
opposite (DNMTP), or matching (DMTP) lever from that extended during the
sample phase. If completed correctly the animal receives a reward and the second
trial begins. The high number of trials (commonly 100) and the fact that a computer
controls the apparatus are two of the main perceived advantages of this task.
Unfortunately rats have been known to use positioning strategies to complete the
task. While the animal nose-pokes in the magazine, they angle their bodies to face
the goal lever. Training mice to complete this task has also proven to be notoriously
difficult (Dr. C Spratt, personal communication), and is reflected in a paucity of




However, the main confound of this task in terms of identifying a therapeutic agent is
the high level of pro-active interference (PI) in the task (Dunnett and Martel; 1990;
Levin and Simon, 1998). PI is a phenomenon whereby previously learned
information interferes with the learning and/or memory of recently presented
material (Melton, 1963). Any compounds that strengthen memory traces will
therefore make the previously learned information harder to forget, further increasing
the proactive interference inherent in the task. Dunnett and Martel (1990) elegantly
demonstrated the existence of this interference in the DNMTP and the resulting
effects of nicotine. Thus performance of a given trial in the task was significantly
worse if the correct response of the previous trial was in the opposite lever and hence
nicotine was found to significantly impair DNMTP task performance (Dunnet and
Martel, 1990). Though the PI effects can be limited by increasing the time between
trials in the task to 15-30 s, the confound remains when assessing pharmacological
manipulations.
1.4.4.3 T-maze
T-maze alternation is another such task that assesses the temporal capacity of spatial
working memory. The apparatus of this task is in the shape of a T, with a start arm
leading to a junction where a turn into the left or right arm can be made (Fig. 1.3c).
During performance of the task, the animal is required to traverse along the start arm,
and then turn in to one arm to receive a reward. It is then placed back in the start arm
and a second trial begins. This time the animal must choose the opposite arm from
its previous entry in order to gain a reward. Therefore to complete the task
successfully the animal must remember which arm it had previously entered in order
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to alternate and enter the opposite arm. Performance of rodents is excellent (>90%
accuracy) when there is no delay between trials (inter-trial interval; ITI), and is only
impaired when ITIs are inserted (performance drops to -80% at a 40 s delay; Levin
et al., 1997). The apparatus can also be used to assess spontaneous alternation (see
chapter 2.4, pp. 67), whereby no rewards are proffered and the innate, exploratory
behaviour of the animal is assessed (Gerlai, 2001). Although Gerlai, (1998) suggests
it is a measure of spatial working memory, this is just one facet that contributes
towards performance in this task, and recently this task has been labelled as a test of
exploratory behaviour (Lalonde et al., 2002). Animal should naturally alternate
when exploring an environment. If it no longer alternated after treatment, or did so
at chance level, this could be due to varying levels of anxiety, age, altered
exploratory behaviour, motoric impediments, or perseverative behaviour. Hence the
reinforced T-maze task is more widely used. However, as in the DNMTP, nicotine
actually impairs rat performance in this task (Levin et al., 1997), whilst
mecamylamine, a nAChR antagonist, improves performance (Moran, 1993; Levin et
al., 1997), likely to be due to the levels ofPI inherent in this task (Levin and Simon,
1998).
1.4.4.4 Radial Arm Maze
The radial arm maze (RAM) is one of the oldest tests of spatial working memory in
rodents (Olton and Samuelson, 1976). The RAM has been used to assess spatial
working memory in a variety of species including rats (Levin et al., 1996; Bettany
and Levin, 2001, Rezvani and Levin, 2002; Levin et al., 2003), mice (Pick and
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Yanai, 1983; Jaffard et al., 1989), rabbits and avians (Lipp et al., 2001) and even
man (Aadland et al., 1985). This task traditionally uses an octagonal central
chamber with eight attached arms (Fig. 1.3d). Each arm can be baited, and the
animal is required to enter each arm and retrieve the reward therein. Thus to
complete the task the animal must not re-enter a previously visited arm, adopting a
win-shift foraging strategy. The spatial working memory of the animal is measured
by the number of baited arms entered prior to re-entering a previously visited arm,
thus the maximum number obtainable is 8. Unfortunately this low number limits its
power to recognise group differences in basic spatial working memory (Lipp et al.,
2001), although 16 arm mazes have been developed in an attempt to overcome this
difficulty (Levin et al., 1997). Also, by never baiting certain arms during task
acquisition, spatial reference memory can also be assessed. Individual search
strategies are evident in the performance of this task, with the animal visiting the
opposite arm after it re-enters the hub, or the adjacent arm, especially when the
animal is hungrier (Hodges, 1996).
This task differs from both the MWM and DNMTP for although spatial working
memory is measured, the RAM assesses spatial working memory span capacity (i.e.
the number of items that can be held on-line in working memory) as opposed to its
temporal capacity (i.e. the length of time one item can be remembered for). As the
rodent is supposed to enter each arm only once, the task is not subject to the levels of
PI inherent in the T-maze and the DNMTP, therefore any drug treatment effects are
likely to reflect levels of spatial memory. Nicotine, at similar doses that caused
deleterious effects on performance in the DNMTP task (Dunnett and Martel, 1990)
46
Chapter 1
and the T-maze (Levin et al, 1996), improves spatial working memory capacity in
rats performing the radial arm maze (RAM), an affect antagonised by co¬
administration of mecamylamine, a non-competitive nicotinic antagonist (Levin et
al., 1996; Bettany and Levin, 2001). In interpreting RAM data, caution has to be
exercised to ensure that the drug does not alter the appetitive state or perception of
reward for the animal (Hodges, 1996), though obviously this holds true for any
appetitively motivated task. Performance in the RAM is consistent and reliable to
such an extent that a human version of the RAM has since been added to the
Cambridge Neuropsychological Test Automated Battery (CANTAB; Fray et al.,
1996), thus increasing the model's face validity.
1.4.4.5 Odour Span Task
Whilst the RAM assesses visuo-spatial working memory span capacity, another task
has recently been developed to assess non-spatial olfactory working memory span
capacity. The odour span task (OST) originally developed for rats (Dudchenko et
al., 2000) has recently been developed for use in mice (see chapter 4, pp. 118 and 5,
pp. 156). In the OST (described in greater detail below, chapter 2.3, pp. 60) the
rodent is placed on a table and presented with a bowl filled with a scented digging
medium (sand/woodchip - rats/mice), in which a reward is buried. The animal must
dig to retrieve the reward, following consumption, the animal is removed from the
table, and a second bowl, filled with a digging medium and a different scent, is
placed on the table. The novel scented bowl is the only one that is baited with a
reward. The location of the old and novel odours on the table is randomly selected.
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The animal must only dig in the bowl containing the novel odour, thus retrieving the
reward and continuing in the task. A third novel scented (baited) bowl is placed on
the table in a random location whilst bowls one and two (no longer baited) are moved
to a new location. Again the animal must dig only in the novel scented bowl to gain
the reward and continue. The task traditionally continues until 12 differently scented
have been presented, though 24 and 22 bowls have been presented to rats and mice
respectively in probe trials (Dudchenko et al., 2000; see chapters 4.3.1, pp. 125, and
5.3.3 - 5.3.5, pp. 184 - 190). Thus to gain the highest score possible, the animal
must only ever dig in the novel scented bowl, remembering the previously scented
odours so as to avoid them.
To ensure the animal does not use any other strategies such as scent marking the
previously presented bowls, or by smelling the bait through the digging medium,
probe trials and counter-measures have been used in rats and mice to ensure neither
strategy is employed. Task performance in rats was found not to rely on the
hippocampus (Dudchenko et al., 2000), whereas a recent version created for humans
found poor performance in hippocampally lesioned patients (Levy et al., 2003). This
may however reflect the extent of damage in the human patients, or the strategy used
by humans may have been different to that used by rats. Humans reported
remembering the names of the presented odours, and whilst the strategy used by rats
is unknown, they may simply remember the odour.
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There is a paucity of tasks that assess the olfactory capabilities in mice, despite the
plethora of evidence of olfactory impairments in patients with Alzheimer's disease
(Larssen et al., 1999; Devanand et al., 2000) and schizophrenia (Kopala et al., 1992;
Wu et al., 1993; Moberg et al., 1997; Kohler, 2001). This is also despite the
observation that these impairments may be an early marker for neurological diseases
and psychosis (Kwapil et al., 1996; Martzke et al., 1997; Devanand et al., 2000).
Therefore the development of this task for use in mice allows greater phenotypic
characterisation of transgenic animal models of CNS disorders. Transgenic mice
may also be used in this task to aid in the identification of the neuro-circuitry
responsible for olfactory impairments. That the entorhinal (olfactory) cortex
connects via a segment of the thalamic mediodorsal nucleus to the orbitofrontal
cortex (Powell, et al., 1965), an area altered in schizophrenic and Alzheimer's
disease patients (Chu et al., 1997), supports the need to identify the possibly
common neural substrate mediating these olfactory deficits (Moberg et al., 1997).
As discussed earlier (section 1.2.2, pp. 12) pathophysiological hallmarks of
Alzheimer's disease are known to deposit in the entorhinal cortex early in disease
progression (Braak and Braak, 1995). This effect is also observed in a transgenic
mouse model of the disease over-expressing the amyloidogenic Swedish mutation of
human APP695 (Mullan et al., 1992; Hsiao et al., 1996; Nordberg et al., 2002). As
the odours presented to the mice are not repeated within a session, PI cannot
confound the results of drug administration as it does in the T-maze alternation and




1.5 Aims of the Thesis
As discussed above, patients with dysexecutive syndrome, including schizophrenic
and Alzheimer's disease patients, exhibit a variety of cognitive deficits. Nicotine has
proven effective in enhancing cognition in these patients and in 'normal' subjects.
However due to its adverse side-effects profile, its use as a therapeutic target is
severely limited. Thus identification of the receptor(s) that mediate this
improvement may facilitate the production of similar cognitive enhancing
compounds with fewer side-effects.
Attempts to identify the receptor(s) responsible have been made, predominantly
using rats in the tasks described above. As yet mice have received limited use,
despite the opportunity to combine both pharmacological and genetic techniques. To
this end I wanted to model nicotine-induced improvement in cognition in mice. I
also wanted to investigate a possible role of the a7 nAChR in this improvement using
a7 nAChR transgenic mice.
As the predominant effect of nicotine appears to be in sustained attention, focus was
placed on modelling this using the mouse 5-CSR task. The odour span task was also
established in mice in order to investigate nicotine's effects on working memory.
Finally, the suitability of the Tg2576 mice as a mouse model of Alzheimer's disease
was also investigated.
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Chapter 2
2.1 Animal Maintenance
All animals were group housed (where possible) in a temperature controlled room
(22 ± 2 °C), with a 12 h light/dark cycle (lights on at 07:30 h) and were tested during
the light phase of the cycle. Mice were maintained at 85% of their free-feeding
weight and were permitted free access to water during training and testing. The
animals were given ad libitum access to food approximately every 5 weeks in order
to re-establish a free-feeding weight. Studies were performed under license by U.K.
authorities (Scientific Animal Procedures Act 1986), approved by the Home Office
and reviewed by the University of Edinburgh Ethics committee.
2.2 5-Choice Serial Reaction-time (5-CSR) task
Chapter 2
The 5-CSR task training protocol for rats was first described in the literature by Carli
and colleagues (1983). Several groups now train rodents in the 5-CSR, and therefore
a variety of protocols are currently employed (Grottick and Higgins, 2000; Hahn and
Stolerman, 2002). The standard protocol used in this thesis and how it differs from
the original (Carli et al., 1983) is detailed below. The schematic of the nine-hole
operant chamber (25 x 25 x 25 cm, Cambridge Cognition, Cambridge, U.K.) utilised
remains the same (Fig. 2.1), with one mechanical difference employed (note no
reduction in box size was incorporated unlike that described by ITumby et al., 1999).
Carli and colleagues (1983) utilised a hinged panel to block the magazine entrance,
where pushing the panel activated a switch, alerting the computer to the rodent's
entry into the magazine. We removed this panel and magazine entry was assessed
using an infra-red beam. The mice therefore had no physical barriers to surmount to
initiate a trial or retrieve their positive reinforcement as such barriers often cause
difficulties in training mice (Drs. C Spratt and L Reid, personal communication).
Positive (liquid) reinforcement (20 /xl of strawberry milkshake; Yazoo®; U.K.) was
delivered by a peristaltic pump to a spigot inside the magazine at the chamber front,
opposite to the 9-hole array. The house light was set into the roof of the operant
chamber, which was housed within a sound-attenuating box, containing a fan that
provided ventilation and a constant low background noise. An infra-red camera was
installed within each box allowing performance to be monitored. Each operant
chamber was interfaced to an Acorn computer (RISC OS). The software required
was programmed in house using the Arachnid extension to BBC Basic (Paul Fray
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Ltd, Cambridge, U.K.). Several modifications were made to the protocols employed.
Carli and colleagues (1983) utilised solid food reinforcers whereas we employed
liquid, allowing the mice to consume the reward in less time. Whilst the original
protocol had the house light constantly on and extinguished only when an error was
made (time out, TO), in our protocol the house light remained off during a session,
and errors were punished with 4 s of house light illumination. The final task length
employed in this thesis was 25 min, or 120 trials, whichever was completed first
(except where noted), in comparison to 30 min and 100 trials in the original paper.
This was to increase the number of responses obtained in one session and because it
was observed that mice readily completed 120 trials in less then 25 min. The inter-
trial interval (ITI) employed in the original protocol was initially 2 s with a 2 s TO,
followed by a 5 s ITI and TO. We employed a 2 s ITI with a 4 s time out (TO) phase





Figure 2.1 Schematic of the '9-hole box' apparatus used in the 5-CSR task
At the rear of the box there are a series of 9 holes, in each of which there is a cue
light with the entrance monitored by a vertical infra-red beam. The entrance to every
hole can be blocked, however traditionally four are blocked, thus creating the choice
of five holes. Any four holes can be blocked with two possibilities shown above.
The four holes on the outside can be blocked, creating a five hole narrow array which
is shaded blue. Alternatively the four intervening holes can be blocked, creating a
five hole wide array, shaded in yellow. The magazine where reinforcement is
delivered is situated at the front of the chamber, and includes a cue light with its
entrance monitored by a horizontal infra-red beam.
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Mice were maintained at 85% of their free-feeding weight and permitted ad libitum
access to water throughout the study. Ad libitum access to food was allowed
approximately every 5 weeks in order to re-establish a free-feeding weight. Mice
were introduced to the strawberry milkshake reinforcer in their homecage prior to
training, reducing the risk of a neophobic response. During the task, mice were
required to respond to visual stimuli (recessed into the holes), with a nose-poke.
Responses were detected by the interruption of an infra-red beam crossing the
entrance of the each hole.
2.2.2 Behavioural handling and procedures
All mice were handled for approximately 10 min per day for 3 days prior to training.
On training days 1 and 2, mice were placed in the 9 hole boxes for 10 min, during
which liquid reinforcement was dispensed every 15s into the well of the magazine,
whilst the magazine was lit. Entry into the magazine caused the light to be
extinguished until the next reinforcement was delivered. At the end of this and
subsequent sessions, the wells beneath the spigots were inspected to ensure no liquid
was present. On day 3, in order to obtain reinforcement, mice were required to nose
poke in any of the 5 lit holes at the chamber rear. This process was repeated every





At the beginning of each session the house light was extinguished and the magazine
was lit. A nose poke in the magazine initiated the session (Fig. 2.2). An inter trial
interval (ITI) of 2 s preceded one of the five response holes being illuminated. If the
mouse nose poked in the lit hole within 12 s (10 s stimulus duration, SD, + 2 s
limited hold (LH, time in which the mice can respond after the cue light is
extinguished)), a correct response was recorded, the cue light extinguished, the
magazine light illuminated, and a reinforcement dispensed. On entry to the
magazine a 4 s reward interval (RI) was initiated. Failure to respond during the SD +
LH resulted in an omission error being recorded and a 4 s time out (TO) initiated.
During a TO the house light was on and all holes were unresponsive, then as the TO
phase ended the house light was extinguished, and the magazine illuminated. The
mouse could then begin a new trial by responding in the magazine. If, during the
choice phase, the mouse responded in a hole other than the one that was lit, the
response was registered as an incorrect response and a TO phase began. If the mouse
responded during the ITI, an anticipatory error was recorded and a TO phase
initiated. Each session lasted 25 min, or 120 trials if completed sooner. The SD was
initially set at 10 s and was only reduced to 8 s following attainment of a mean
correct latency half that of the SD and a minimum of 10 correct responses per
session, maintained for over two consecutive sessions. The SD was further reduced
to 4, 2 then 1 s based upon these response latency criteria. Successful acquisition of
the task was defined as attainment of a 1 s SD, with proportion correct > 0.8, and
omission levels of < 40 %. This required approximately 3 months of training.
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NP = Nose Poke ^ ^ = Input to ComputerRI = Reward Interval




Asymptotic performance was assessed over a four-day period (Tuesday - Friday)
once the mice had attained acquisition and a stable level ofperformance.






% omissions = omissions / (correct + incorrect + omissions)
Proportion correct = correct / (correct + incorrect + anticipatory errors)
Mean correct latency = cumulative correct latency / number correct
2.2.5 Increased attentional load
This challenge increased the attentional load placed on the mice by increasing the
session length from the standard 25 to 40 min. The maximum number of trials
possible was increased from 120 to 1000. However, due to the minimum length of
time taken to complete one trial (e.g. a latency to correctly respond (0.5 s) + ITI (2 s)
+ time to collect reward and start next trial (0.5 s), equates to 1 trial in every 3 s and
1000 trials in 50 min) the trial number was effectively unlimited and hence the
session ended only once 40 min had elapsed. Extension of the session length
increases the sustained attentional load placed upon the mice as they are required to
maintain performance for a longer period, thereby increasing the likelihood of a
vigilance decrement being observed (Parasuraman et al., 1998; Grottick et al., 2003).
Analysis of mean reward latency (cumulative time taken to collect the reward /
correct) was added to this program at a later date. This measure is reported to be a




This challenge assessed the ability of bursts of noise to distract mice during
asymptotic performance of the 5-CSR task. Bursts ofnoise (0.5 s, 100 Hz - 20 k Hz)
were presented at two possible intervals; 1) halfway through the ITI (i.e. 1 s prior to
onset of cue stimulus), 2) at the end of the ITI (i.e. coinciding with cue stimulus). No
noise trials were also included, with the three possibilities were randomly assigned.
2.2.7 Statistical Analysis
The main dependent behavioural variables analysed, included % omissions,
proportion correct, mean correct latency, total trials and mean reward latency. If
proportion correct was not normally distributed, the data were arc-sine transformed.
If mean correct latency or mean reward latency were not normally distributed, the
data were logarithmically transformed. However, for all figures shown in the thesis
the raw data are presented. Each variable in chapters 3.3.3 (pp. 86), and 3.3.4 (pp.
88) were compared to the mean scores obtained with saline using a 3-Way ANOVA
(dose, day, and ITI time), with Tukey post hoc analysis. All other asymptotic
performance data were analysed using a 2-Way repeated measures ANOVA.
Acquisition performance was analyzed by assessing the increase in proportion
correct across sessions per subject, and the data fitted using a 4-parameter logistic.
The number of sessions required to attain 0.50 proportion correct (A50) was
calculated for each subject, and compared between the groups using a t-test. All
statistics were performed using Sigma Stat, (v. 3.0) SPSS, U.S.A..
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2.3 Odour Span task
One of the main challenges in this thesis was the development of a mouse version of
the odour span task (OST). The OST was first described by Dudchenko and
colleagues (2000) and was established using rats. To adopt the task for use in mice,
the bowls utilised were reduced in size, as was the table the task was performed on.
In addition woodchip was employed as the digging medium as opposed to sand as
digging in sand appeared aversive to mice. To mask the scent of the reinforcement
pellets (Noyes Precision Pellets, 45 gm, Lancaster, U.K.), 18 pellets were crushed
and added to the mix ofwoodchip and scent when it was first created (see below).
2.3.1 Training in the Odour Span task
As described for the 5-CSR task, mice were maintained at 85% of their free-feeding
weight and were permitted ad libitum access to water. Ad libitum access to food was
provided every 5 weeks in order to re-establish a free-feeding weight. Mice were
introduced to the pellet reinforcers in their homecage prior to training, to reduce the
risk of a neophobic response.
2.3.2 Behavioural Apparatus
Training and testing took place on a platform (61 X 61 cm) raised 76 cm above the
floor. The platform was numbered 1 - 24 around its perimeter. The odours used
were as follows: ground cinnamon, nutmeg, coriander, allspice, fenugreek and
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ginger; dried thyme, parsley sage, mint oregano and rosemary; plus caraway seed,
onion powder, paprika, Chinese five spice, celery salt, coffee powder, dill, lemon tea,
cocoa and English breakfast tea (all odours purchased locally). Ground cumin and
garlic were found to be aversive to mice and were not employed (see table 2.1). All
odours were created as follows: 3 g of an odour was added to 100 g of sawdust, and
18 crushed pellets. Approximately 3 g of this scented mix was placed in white
porcelain bowls (5.5 cm in diameter and 3.5 cm high; Fisher, Loughborough, UK),
individually marked with a letter corresponding to each particular odour.
Odours utilised
Dried Ground Miscellaneous
Mint Allspice Caraway seed
Oregano Cinnamon Celery Salt
Parsley Coriander Chinese five spice
Rosemary Fenugreek Cocoa





Table 2.1 Odours utilised in the OST
List of odours utilised in the OST. Ground cumin and garlic were found to be
aversive to mice and were not used.
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2.3.3 Behavioural Handling and Procedures
Initially, all mice were handled for approximately 10 min per day for 3 days prior to
training. On day 1 of training mice were placed in an clear cage (44.5 X 22 X 19
cm) on the platform, which contained a bowl of unscented sawdust filled with 10
reward pellets, and were left in situ until every pellet was retrieved (approximately
15 min). On day 2, 18 crushed pellets were added to 100 g of sawdust, and
approximately 3 g of this mixture was placed in two bowls, one of which was baited
with 5 reward pellets. Both bowls were then placed in the cage with the mouse, until
the mouse retrieved all 5 pellets after which the task was immediately repeated once.
On day 3 a scented odour was chosen at random, 1 pellet was added and the bowl
placed in the cage alongside a second bowl with unscented sawdust, after which the
mouse was also placed in the cage. Once the pellet was retrieved, the mouse was
removed to a second clear cage below the table, the locations of the bowls were
randomly swapped, a pellet again placed in the scented bowl and the mouse returned
to the first cage. This was repeated a further 8 times, with constant monitoring
ensuring the pellet was retrieved each time. This process was repeated on days 4, 5
and 6 to ensure rapid retrieval (10 pellets in < 8 min.) of the pellet.
2.3.4 Odour span task
In the first span, a random odour and location were chosen using an in-house written
program in Arachnid on-line control language (Paul Fray Ltd, Cambridge, UK)
interfaced to an Acorn computer (RISC OS). A bowl was filled with the scented
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mix, baited and placed on the platform at the appropriate randomly chosen location.
A mouse was then placed on the platform, at which point the session and a timer
began (Fig. 2.3, pp. 64). The mouse was then required to dig in the bowl for the
reward, and remember the odour in that bowl. Upon consumption of the reward the
mouse was then placed in the same clear cage positioned below the platform. A new
odour and location was then randomly selected, the bowl baited, and placed on the
platform, with the first odour (not baited) moved to a new location. The second span
began when the mouse was placed back on the platform and the timer started. The
mouse was required to dig only in the novel odour. The timer was stopped as soon
as the mouse dug in an odour (bowl), and it was returned to the clear cage. If the
correct odour was dug in, the mouse was given time to consume the reward prior to
being returned to the cage and a third baited odour was then introduced. If an
incorrect choice was made, the odours were randomly relocated, and span 2 repeated
until a correct response was made. The next span (span 3) then included the 2
previously sampled odours (not baited) and 1 novel odour (baited) placed on
randomly selected locations. This process continued until 12 (span 12) odours had
been introduced, or the mouse had spent 10 min on the platform (Fig. 2.4, pp. 65). If
at any time the mouse dug in an incorrect odour, it would be removed, and the timer
stopped. The odours would then be randomly relocated, and the mouse reintroduced
to that span, with the same baited odour as before. If a mouse made 10 consecutive
incorrect responses, the task would be terminated. The number of odours the mouse
successfully remembered prior to making an error was taken to be that subjects' span
length for that session. Thus with 12 odours the maximum possible span length was
11, for at span 1 the mouse did not choose and hence had no odour to remember.
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To ensure that the mice were not scent marking the bowls, a bowl that had previously
been dug in was randomly selected on every third span and replaced with an identical
bowl (filled with the identical odour), but one which the mouse had not previously
sampled. If the subjects relied on this method, then performance would be severely
disrupted at those spans. The table was wiped down with ethanol between sessions.
Mice were deemed to have acquired the task when a span length (number of correct
digs prior to an error) of 5 was achieved for 2 consecutive days. Mice were then
continuously trained until a stable level of performance had been reached.
Span 0 Span 1 Span 2 Span 1!
Figure 2.3: Schematic of the OST (from Dudchenko et al„ 2000)
Mice are first presented with a bowl of woodchip scented with a specific odour (e.g.,
parsley, A). After retrieving a buried reward, the mouse is removed from the table,
and a second bowl of woodchip, scented with a different odour (e.g., Fenugreek, B)
is added. The mouse must remember odour A in order to dig only in the novel odour
(B). This continues until 12 odours are presented (representing a span of 11) or the














Mouse returned to opaque
bucket below table
Key: LL = Left Lever NP = Nose Poke
RI = Reward Interval RL = Right Lever
TO = Time Out ( )= Input to Computer




Asymptotic performance was assessed over a four-day period (Tuesday - Friday)
once mice had attained acquisition and stable performance. Measures include:
Span length Total number of spans completed
Errors Simple discrimination (span 1)
Mean span latency Time taken to engage in the task (i.e. dig in bowl 1)
2.3.6 Extended Version (22-OST)
To increase the working memory load placed on mice thus accommodating for
potential ceiling effects, an extended version of this task which utilises 22 odours
instead of 12 was developed. This allowed the mice to potentially complete 21 spans
in each session within the 10 min time limit.
2.3.7 Statistical Analysis
Acquisition was assessed by comparing the total number of days each group took to
attain criteria and analysed using a One-Way ANOVA. Span length, maximum
spans, error numbers and simple 2-odour discrimination were compared using a
Mann Whitney Rank Sum test between 2 groups, and a Kruskall Wallis Rank Sum
Test between more than 2 groups (for example during drug administration; see
chapters 4.3.1 - 4.3.2, pp. 125 - 128). Mean span latency and time taken for initial
response was compared using a Two-Way Repeated Measures ANOVA with day and
genotype as between subject factors. Due to the low group sizes utilised in this task,
significant results may be as a result of sampling error and thus caution must be
taken when drawing conclusions.
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2.4 T-maze continuous alternation task (T-CAT)
Spontaneous alternation on the T-maze is recognised as a method with which to
measure innate exploratory behaviour (Lalonde et al., 2003). Traditionally,
assessment requires handling, when the animal is moved from its chosen arm back to
its start arm. However constant handling of the test subject may confound results as
initial handling can produce an anxiogenic effect, whilst chronic handling can act as
an anxiolytic (unpublished observations). The production of either can alter levels of
spontaneous alternation. Gerlai (1998) developed the T-maze continuous alternation
task (T-CAT) which allows the test animal to return to the start arm by its own
volition. Thus the next trial can automatically begin and no handling is required.
2.4.2 T-maze apparatus and testing
Unlike the previous two tasks, the T-CAT requires no training, and performance is
monitored on a single day, with the mice maintained on ad libitum feeding. Testing
apparatus consists of an octagonal hub (14 cm across), with two arms (61 cm long)
attached opposite each other and one (72 cm long) attached to the side of the hub
between the first two arms (Fig. 2.5). Thus viewed from above the apparatus
resembles a T (Fig. 1.3c, pp. 41). A door which can be either open or closed is
positioned where each arm is attached to the central hub. In total there are 16 trials,
with trials 1 and 2 being forced entries, whilst the remaining 3 - 16 are free-choices
(Fig. 2.6). For trial 1 the mouse begins in the central arm with all three doors closed.
The start-arm door and either the left or right door are raised, leaving one arm
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inaccessible. The mouse must then enter the novel arm, progress at least halfway,
and re-enter the start arm, after which all 3 doors are closed. After a 5 s period in the
start arm, trial 2 begins which is also a forced entry trial. The start-arm door is
opened as is the previously lowered door, and thus the mouse can only enter the
previously inaccessible arm. Again after reaching halfway down the accessible arm,
the mouse must return to the start arm, again after which all 3 doors are closed. The
following 14 free-choice trials use the same following format. After a 5 s delay in
the start-arm all 3 doors are opened. The mouse is free to explore either arm, but
once halfway down the left or right arm, the choice and time is recorded and entry to
the opposite arm is rescinded as its door is lowered. Once the mouse returns to the
start-arm, the remaining two doors (start-arm and chosen arm doors) are closed. The
mouse is given a 30 min time limit in which to complete all 16 trials. If < 8 free
choice trials are completed within the 30 min period then the subject is removed
from the analysis. Otherwise, the numbers of alternations (entering the opposite arm
from the previously entered arm) are recorded as a percentage:
Number of alternations X 100
Total free choice arm entries
2.4.2 Statistical Analysis
Exploratory behaviour was measured by the percentage of spontaneous alternation.
Any differences in the percentage of spontaneous alternation between groups were
compared using a student's t-test. To assess whether any group were performing at
better than chance levels (50%) a one-sample t-test was performed. Session latency
data were compared using a one-way ANOVA.
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Figure 2.5: Schematic of the T-maze apparatus
The apparatus used is so-called as the start, left and right arms join to form a T.
Entry to the arms is controlled by doors located at their joining to the central
chamber. If reinforced alternation is being assessed, the animals can be fed by food











Figure 2,6: Two examples of performance in the T-CAT
Spontaneous alternation on the T-maze continuous alternation (T-CAT) is measured
in terms of % alternation. In both examples, trial 1 and 2 are forced entries, whereby
on trial 1 one arm is closed (here the right arm) to ensure the mouse enters the
opposite arm. In trial 2 the opposite arm is closed (here left arm), ensuring the
mouse enters the right arm. Thus the mouse has experienced both arms prior to the
14 choice trials (though 3 - 8 are only given in the .examples). A mouse with high
spontaneous alternation (83%), and thus exploratory behaviour, would consistently
alternate in their choice trials (example 1). Poor spontaneous alternation (33%)
would be exemplified by a mouse consistently choosing the same arm to enter in a
given choice trial (example 2).
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Individual mice were placed into locomotor cages (RS Biotech, Alva,
Clackmananshire, UK; Fig. 2.7) for 40 min per day for 5 consecutive days. Two
infrared photo-beams were positioned 4 cm from each end and 2.2 cm above the
floor. One locomotor count was recorded by the computer (program written in-
house) if the two beams were consecutively interrupted. Each cage was interfaced to
an ACORN computer (RISC OS) and programmed using Arachnid on-line control
language (Paul Fray Ltd, Cambridge, UK).
2.5.1 Statistical Analysis
Spontaneous locomotor activity was compared using a Two-Way Repeated Measures




atic of a spontaneous locomotor activity cage
locomotor cages used are depicted above. The two infra-red beams
from either end of the cage, and 2.2 cm above the floor. One




For confirmation of the genotype of the transgenic mice, animals were tail tipped
under halothane/nitrous oxide anesthesia, and DNA obtained by proteinase K
treatment of tail samples (Promega, Southampton, U.K.). a7 nAChR transgenic mice
were genotyped as follows: Three primers were used, corresponding to both wild-
type (forward primer 5'-CCT GGT CCT GCT GTG TTA AAC TGC TTC-3',
reverse primer 5'-CTG CTG GGA AAT CCT AGG CAC ACT TGA G-3',
producing 440 bp product) and disrupted (same forward primer as for wild-type, but
reverse primer 5'GAC AAG ACC GGC TTC CAT CC-3', producing 750 bp
product) alleles. Caspase-3 over-expressing mice were genotyped as follows: Tissue
was heated at 95°C for 20 min in 25mM NaOH/O.2 mM EDTA then neutralised by
the addition of an equal volume of 40mM Tris-HCl. Three primer pairs
corresponding to both YAC ends (long arm: forward primer 5'-ATT GCT AAC
GCA GTC AGG CAC C-3', reverse primer 5'-TAG TGG CTC CAA GTA GCG
AAG C-3', producing 278 bp product; and short arm: forward primer 5'-TCT CCG
AAC AGA AGG AAG AAC G-3', reverse primer 5'-TGT TAC TTC TGC CGC
CTG C-3', producing 568 bp product) and human caspase-3 (3'-UTR: forward
primer 5'-TGA TGA TGT GGA AGA ACT TAG G-3', reverse primer 5'-ACG GCT
CCG CAC CTG CTG AGG C-3' producing 944 bp product) were used for PCR
genotyping. Genotyping of the Tg2576 mice required two primers (forward primer
5'-CTG ACC ACT CGA CCA GGT TCT GGG T-3', and reverse primer 5'-GTG
GAT AAC CCC TCC CCC AGC CTA GAC CA-3', producing no band for wild-




2.7.1 Tissue procurement and P2 synaptosomal membrane preparation
For radioligand binding studies, P2 synaptosomal membranes were prepared as
described previously (Maemoto et al, 1997). Mice were sacrificed by cervical
dislocation, the brains removed, and immediately placed in ice-cold saline (0.9%
NaCl). The whole brain minus cerebellum (due to the low density of a7 nAChRs)
was used for preparation of synaptosomal membranes. Brain tissue from each
animal was treated independently in the al nAChR KO study. Tissue samples were
homogenized in 15 volumes (15 vol.) of ice cold (4°C) 0.32 M sucrose using a
glass/Teflon homogenizer, centrifuged at 1 000 g for 10 min (4°C), and the resulting
supernatant centrifuged at 17 000 g (20 min, 4°C). The synaptosomal/mitochondrial
P2 pellet was lysed in 30 vol. of ice-cold (4°C) milliQ H2O for 60 min and
centrifuged at 50 000 g (10 min, 4°C). The membrane pellet was then resuspended
in 30 vol. of ice cold (4°C) 50 mM potassium phosphate assay buffer (50 mM
potassium phosphate, 1 mM EDTA and 0.01% sodium azide, pH 7.4), centrifuged at
50 000 g for 10 min (4°C) and resuspended in 5 vol. (original tissue weight) of assay
buffer and stored at -20°C. On the day of use, frozen membranes were thawed,
diluted to 30 vol. with ice cold (4°C) assay buffer and the suspension centrifuged at
50 000 g for 10 min at 4°C. The pellet was then resuspended in the appropriate
volume of assay buffer and the protein content determined as described previously
(Finlayson et al, 2001).
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2.7.2 [3H]-Methyllycaconitine ([3H]-MLA) binding to the al nAChR
[3H]-MLA (19.8 Ci/mmol; Tocris, Bristol, U.K.) binding to the a7 nAChR was
carried out as previously described (Davis et al, 2000). Binding assays were
conducted in a total volume of 250 pi; consisting of 50 or 100 pi (no drug present) of
potassium phosphate assay buffer, 50 pi of test drug, 50 pi of [3H]-MLA (final, 2
nM), and 100 pi of membrane suspension. Test compounds (methyllycaconitine and
(±) epibatidine, Tocris, Bristol, U.K.; (-)nicotine bitartrate and d-tubocurarine
chloride, Sigma, Poole, U.K.) were prepared by serial dilution in assay buffer. Non¬
specific binding was determined in the presence of 1 mM d-tubocurarine. Binding
was initiated by the addition ofmembranes, and samples were incubated for 60 min
at 25°C. Binding was terminated by filtration onto glass fiber filters (GF/B,
Whatman; pre-soaked for 3 h in 0.3% polyethylenimine) using a Brandel cell
harvester, followed by three rapid (1 ml) washes with ice cold phosphate buffered
saline (20 mM Na2HP04, 5 mM KH2PO4, 150 mM NaCl, pH 7.4). Filter disks were
transferred to RT30 tubes (Sterling, UK) and radioactivity determined using a
Packard 2500TR liquid scintillation counter.
2.8 Histopathology
Mice were killed by cervical dislocation, the brains removed, and immediately
placed in isopentane (-42°C) for three min. Cryostat sections were taken at 20 pm
and Nissl stained with thionin.
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Chapter 3: Nicotinic modulation of sustained attention in mice
3.1 Introduction
Attentional impairments are common in patients with dysexecutive syndrome
(Cornblatt and Kelip, 1994; White and Levin, 1999; see chapter 1.3.2, pp. 21). It has
been proposed that these impairments may underlie the psychopathology of
Schizophrenia (Cullum et al., 1993; Cornblatt and Keilp, 1994). As described in
chapter 1.3.2 (pp. 21) human attentional performance is commonly assessed using
the continuous performance test (CPT), where subjects have to attend to visual
stimuli over a sustained period of time (Levin et al., 1998; White and Levin, 1999;
Shytle et al., 2002). Nicotine has been shown to enhance sustained attention in
normal humans by reducing omission levels (Levin et al., 1998). Moreover, it has
been suggested that nicotine can lock the brain in to an attentional processing mode
whereby there are fewer lapses in attention and therefore less omissions (Mancuso et
al., 1999). Critically, this beneficial effect of nicotine on attentional performance
translates to every-day tasks in real life-scenarios (Rusted et al., 2000). This
property of nicotine may underlie its ability to enhance attention and improve
symptomatology in various human diseases including schizophrenia (Yang et al.,
2002), Alzheimer's disease (White and Levin, 1999), attention deficit hyperactivity
disorder (Shytle et al., 2002), Parkinson's disease (Kelton et al., 2000), and
Tourette's syndrome (Sanberg et al., 1997). Unfortunately the side-effect profile of
nicotine includes addiction, nausea, and cardiovascular stress, all limiting its
potential role as a therapeutic agent as these side-effects outweigh nicotine's
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potential benefits (Waldum et al., 1996; Levin, 2002; Shytle, 2002; White and Levin,
2004; Yildiz, 2004).
Thus identifying the nicotinic acetylcholine receptor (nAChR) subtype(s) that
mediate the cognitive enhancing effects of nicotine may facilitate the generation of
compounds that have a reduced side-effect profile (Levin, 2002). The roles these
receptors play in rat sustained attention have been examined using the 5-choice serial
reaction-time (5-CSR) task (Mirza and Stolerman, 1998; Blondel et al., 1999;
Grottick and Higgins, 2000; Stolerman et al., 2000; Mirza and Bright, 2001; Hahn et
al., 2002; Terry et al., 2002; Grottick et al., 2003; Hahn et al., 2003a,b; see chapter
1.4.1, pp. 34). However, no consistent nicotine-induced improvements in sustained
attention have been reported in unimpaired rats (Mirza and Bright, 2001; Terry et al.,
2002). While nicotine-induced improvements in sustained attention have been
reported in rats, these studies have required the additional complexities afforded by
brain lesions, poorly performing subjects, or task challenges (Muir et al., 1995;
Grottick and Higgins, 2000; Hahn et al., 2002). The improvements observed may
therefore not reflect enhanced attention as nicotine has been shown to enhance
learning (Faiman et al., 1991), a confound introduced when utilising both task
challenges or poor performers, whilst lesion studies are complicated in that an
abnormal state has been introduced.
Clear identification of the receptor subtypes underlying the beneficial effects of
nicotine is made more onerous by the difficulties associated with producing nAChR
subtype selective drugs (Gotti et al., 2000; Broad et al., 2002; Shoaib et al., 2002). It
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has therefore been suggested that a combined approach of pharmacological
interventions and transgenic animals may help delineate the nAChR subtypes
involved (Gotti et al., 2000, Chapman, 2002; Levin, 2002).
As noted on the previous page, since its first description by Carli et al in 1983, the 5-
CSR task has been extensively used in rat studies. In contrast, the task has received
only limited and comparatively recent attention in mice (Humby et al., 1999;
Marston et al., 2001). Hitherto, no reports addressing the effects of nicotine on the
performance of mice in the 5-CSR task have been published. Such information
would be advantageous, as a variety of nAChR transgenic mice have been generated
including a3, a4, a5, al, (32 and (34 nAChR knockouts, and a4 and al nAChR
knockins (hypersensitive to nicotine, Picciotto et al., 1995; Orr-Urtreger et al., 1997;
Marubio et al., 1999; Xu et al., 1999; Zoli et al., 1999; Rossi et al., 2001; Lester et
al., 2003; Salas et al., 2003). Therefore establishing mouse 5-CSR provides the
opportunity to assess by both pharmacological and genetic manipulations, which
nAChR may mediate the nicotine-induced improvement in sustained attention.
Therefore in this chapter I will describe the development and use of the 5-CSR task
to examine the hypothesis that nicotine can improve sustained attention in mice. In
addition, due to the lack of commercially available selective agonists, the role that
the al nAChR plays in attention was examined by using al knockout (KO;
B6.12957- Chrna7tmlbay, Orr-Urtreger et al., 1997; creation of which are detailed in
Appendix I, pp. 256) mice in the task. These were examined due to the purported
role of the al nAChR in preattention and it's possible link to sustained attention (see
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chapter 1.4.3, pp. 37). If the a7 nAChR plays a role in sustained attention these mice
should exhibit a deficit as identified as an increase in omission levels and a decrease
in proportion correct. Attempts to combine the two approaches and ensure




3.2.1 Animal maintenance and genotyping
C57B1/6J male mice were used in sections 3.3.1 - 3.3.4 (sections 3.3.1 - 3.3.3, n =
16; and section 3.3.4, n = 25, Charles River, Margate, UK). The same group was
used for sections 3.3.1, 3.3.2, and 3.3.3. The mice weighed between 22 and 26 g at
the start of each study. Eight a7 nAChR KO (B6.12957 - Chrna7tmlbay; Jackson
Laboratories, Bar Habor, U.S.A.) and eight age-matched littermates (backcrossed
onto a C57B16/J background 8 times), weighing between 22 and 27 g at the start of
the study, were used in sections 3.3.5 and 3.3.6. The mice used in section 3.3.7 were
comprised of a group of ten a7 nAChR KO, ten heterozygote, and twelve age-
matched littermate mice (age range; 19-28 weeks; backcrossed onto a C57B16/J
background 11 times), all weighing between 21 and 31 g at the start the study.
3.2.2 Behavioural apparatus and 5-CSR training
The behavioural apparatus used in all studies was as described in chapter 2.2 (pp.
52), though some modifications were introduced. In sections 3.3.1, 3.3.2 and 3.3.5,
training and testing utilised the narrow array format, whereas the wide array format
was used in all other studies (including section 3.3.2). In every study the mice were
trained using a constant inter-trial interval (ITI). In sections 3.3.3, 3.3.4, and 3.3.6,
when acquisition criteria had been attained, the mice were moved to a 3 - 7 then a 2




3.3.1 (-)Nicotine had no effect on sustained attention in mice in the standard 5-
CSR task
Initially, mice (n = 16) were trained to perform the 5-CSR task using the narrow
array (holes 3 - 7), and a constant 2 s ITI. All mice attained criteria and were
administered saline or three different doses of (-)nicotine (3, 30, and 100 /xg/kg)
according to a Latin-square design and tested over a 10-week period (table 3.1). The
mice were administered their allocated dose for four consecutive days (Tuesday -
Friday), with each 4 day dosing period separated by a 10-day washout period,
ensuring a baseline response to saline was re-established. Overall no significant
effect of drug or test week was observed. A 2-Way ANOVA with nicotine dose, and
day as between subject factors, yielded no significant main effects of drug (Fig. 3.1)
or day. There was no effect of nicotine dose on % omissions (F(3,192) = 0.668, p =
0.573; Fig. 3.1a), proportion correct (F(3,192) = 0.437,p = 0.727; Fig. 3.1b) or mean
correct latency (F(3,192) = 2.257, p = 0.083; Fig. 3.1c) was observed. Likewise no
significant main effect of day was observed on % omissions (F(15, 192) = 0.488, p =
0.945), proportion correct (F(15, 192) = 1.412, p = 0.145) or mean correct latency
(F(15, 192) = 1.172, p = 0.297). Also there was no significant interaction between
the two factors on % omissions (F(45, 192) = 0.845, p = 0.745), proportion correct




Week Cohort A Cohort B Cohort C Cohort D
1 Saline Saline Saline Saline
2 Saline 3 /ig/kg 30 /ig/kg 100 /ig/kg
3 Saline Saline Saline Saline
4 3 ng/kg 100 /ig/kg Saline 30 /ig/kg
5 Saline Saline Saline Saline
6 100 /ig/kg 30/ig/kg 3 /ig/kg Saline
7 Saline Saline Saline Saline
8 30 /xg/kg Saline 100 /ig/kg 3 /ig/kg
9 Saline Saline Saline Saline
10 Saline Saline Saline Saline
Table 3.1: Design of section 3.3.1
Mice (n = 16) were separated into four cohorts in a counterbalanced design. They
were then administered saline subcutaneously (s.c.) or (-)nicotine (s.c., 3, 30 or 100
/ig/kg) over four consecutive days (Tuesday - Friday) in the sequence illustrated.
The intervening weeks of saline administration provided a 10 day washout period.
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Saline 3 30 1 00
Nicotine Dose (pg/kg)
Figure 3.1: (-)Nicotine had no effect on mice performing the standard 5-CSR task
A group of C57B1/6J mice (n=16) were trained to perform the standard 5-CSR task.
They were then split into four groups in a counter-balanced design, and administered
(-)nicotine (s.c.; 3, 30 or 100 yug/kg) their allocated dose over four consecutive days
(Tuesday - Friday) in a Latin square design (table 3.1). No effect of drug was
observed on any parameter measured. Parameters measured included % omissions




3.3.2 Baseline performance ofmice was lowered by modification of 5-CSR task
Examination of the literature and Fig 3.1 suggested that the 5-CSR task is subject to
ceiling effects (Grottick and Higgins, 2000; Hahn and Stolerman, 2002). Therefore a
nicotine-induced improvement in performance would be difficult to achieve in
animals that had achieved asymptote. Newhouse and colleagues who work
extensively with control and patient groups suggested in 1997 that improvements in
performance following drug administration are more likely to be observed if baseline
performance is already low. Indeed Bates and colleagues (1995) had previously
widened the array that human subjects had to attend to in order to increase task
difficulty, and had reduced baseline performance in an attentional task. Using this
principal I subsequently modified the 5-CSR task by opening apertures 1, 3, 5, 7 and
9 (wide array) as opposed to apertures 3-7 (narrow array; Fig. 2.1, pp. 54) in an
attempt to increase task difficulty. Performance in the task was assessed by
comparing performance of one group ofmice (n = 8) in the (standard) narrow array,
with a second group (n = 8) in the (modified) wide array over a period of four
consecutive days (Tuesday - Friday). As can be seen in Fig. 3.2, widening the array
clearly decreased performance as measured by % omissions, proportion correct and
mean correct latency. A 2-way Repeated Measures ANOVA, with array width and
day as between subject factors revealed a significant main effect of array width on %
omissions (F(l,42) = 11.793, p < 0.005; Fig. 3.2a), proportion correct (F(l,42) =
6.38,/? < 0.05; Fig. 3.2b) and on mean correct latency (F(l,42) = 14.585,/? < 0.005;
Fig. 3.2c). Also there was no significant interaction between the two factors on %
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omissions (F(3,42) = 0.606, p = 0.615), proportion correct (F(3,42) = 0.832, p =
0.484) or mean correct latency (F(3,42) = 2.047, p = 0.122).
Figure 3.2: Modification of the mouse 5-CSR task lowered baseline performance
The mice (n = 16) trained in the previous study were split into two groups in a
counter-balanced design. Over a period of four consecutive days (Tuesday - Friday),
performance of the two groups was assessed in a narrow array (NA) and a wide array
(WA). Increasing the width of the array had significant effects on every measure
assessed resulting in higher % omissions (a), lower proportion correct (b) and a
slower mean correct latency (c). Data presented as mean + s.e.m. (* denotes p < 0.05
when compared with the standard narrow array).
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In addition to widening the array a variable ITI, akin to that used for acute challenges
in the rat 5-CSR task (Hahn et al., 2002), and that used as a standard protocol in
many human measures of attention (Riccio et al., 2002), was also introduced.
Robbins, (2002) described that differences observed whilst using a variable ITI are
'more likely to reflect attentional than simple sensory functions'. These two
modifications differ from the acute challenges utilised for rats as they are employed
in both training and testing days, thus bearing greater resemblance to their use in the
human literature and reducing any confounding effects of learning.
3.3.3 (-)Nicotine improved mouse performance in the modified 5-CSR task
Following a further 3-week washout period the mice (n = 16) used in sections 3.3.1
(pp. 81) and 3.3.2 (pp. 84) were again administered saline or (-)nicotine (3, 30 and
300 /xg/kg) over four consecutive days (Tuesday - Friday). As can be seen in Fig.
3.3, the 3 pg/kg dose of nicotine produced a significant reduction in % omissions and
an increase in proportion correct when compared to the control group. A 3-Way
ANOVA with nicotine dose, ITI time, and day as between subject factors, yielded
significant main effects of: nicotine dose on % omissions (F(3,36) = 17.4, p < 0.001;
Fig. 3.3a), proportion correct (F(3,36) = 8.83, p < 0.001; Fig. 3.3b), and mean correct
latency (F(3, 36) = 5.27, p = 0.004; Fig. 3.3c); ITI time on % omissions (F(3,36) =
28.2,/? < 0.001), and on mean correct latency (F(3,36) = 57.8,/? < 0.001); and day on
proportion correct (F(3,36) = 5.15,/? = 0.005). Tukey post hoc analysis on nicotine
dose revealed a significant effect of 3 /xg/kg of nicotine on % omissions (F(3,36) =
17.4, p <0.001), and proportion correct (F(3,36) = 8.83, p <0.05) compared to the
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saline group. Nicotine at 300 /xg/kg also increased proportion correct (F(3,36) =
8.83, p =0.001), and decreased mean correct latency (F(3,36) = 5.27, p <0.005), but
had no effect on % omissions. No effect was observed at the intermediate nicotine
dose of 30 /xg/kg on any parameter examined.
Figure 3.3: (-)Nicotine improved mouse performance in the modified 5-CSR task
Each mouse in this study had received extensive training and repeated nicotine (s.c.)
injections 3 weeks prior to testing. The mice (n = 16) were separated into four
groups in a counter-balanced design and administered saline or their allocated dose
of (-)nicotine (3, 30, 300 /xg/kg) for four consecutive days (Tuesday - Friday). The 3
/xg/kg dose of (-)nicotine significantly reduced % omissions (a) and increased
proportion correct (b) without affecting mean correct latency (c). In contrast, 300
/xg/kg of (-)nicotine had no effect on omissions whilst increasing proportion correct
(b), and reducing mean correct latency (c). The 30 /xg/kg dose of (-)nicotine had no




3.3.4 (-)Nicotine improved drug-nai've mouse performance in the modified 5-CSR
task
As the study conducted in section 3.3.3 was performed using mice that had been
repeatedly exposed to nicotine, the significant improvements observed in sustained
attention could have been confounded by factors such as receptor upregulation and/or
desensitisation of multiple nAChRs (Paradiso and Steinbach, 2003; Maggi et al.,
2004). Therefore it was important to examine the cognitive effects of nicotine on
drug-naive in the modified 5-CSR task. As the 3 /xg/kg dose of nicotine had
produced the most robust improvement in performance the effect of nicotine was
examined at 1, 10 and 100 /xg/kg. A new group of C57B1/6J mice (n = 25) were
trained to perform the modified 5-CSR task as described previously. Nicotine
significantly improved the performance of drug-naive mice in the modified 5-CSR
task (Fig. 3.4). A 3-Way ANOVA with nicotine dose, ITI time, and day as between
subject factors, yielded significant main effects of: nicotine dose on % omissions
(F(3,36) = 211, p < 0.001; Fig 3.4a), proportion correct (F(3,36) = 3.285, p < 0.05;
Fig. 3.4b), and mean correct latency (F(3,36) = 13.3, p < 0.001; Fig 3.4c); ITI time
on % omissions (F(3,36) = 40.4,/? < 0.001), proportion correct (F(3,36) = 3.512,p =
0.016), and on mean correct latency (F(3,36) = 9.83,p < 0.001); day on % omissions
(F(3,36) = 6.58, p = 0.001). Tukey post hoc analysis on nicotine dose revealed
significant effects of 1, 10 and 100 /xg/kg of nicotine on % omissions (F(3,36) =
22.6, p <0.001). Moreover the 1 /xg/kg dose of nicotine significantly increased
proportion correct, whilst the 10 /xg/kg dose significantly altered mean correct
latency. There were significant main effects of the 1 /xg/kg dose of nicotine on
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proportion correct (F(3,36) = 3.29, p = 0.05), and the 10 pig/kg dose significantly
increased mean correct latency (F(3,36) = 13.3, p <0.05).
Saline 1 10 100 Saline 1 10 100 Saline 1 10 100
Nicotine (/sg/kg) Nicotine (/ug/kg) Nicotine (/sg/kg)
Figure 3.4: (-)Nicotine improved drug-naive mouse performance in the modified 5-
CSR task
Mice (n = 25) were trained specifically for this study and as such were nicotine
naive. The mice were separated into four groups in a counter-balanced design and
administered saline subcutaneously (s.c.) or their allocated dose of (-)nicotine (0, 3,
30, 300 p.g/kg) for four consecutive days (Tuesday - Friday). Every dose of (-
)nicotine examined significantly reduced % omissions (a), with 1 p.g/kg increasing
proportion correct (b). The 10 /^g/kg dose of (-)nicotine produced a significant
increase in mean correct latency (c). Data presented as mean + s.e.m. (* denotes p <
0.05 when compared with saline).
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3.3.5 a7 nAChR KO mice exhibit impaired acquisition and asymptotic
performance of the standard 5-CSR task
The debate over which nicotinic receptor subtype is responsible for the cognitive
enhancing effects of nicotine is far from resolved. As discussed in chapter 1.3.4 (pp.
24), there has been considerable interest in the influence of the a7 nAChR in
attentional processing. Therefore I examined the effect of performance of a7
nAChR knockout (KO) mice in the standard 5-CSR task. The a7 nAChR KO (n = 8)
mice and their age-matched littermates (WT, n = 8) were trained to perform the
standard 5-CSR task (constant ITI and narrow array). As Fig. 3.5a shows, a7 KO
mice took significantly longer to acquire the task when compared to their age-
matched littermates (WT), with the time taken to reach 50% of asymptotic
performance (A5o) approximately 5 days longer (F(l,12) = 4.76,/? = 0.05; Fig. 3.5b).
Once a stable baseline performance had been attained, the two groups were
compared over four consecutive days (Tuesday - Friday). The a7 KO mice
exhibited significantly higher levels of % omissions in comparison to the WT mice.
A two factor ANOVA of repeated measures with genotype and day as between
subject factors yielded significant main effects of genotype on % omissions (F(l,36)
= 7.67,/? < 0.05; Fig. 3.5c) and day on proportion correct (F(l,36) = 4.50,/? < 0.01).
There were no significant effects of genotype on proportion correct (F(l,36) = 0.096,
p = 0.762; Fig. 3.5d), or mean correct latency (F(l,36) = 0.354,/? = 0.563; Fig. 3.5e).
Nor were there significant interactions between day and genotype in % omissions
(F(3,36) = 0.213,/? = 0.887), proportion correct (F(3,36) = 0.409,/? = 0.747) or mean














































Figure 3.5: a7 nAChR KO mice exhibit impaired acquisition and asymptotic
performance in the standard 5-CSR task
oc7 nAChR KO mice (n = 8) and wildtype littermates (WT, n = 8) were trained in the
narrow array in combination with the constant ITI. The a7 nAChR KO had impaired
acquisition as shown in (a) with data shown as proportion correct across session days
for one representative subject from each group, and (b) the mean time taken by each
group to reach halfway to asymptote (A50). a7 nAChR KO mice were also impaired
in asymptotic performance of the task, as measured over four consecutive days
(Tuesday - Friday). A significant effect of genotype was measured in % omissions
(c). Proportion correct (d) and mean correct latency (e) are also shown but were
unaffected by al nAChR KO in the standard task. Data presented as mean + s.e.m.
(* denotes p < 0.05 when compared to WT mice).
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3.3.6 (-)Nicotine does not improve performance of a7 nAChR KO mice in the
modified 5-CSR task
The mice used in the previous study (3.3.5) were retrained (at ~ 18 months; WT n =
6, KO n = 7) in the modified 5-CSR task (2 - 10 s variable ITI and wide array).
Such small group sizes prevented the possibility of utilising the same dosing protocol
that was used in sections 3.3.3 and 3.3.4 (pp. 86 - 88). Both groups were
administered saline on the Thursday, Friday and Monday prior to testing. In week 1
every subject received five consecutive days saline injections (Tuesday - Monday).
In week 2, the mice were administered 1 jUg/kg of (-)nicotine on following four days
(Tuesday - Friday). After confirmation of a lack of day effect, the data were
analysed using a 2-Way Repeated Measures ANOVA. No significant main effect of
drug or genotype was identified for every measure tested. Whilst there appeared to
be increased % omissions in the KO mice in both saline and nicotine treated weeks,
this was not significant (F(1,11) = 1.37, p = 0.267; Fig. 3.6a). There was no
genotypic effect on proportion correct (F(1,11) = 0.003,/? = 0.96; Fig. 3.6b) or mean
correct latency (F(l,ll) = 0.128,/? = 0.727; Fig. 3.6c). The trend towards lower %
omissions and increased proportion correct only in WT mice was not significant (%
omissions - F( 1,11) = 0.004, p = 0.948; Fig. 3.6a; proportion correct; F(l,l 1) = 1.16,
p = 0.305; Fig. 3.6b). Nor was there a significant effect on mean correct latency
(F(l,l 1) = 0.032, p = 0.86; Fig. 3.6c). Finally no genotype by drug interaction was
observed for any measure including % omissions (F( 1,11) = 0.226,/? = 0.644; Fig.
3.6a), proportion correct (F(l,11) = 1.339, p = 0.272; Fig. 3.6b) or mean correct
latency (F(l,l 1) = 0.213,/? = 0.654; Fig. 3.6c).
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Figure 3.6: (-)Nicotine did not improve performance of the al nAChR KO mice in
the modified 5-CSR task
oc7 nAChR KO mice (n = 8) and wildtype littermates (WT, n = 8) were retrained in
the modified (wide array and variable ITI) 5-CSR task. Training continued until
asymptotic performance was attained. The mice were administered saline (s.c.) for
four consecutive days (Tuesday - Friday, WTs and KOs - no pattern). The
following week all the mice were injected with 1 /rg/kg (-)nicotine (s.c.) for four
consecutive days (Tuesday - Friday, WTn and KOn - diagonal bands). Measures of
performance assessed included % omissions (a), proportion correct (b) and mean
correct latency (c). No effect of nicotine or genotype was observed in any measure.
Whilst the KO mice appeared to exhibit higher levels of % omissions than WT mice,
this was not significant. No effect of nicotine administration was observed for any
measure. Data presented as mean + s.e.m..
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3.3.7 Reproduction of the deficit observed in a.7 nAChR KO performing the 5-
CSR task
A group of drug naive a7 KO, heterozygote (HT) and WT mice (n = 10, 10 and 12
respectively) were trained to perform the 5-CSR task. They were trained with a
constant 2 s ITI and wide array. This was designed to be a longitudinal study, where
asymptotic performance, and the effect of introducing challenges would be measured
at 6, 12, and 18 months. After 18 months the mice were to be administered nicotine
in the same manner described in sections 3.3.3 and 3.3.4 (pp. 86 - 88). The
following challenges were to be used on a Tuesday and Thursday, with training days
on Monday, Wednesday and Friday:
1) Extended session; whilst the protocol remained the same, the session
length was extended to 40 min and there was no limit to the number of trials.
2) Variable ITI; a 2 - 10 s ITI was introduced and was used as an acute
challenge to assess the dependence of each strain to a temporal mediating strategy.
3) Stimulus duration reduction; the protocol was unchanged from
training (wide array and constant 2 s ITI), but the SD was altered from 1 s to 0.85,
0.7, 0.55, 0.4, 0.25, 0.4, 0.55, 0.7, 0.85 then back to 1 s over the course of 10
consecutive days assessing their ability to maintain attention with increasing degrees
of difficulty, and the speed with which their performance recovered.
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Acquisition is shown for a representative mouse from each of the three groups (Fig.
3.7a), with proportion correct represented across time between 3 and 5 mth. No
significant group difference was observed in the ability of each group to acquire the
5-CSR task as measured by the time latency to reach 50% of asymptotic performance
(A5o, F(2,25) = 1.586, p = 0.225; Fig. 3.7b). This was in contrast to previous
findings for a7 nAChR KO mice (section 3.3.5, pp. 90). Having attained acquisition
criteria and a stable baseline, asymptotic performance (at 6 mth) was assessed over
four consecutive days (Tuesday — Friday). No genotypic differences were observed
in their performance in this task. A 2 way Repeated Measures ANOVA with
genotype and day as between subject factors revealed no significant main effects of
genotype or day for any measure. No significant differences were observed between
the three groups in % omissions (F(2,77) = 1.05,/? = 0.355; Fig. 3.7c) or levels of
proportion correct (F(2,77) = 0.775,p = 0.464; Fig. 3.7d). Also mean correct latency
did not differ significantly between the three groups (F(2,77) = 1.627,/? = 0.203; Fig.
3.7e). Also there were no significant interactions between day and genotype as
measured by % omissions (F(4,77) = 1.022,/? = 0.401), proportion correct (F(4,77) =
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Figure 3.7: Normal acquisition and asymptotic performance of a7 nAChR mice in
the 5-CSR task
A group of al nAChR knockout (KO, n = 10), heterozygote (HT, n = 10) and wild-
type age-matched littermate (WT, n = 12) mice (3 - 5.5 mth) were trained in the 5-
CSR task with wide array format. There was no difference in acquisition of the three
groups as shown in (a) with data shown as proportion correct across session days
(one representative subject from each group). In (b) the mean time taken by each
group to reach halfway to asymptote (A50) was not significantly different. Training
continued after acquisition until a stable level of performance had been reached
(asymptote, 6 mth) and the following measures were assessed over four consecutive
days (Tuesday - Friday): % omissions (c), proportion correct (d) and mean correct
latency (e). There were no significant differences in asymptotic performance
between the three groups. Data plotted as mean + s.e.m..
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Two weeks later the same mice were then assessed on an extended session probe.
The session length was increased from 25 to 40 min. while the trial limit was
increased from 120 to 1000 trials. The mice were assessed over a two-day period
(Tuesday and Thursday) interspersed with training days (Monday, Wednesday and
Friday). This schedule is commonly used in the literature (Hahn and Stolerman,
2002; Grottick et al., 2003). A 2 way Repeated Measures ANOVA revealed no
significant main effects on day of testing for any measure. However, a main effect of
genotype was observed in % omissions (F(2,55) = 3.201, p < 0.05; Fig. 3.8a), with
Dunnett's post hoc analysis suggesting the KO mice made significantly higher %
omissions when compared to WT mice. The % omissions of the HT mice appeared
to lie in between the two groups, although they did not differ significantly from
either group. There was no significant main effect of genotype on levels of
proportion correct (F(2,55) = 0.446, p = 0.642; Fig. 3.8b) or in mean correct latency
(F(2,55) = 1.756, p = 0.182; Fig. 3.8c). Nor were there any significant interactions
between the two factors as measured by % omissions (F(2,55) = 0.365, p = 0.696),






Figure 3.8: a7 nAChR KO mice exhibit impaired performance of the extended
session 5-CSR task
The same group of a7 nAChR knockout (KO, n = 10), heterozygote (HT, n = 10) and
wild-type age-matched littermate (WT, n = 12) mice were then assessed for their
ability to perform the extended session 5-CSR task with wide array format. This task
differed from the previous simply by increasing the length of the session by 15 min,
and removing the 120 trial number limit. Performance was assessed over two days
(Tuesday and Thursday) interspersed with training days (Monday, Wednesday and
Friday). The KO mice exhibited significantly higher % omissions when compared
with WT mice (a). No differences were observed in any other measure including
proportion correct (b) and mean correct latency (c). Data plotted as mean + s.e.m. (*
denotes p < 0.05 when compared with the WT mice).
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At this stage the mice were currently 7 months old, and until this time these mice had
exclusive use of the 5-CSR task apparatus. However after this time the apparatus
was to be used in the afternoon for a different mouse 5-CSR task study. Whilst the
mice in my study continued to be trained in the morning, the a7 KO, HT and WT
mice appeared to be able to detect the presence of the second group of mice. On
closer inspection it was clear that performance differed from that observed in the
previous week, with fewer trials completed, an increase in the number of omissions,
and a rise in mean correct latencies for every group. The mice appeared to spend
more time exploring the operant box than previously, ultimately attending to the
array less often {personal observation). However, training of the mice in the task
continued until my mice habituated to the presence of the new group of mice and
once more attended to the task; this took approximately 1 month. Unfortunately the
performance exhibited by the mice after this month different to that previously
measured. It appeared that the distraction caused by the exposure to a novel group of
mice either impaired the performance of the WT mice or enhanced the performance
of the al KO mice, though the former is more likely (data not shown).
The variable ITI and SD reduction challenges only served to further compound these
effects. No significant effect of genotype on performance was observed in either
challenge. The mice were then given 5 months of ad lib feeding and no training,
then subsequently retrained and reassessed in the 5-CSR task. However,
performance continued to be different to that observed at 6 months, prior to the
introduction of the second group. The mice were therefore not retested at 18 months
and nicotine was not administered as the study was abandoned.
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3.3.8 Genotyping and characterisation of [3H]-MLA binding sites in a.7 nAChR
KO and littermate mice
To confirm the behavioural deficits observed for the a.7 KO mice, genotyping was
performed and a radioligand binding assay using the putatively selective a7 nAChR
antagonist [3H]-MLA was established. Genotyping was performed with a7 nAChR
specific primers that identified wild type (W) and disrupted (D) alleles (Fig. 3.9a)
with representative subjects shown for clarity. For each subject, two lanes are
presented, the first lane confirming the presence of the wild type allele, and the
second lane showing the presence of the disrupted allele. Hence for WT mice, a
band is visible in lane one, whereas for the KO mice, a band is visible in only lane
two, showing disrupted alleles. As the al nAChR heterozygous (HT) mouse has both
wild type and disrupted alleles, bands are clearly visible in both lanes. The positive
(+ve) and negative (-ve) controls were included to ensure the primers were
functioning accurately and that no cross-contamination had occurred. Verification of
the absence of al nAChRs at the protein level was obtained by establishing a [3H]-
MLA binding assay. P2 synaptosomal membranes were prepared from WT mice and
a range of cholinergic drugs were examined for their ability to inhibit [3H]-MLA
binding. All four drugs examined inhibited [3H]-MLA binding in a concentration
dependent manner with the following rank order of potency; MLA > epibatidine > d-
TC > nicotine (Fig. 3.9b). The affinity of MLA was 1.31 ± 0.35 nM (nH = 0.81 ±
0.02; n = 43), with K values of 167 ± 106 nM (nH = 1.46 ± 0.14; n = 3) for
epibatidine, 1.80 ± 0.07 /xM (nH = 1.48 ± 0.44; n = 3) for d-Tc and 1.41 ± 0.82 /xM
for nicotine (nH = 1.06 ± 0.09; n = 3). For al KO mice and their WT littermates,
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each brain was treated individually. As Fig. 3.9(c) clearly shows, in WT littermates
the level of specific [3H]-MLA binding was approximately 60% of total binding,
whereas no specific binding was observed for the a7 KO mice.
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Figure 3.9: Genotyping PH1MLA binding of a7 nAChR transgenic mice
Confirmation of the genotypes of a7 nAChR knockout (KO) and wild-type littermate
(WT) mice are shown in panel (a). Two lanes are shown for each mouse, the former
exhibiting the presence of wild type (W) alleles (440 bp product), and the latter
exhibiting the presence of disrupted (D) alleles (750 bp product). Hence WT mice
have only W alleles, whilst KO mice exhibit only D alleles. An a7 nAChR
heterozygous (HT) mouse is included for comparison, and contains both W and D
alleles. Panel (b) shows the concentration dependent inhibition of [3H]-MLA (2nM)
binding in P2 synaptosomal brain membranes from WT mice, by a range of
cholinergic drugs. In panel (c) the level of specific [3H]-MLA binding in P2
membranes prepared from individual control and transgenic mice (n = 4 per group) is
shown. Clear specific [3HJ-MLA binding was observed for control animals, which is
absent in a.7 KO mice.
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3.3.9 No overt differences were observed in the histopathology of al nAChR KO
and WT mice
To show that ablation of the al nAChR introduced no gross CNS abnormalities the
neuroanatomy of al nAChR KO and WT mice was assessed. Mice from section
3.3.6 (pp. 92) at 20 months were used for histopathalogical assessment. Mice were
killed by cervical dislocation, the brains removed, and immediately placed in
isopentane (-42°C) for three min. Cryostat sections were taken at 20 /xm and Nissl
stained with thionin. In general the histopathological analysis revealed no overt
differences between al nAChR KO and WT mice. Whilst the highest expression of
the al nAChR is in the hippocampus (Breese et al., 1997), no hippocampal
abnormalities were detected (Fig. 3.10a and b). Also the infralimbic cotex (Fig.
3.10c), orbital cortices (Fig. 3.10d) and pedunculopontine tegmental nucleus (Fig.
3.10e) all appeared ostensibly normal. Therefore the impaired attentional




Figure 3.10: No overt differences were observed in the histopathology of the a7
nAChR mice
Histopathology of 20 mth old al nAChR knockout (KO, left panels) mice and their
wild-type age-matched littermates (WT, right panels) was assessed. Cryostat
sections of 20 /xm were Nissl stained with thionin. No overt differences were
observed in sections of: the hippocampus at magnification x 40 (a) and x 100 (b); the
infralimbic cortex at magnification x 100 (c); the medial and lateral orbital cortices at
magnification x 100 (d); and of the pedunculopontine tegmental nucleus at




3.4.1 Nicotine improved sustained attention in C57B1/6J mice after modification of
the 5-CSR task
Initial attempts to mimic, in mice, the nicotine-induced improvement in sustained
attention observed in normal humans proved challenging (Levin et al., 1998; section
3.3.1, pp. 81). As discussed previously, attempts at producing this effect in rats have
also proven difficult to attain (Mirza and Stolerman, 1998; Blondel et al., 1999;
Grottick and Higgins, 2000; Stolerman et al., 2000; Mirza and Bright, 2001; Hahn et
al., 2002; Terry et al., 2002), with improvement of baseline performance deemed
improbable as a consequence of ceiling effects (Grottick and Higgins, 2000; Hahn
and Stolerman, 2002). In contrast, ceiling effects were not a problem when assessing
performance in normal humans (Levin et al., 1998; Mumenthaler et al., 2003).
However whilst the 5-CSR task is regarded as analogous to the continuous
performance test (CPT) used to assess sustained attention in humans (Jones and
Higgins, 1995), it is not a precise mimic. In the human CPT factors such as a
variable inter-trial interval (ITI), non-target stimuli, and an increase in the array
width the subjects are required to attend to have been introduced in order to observe
cognitive enhancing effects (Bates et al., 1995; Riccio et al., 2002). This increase in
complexity of the CPT supports the assertion of Vorhees (1991) that more
pronounced experimental effects would be observed with increased task complexity.
Therefore nicotine would be more likely to improve attention if baseline performance
was low at the outset (Newhouse et al., 1997; 2004).
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In mice, performance of the saline group in the 5-CSR task (section 3.3.1, pp. 81)
was excellent following training (% omissions ~ 20%, proportion correct -0.92; Fig.
3.2, pp. 85). It is therefore probable that their performance was also subject to the
ceiling effects observed in both the rat and human literature (Bates et al., 1995;
Mirza and Stolerman, 1998; Blondel et al., 1999; Grottick and Higgins, 2000;
Stolerman et al., 2000; Mirza and Bright, 2001; Hahn et al., 2002; Terry et al.,
2002). Thus for experimental effects to be observed, it was obvious that task
complexity needed to be increased in order to reduce baseline performance (Vorhees,
1991; Newhouse et al., 1997; 2004). The 5-CSR task was made more complex by
firstly increasing the width of the array (section 3.3.2, pp. 84), which led to a
reduction in baseline performance (Fig. 3.2, pp. 85), and then introducing a variable
ITI (minimising the possibility of mice using temporal mediating strategies). It has
been suggested that results gleaned using a variable ITI are more likely to reflect
attentional as opposed to sensory processing (Robins, 2002).
Following the modification of the 5-CSR task the same mice were retrained (for 2
mth) and then administered nicotine to assess its effect on performance (section
3.3.3, pp. 86). The drug treatment protocol was simplified with nicotine
administered over a four day period rather than over 10-weeks (table 3.1, pp. 82).
This adaptation is similar to dosing regimens described in the literature (Grottick and
Higgins, 2000; Hahn and Stolerman, 2002) and limits a number of possible
confounding variables (see section 3.4.2, pp. 112). The doses of nicotine examined
were based upon previous rodent and human studies (Faiman et al., 1991; Jones et
al., 1992; Acri et al., 1994; Muir et al., 1995; Grobe et al., 1998, Stolerman et al.,
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2000; Mirza and Bright, 2001). A significant improvement in sustained attention
following nicotine administration was observed (Fig. 3.3, pp. 87). The 3 /xg/kg dose
of nicotine produced a clear improvement in performance, with a significant
reduction in percent omissions and a concomitant increase in proportion correct.
This outcome is consistent with the hypothesis of Mancuso and colleagues (1999)
whereby the nicotine-induced improvement in attention is a consequence of nicotine
acting to 'lock the brain into the attentional processing mode and so there are fewer
lapses in attention' and therefore fewer errors of omission would be expected. As the
300 ng/kg dose of nicotine did not affect % omissions (Fig. 3.3a, pp. 87), it suggests
that the improvement of proportion correct at this dose was not a true reflection of
nicotine improving attention. Moreover as this dose also reduced mean correct
latency (Fig. 3.3c, pp. 87), it suggests that the increase in accuracy may reflect
psychomotor stimulation, an increased readiness to respond (Grottick and Higgins,
2000), which resulted in the mice consequently not attending to the cue array any
more than control subjects. This would be consistent with nicotine being reported to
produce motoric excitation in mice at doses of 125 and 250 /xg/kg in mice (Nordberg
and Bergh, 1985).
As pre-exposure to nicotine is known to alter nAChR density (Gentry and Lukas,
2002), confirmation that the observed improvements were not merely a consequence
of alterations in the proportion or density of nAChRs necessitated that the effects of
nicotine be examined in groups of drug-naive mice. Therefore, a new study (section
3.3.4, pp. 88) was conducted using a modified dose range that took cognisance of the
improvements observed at the 3 /xg/kg dose of nicotine. This study demonstrated a
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significant enhancement in sustained attention in drug-naive mice at all three doses
(1, 10 and 100 /xg/kg) of nicotine examined (Fig. 3.4, pp. 89). All three doses
significantly lowered % omissions (Fig. 3.4a), again consistent with the hypothesis
of Mancuso and colleagues (1999). Moreover 1 /xg/kg significantly increased levels
of proportion correct (Fig. 3.4b) exhibiting a similar effect to that of the 3 /xg/kg dose
ofnicotine used in the previous study (section 3.3.3, pp. 86).
The doses of nicotine used are consistent with those reported to improve attention in
normal humans and pre-attention in normal rats (Acri et al., 1994; Levin et al., 1999;
Heishman and Henningfield, 2000; Min et al., 2001). In contrast, the doses of
nicotine used in rat 5-CSR task studies are generally higher and the studies have
required the inclusion of lesions, task challenges and poor performers (Muir et al.,
1995; Mirza and Stolerman, 1998; Stolerman et al., 2000; Hahn et al., 2002; Grottick
et al., 2003; Hahn et al 2003a,b). Moreover, whereas nicotine reduced % omission
in normal mice in the current study, consistent with reports in normal human subjects
(Levin et al., 1998), in rats, the most consistent manifestation of an improvement in
attention is an increase in accuracy (proportion correct; Stolerman et al., 1998, Hahn
and Stolerman, 2002). The reasons underlying the different effect on omissions
between rat, mouse and human studies have yet to be clearly defined. One possible
explanation is that in rats, the lack of effect of nicotine on % omission may be due to
a floor effect as baseline % omissions are already < 10%. This is in contrast to mice
where % omissions are higher at ~ 20% (Inglis et al., 2001; Spratt et al., 2001). This
difference in % omissions cannot be attributed simply to the fact that mice were
tested in the same size of apparatus commonly used for rats, for when the operant
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box was scaled down, omission levels were still ~ 20% (Humby et al., 1999). The
reduction in % omissions observed in mice is therefore consistent with the nicotine-
induced improvement in attention hypothesis proposed by Mancuso and colleagues
(1999). Whilst it appears that the 1 and 3 jUg/kg doses of nicotine enhance sustained
attention, at higher doses the physiological effects become increasingly complex
(Picciotto et al., 2003; Fig. 3.11, pp. 111). Between 10 and 100 /xg/kg the overall
trend continued to be that of a reduction in omissions, but with no effect on
proportion correct. In contrast, at 300 /xg/kg nicotine increased proportion correct
without altering % omissions. As this dose also reduced mean correct latency, this
suggests the increase in accuracy may reflect psychomotor stimulation (Grottick and
Higgins, 2000), with these mice consequently not attending to the cue array any more
than control subjects. This would be consistent with nicotine being reported to
produce motoric excitation in mice at 125 and 250 /xg/kg (Nordberg and Bergh,
1985). Further increases in nicotine dose have lead to motoric inhibition and
hypothermia (Marks et al., 1983; Fig. 3.11, pp. 111). These physiological effects
may have confounded the interpretation of studies which examined the effect of
nicotine in mice. For example improvements in active avoidance learning have been
observed in mice receiving doses of nicotine that cause hyperlocomotion (Castellano,
1976; Sasone et al., 1994), whilst improved passive avoidance learning has been
observed after doses of nicotine that induce hypothermia and thus hypolocomotion
(Zarrindast et al., 1996). However, Faiman and colleagues (1991) observed
improved passive avoidance learning in mice, following administration of similar
doses of nicotine to those used in the previous studies (1 - 30 /xg/kg; 20 - 1500 fold
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lower than the doses used by Zarrindast et al., 1996) in which no confounding
physiological effects have yet to be reported.
In conclusion I have modified the 5-CSR task so that nicotine-induced improvements
in mice sustained attention has been observed. Moreover this improvement is
consistent with that observed in humans. Therefore a protocol now exists with which
to use both pharmacological and genetic manipulations in the attempt to identify the
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Figure 3.11: Schematic representation of nicotine-induced behavioural effects in
mice
Nicotine exerts both cognitive and physiological effects that are largely dose
dependent. The present studies (sections 3.3.3 and 3.3.4, pp. 86 - 88) suggest that
low doses of nicotine (1-3 /rg/kg) produce improvements in sustained attention.
Higher doses appear to reduce mean correct latency, suggesting an enhancement of
motoric capabilities, consistent with previous studies (Nordberg and Bergh, 1985).
Doses of nicotine of 500 mg/kg and above inhibit motoric responses, with
hypothermic effects observed. A further increase to 5 mg/kg has been shown to
induce seizures in mice (Damaj et al., 1999).
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3.4.2 Impaired 5-CSR task performance of a7 nAChR knockout mice
a7 nAChR knockout (KO) mice were impaired in the acquisition of the 5-CSR task
which suggests that this nAChR may indeed be required for either normal learning,
or at least the learning of an attentional operant procedure (Fig. 3.5a and b, pp. 91).
Moreover, as the impaired performance in the task was reflected by an increase in %
omissions (Fig. 3.5c), this suggests that the a7 nAChR may also be required for
sustaining attention in normal mice. Whilst the second group of a7 nAChR KO mice
trained in the 5-CSR task did not exhibit a significant impairment in task acquisition,
the age matched littermate (WT) mice did appear to acquire the task quicker than
both the heterozygote (HT) and KO mice (Fig. 3.7a and b, pp. 96). However, whilst
no difference in baseline performance was observed for the three groups in the task
(3.7c, d and e), as observed in section 3.3.5 (Fig. 3.5c, pp. 91), the a7 nAChR KO
mice were significantly impaired in the more attentionally demanding extended
session version of the task, and again this deficit was reflected by an increase in %
omissions (Fig. 3.8a, pp. 98). Interestingly, HT mice which had 50% reduction of
[3H]-MLA binding sites, exhibited % omissions halfway between that ofWT and KO
mice, though were not significantly different from either group. Thus it appears that
task performance as measured by % omissions are robust and that it appears to be
related to the binding site density of a7 nAChRs.
It appears unlikely that the deficiencies observed for the a7 nAChR KO and HT mice
are attributable to developmental problems that are a consequence of the genetic
manipulation, as these animals have an ostensibly normal appearance; with standard
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growth, survival, gait, anatomy, and no apparent nervous system abnormalities (Orr-
Urtreger et al., 1997), sections were taken from all three groups ofmice (though KO
and WT mice shown only) and as Fig. 3.10 (pp. 104) shows, we confirmed there
were no gross abnormalities in areas deemed important to learning and 5-CSR task
performance. In addition, Paylor et al., (1998) reported no differences in the
behavioural phenotype of a7 nAChR KO mice and their WT littermates when
subjected to a battery of behavioural tests, including contextual and auditory fear
conditioning, spatial learning in the Morris water maze, and anxiety tests. However,
unexpectedly it was noted that these mice did not exhibit a sensory gating deficit in
the PPI paradigm (Paylor et al., 1998), although these results may have been
confounded by the use of female mice in the tests. As the deficit in sustained
attention observed for the a7 nAChR KO mice was in the same parameter by which
nicotine improved attention (i.e. % omissions), this suggests the al nAChR may be
central to the nicotine-induced improvement in sustained attention. Conversely if
nicotine administration had improved attentional performance in the al nAChR KO
mice this would imply that the al nAChR is not the only nAChR involved in
attention in mice. The data in section 3.3.6 (pp. 92) show that nicotine
administration did not improve performance in the al nAChR KO mice which is
consistent with a key role for this receptor in sustained attention (Fig. 3.6, pp. 93).
However, nicotine did not significantly improve the performance in the WT mice
either, despite a reduction in % omissions (Fig. 3.6a) and increase in proportion
correct (Fig. 3.6b). Overall, the studies do however suggest that the al nAChR may
play a role in mediating the cognitive enhancing effects observed with nicotine.
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One unexpected finding was that these mice performed at a slower rate than
traditionally observed (section 3.3.5, Fig. 3.5, pp. 91). Whilst this could reflect age
and task complexity (use of a wide array and variable ITI as opposed to narrow array
and constant ITI in section 3.3.5, pp. 90), in the two studies, other old mice (17.5
month) have been assessed in the wide array 5-CSR task, and they did not exhibit
such slow latencies (see section 5.3.2, Figs 5.4 and 5.5, pp. 175 and 177). The use of
the variable ITI appeared to slow performance (Fig. 3.3 and 3.4, pp. 87 and 89) but
again not to the extent observed in Fig. 3.6 (pp. 93). The relative slowing of
response to the extent observed here has only been noted when noise distracters were
employed (section 5.3.2, Figs. 5.4 and 5.5).
One possibility that needs to be considered is that unfortunately at the time this
study, major building work was being conducted on the floors below. Whilst the
mice were assessed in sound attenuating boxes during testing and training, these are
not 'sound-proof boxes, and the resulting noise which varied in intensity and
duration from day to day was likely to confound performance. Noise has been used
as a distracter in attentional tasks in man (Wolach and Pratt, 2001), monkeys (Terry
et al., 2002), rats (Robbins 2002) and mice (Humby et al., 1999; see section 5.3.2.3
and 5.3.2.4, pp. 178 - 180) with the effects dependent on the background strain
(Humby et al., 1999; see section 5.3.2; Fig. 5.4 and 5.5, pp. 175 and 177). In
addition, drilling occurred at intermittent times during testing which caused
considerable vibration in the buildings structure. This also caused the 9-hole boxes
to vibrate, an effect which was likely to distract the mice. Such tactile distracters
have been used to induce startle responses in mice and the response can vary
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depending on the background strains (Logue et al., 1997). During this period there
was a notable reduction in litter numbers throughout the mouse holding room during
building work (Dr. L. E. Kerr et al., personal communication). In conclusion, the
noise and vibrations that occurred at unpredictable times may unfortunately have
added an uncontrollable confound to the latter part of this study and made it difficult
to observe a significant effect of nicotine on the performance of WT mice. The
second a7 nAChR transgenic study (WT, HT and KO mice; section 3.3.7, pp. 94)
was designed to be a longitudinal study with nicotine administered to drug-naive
mice at 18 months. However, the baseline performance of these mice changed
following procedural difficulties and repeated testing, such that a deficit was no
longer observed in the al nAChR KO mice (see section 3.3.7, pp. 94). In conclusion
however the data supports the al nAChR as essential for maintenance of sustained
attention in mice. Furthermore the protocols I have developed in this thesis can
further assist in addressing its validity as a therapeutic target for the nicotine-induced
improvement in cognition.
There is a plethora of evidence demonstrating nicotine-induced improvements in
attention in different species. However there has been no definitive identification of
which nAChR subtype(s) underlie this effect. Several studies indicate that the al
nAChR appears crucial in maintaining pre-attention (sensory gating; Stevens et al.,
1996; 1998; Simosky et al., 2001). Schizophrenics have poor sensory gating with a
reduction in the P50 auditory evoked potential (Waldo et al., 1995). This deficiency
has been linked to a dinucleotide polymorphism on chromosome 15ql3-14, proximal
to the locus of the al nAChR gene CHRNA7 (Freedman et al., 1997; Stassen et al.,
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2000). Moreover, the DBA/2 mouse strain, which has a natural reduction in a7
nAChR density in the hippocampus, show sensory gating deficits (Stevens et al.,
1996), that can be ameliorated by treatment with the a7 partial agonist DMXBA
(GTS-21; Stevens et al., 1998; Simosky et al., 2001) and atypical anti-psychotics
(Simosky et al., 2003). DMXBA also attenuated the sensory gating deficits observed
in rats that were reared in isolation (O'Neill et al., 2003), an animal neuro-
developmental model of schizophrenia (Geyer et al., 1993). Furthermore, both
DMXBA (Kem, 2000) and the full al nAChR agonist AR-R17779 (Mullen et al.,
2000) are able to replicate the beneficial effects observed with nicotine on working
memory (Felix & Levin, 1997; Levin & Simon, 1998). In contrast, and perhaps
somewhat surprisingly, recent studies in rats suggested that AR-R17779 had no
effect on attention in the 5-CSR task (Grottick and Higgins, 2000; Grottick et al.,
2003; Hahn et al., 2003). Van Kampen and colleagues (2004) recently suggested
that these findings be re-examined. To date, independent evaluation of these agents




In conclusion, I established a modified version of the 5-CSR task for mice that
lowered baseline performance, facilitating the demonstration of an enhancement in
sustained attention following administration of low doses of nicotine. Moreover, I
have also shown that a7 nAChR KO mice have a profound and reproducible deficit
in attention. Interestingly heterozygote mice with a 50% reduction in a7 nAChR
density showed an intermediate performance level. The sensitivity of environmental
confounds and repeated testing on mouse performance in the 5-CSR task were also
highlighted. In summary, these data support the conclusion that a7 nAChRs play a
role in sustained attention in mice.
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Chapter 4 - Nicotinic modulation of working memory
4.1 Introduction
Nicotine has been shown to improve working memory performance in patients
suffering from dysexecutive syndrome (see chapter 1.3.6, pp. 26), including
Alzheimer's disease (Newhouse et al., 1988; Sahakian et al., 1989; Parks et al.,
1996) and schizophrenia (Levin et al., 1996; Smith et al., 2002). However, not all
studies report a positive effect of nicotine (Sahakian et al., 1989; Wilson et al., 1995;
Heishman and Henningfield, 2000; Harris et al., 2004). It has been proposed that
nicotine-induced improvements in working memory are more likely to be observed
when there is a high attentional load placed upon the subject during task performance
(Warburton and Rusted, 1993; Phillips and Fox, 1998; Newhouse et al., 2004; Fig.
4.1).
Studies attempting to identify the nAChR involved in nicotine's beneficial effects on
working memory have largely utilised rats and the radial arm maze (RAM; Levin et
al., 1993; Kim and Levin, 1996; Felix and Levin, 1997; Levin et al, 1999; Bancroft
and Levin, 2000; Bettany and Levin, 2001; Levin et al., 2002, Addy et al., 2003; see
chapter 1.4.4.4, pp. 45). This task is not confounded by proactive interference, as
each session does not involve repetition of similar trials. As performance becomes
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Figure 4.1: Proposed model for nAChR modulation of cognitive function
The model proposed by Newhouse and colleagues (2004), relates to the effects of
nAChR stimulation on neurotransmitter regulation and attentional function. In their
model, nAChR stimulation is presumed to lead to enhanced neurotransmitter release
in particular brain areas that are relevant to arousal, sustained attention, inhibitional
processes and processing/motor speed. Sensory selectivity is conceptualised as being
secondary to improved attentional performance. There is then an effect on the
central executive component of Baddeley's model (1986; equivalent to the
supervisory attentional system by Norman and Shallice, 1980) for working memory,
resulting in improved working memory and acquisition of information.
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The odour span task (OST), originally developed for rats (Dudchenko et al., 2000;
see section 1.4.4.5, pp. 47), is similar to the RAM as it is not subject to the proactive
interference confounds. Likewise, as a session continues, the cognitive demand
placed upon the animal increases, thereby increasing the attentional load. However,
the OST assesses non-spatial olfactory working memory by utilising randomly
located odours, whereas the RAM assesses spatial working memory by utilising
visual cues to identify location. The use of olfactory cues in the OST is potentially
advantageous as rodents exhibit preferential attendance to olfactory as opposed to
visual cues (Jennings and Keefer, 1969). Assessing olfactory memory may also
provide ethologically relevant stimuli, an importance stressed by Gerlai and Clayton
(1999) and Slotnick (2001), when phenotyping transgenic mice.
Therefore the task may prove suitable for behaviourally phenotyping the various
transgenic mouse models of Alzheimer's disease that have been created (see table
5.1, pp. 158). Moreover, several clinical groups suffer form impaired olfactory
capabilities, including Alzheimer's disease and schizophrenic patients (Kopala et al.,
1992; Wu et al., 1993; Moberg et al., 1997; Larssen et al., 1999; Devanand et al.,
2000; Kohler, 2001), which have been postulated as a possible early marker for
neurological diseases and psychosis (Kwapil et al., 1996; Martzke et al., 1997;
Devanand et al., 2000). As such the OST may provide greater phenotypic
characterisation of the transgenic mouse models of these disorders, and assess the
validity of olfactory impairments being an early marker for the disorders. The OST
could also assist in the identification of the nAChR that mediates the nicotine-
induced improvement in working memory/cognitive function, as both
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pharmacological and genetic manipulations could be utilised. However, no reports
have been published on the use of the OST in mice. Therefore during my thesis I
tried to establish the OST for use in mice. The OST was validated in caspase-3 over-
expressing mice (Kerr et al., 2004, the creation of which is detailed in Appendix I,
pp. 256) as the expression of caspase-3, the main proapoptotic effector caspase in the
CNS, is highest within the olfactory system (de Bilbao et al, 1999; Cowan et al,
2001), an area thought to mediate a rodent's ability to remember odours (Staubli et
al., 1986; Slotnick and Thanos, 1997), particularly projections to the entorhinal
cortex (Fig. 4.2). It was hypothesised that the over-expression of caspase-3 may
affect the apoptotic processes within these structures with a detrimental effect on
learning and memory, thus providing a suitable model for validation of this task.
Therefore the performance of caspase-3 over-expressing mice was assessed in this
task, and as these mice may exhibit enhanced neurodegeneration, longitudinal
performance was also measured. Finally the ability of nicotine to rescue any deficit
these mice exhibited was assessed. The effects of nicotine on the performance of
normal mice in the OST were also assessed in a group of C57B1/6J mice trained in
the task. Preliminary studies indicated that the performance of C57B1/6 mice was
excellent in the task and ceiling effects would be expected in the standard 12 odour
OST. Thus task difficulty was immediately increased to 22 odours in order to try to
observe a nicotine-induced improvement in standard performance. Finally, as the al
nAChR mice showed a deficit in the 5-CSR task it was hypothesised that they would
also exhibit impaired performance in this task due to its high attentional load.
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Figure 4.2: Schematic diagram of the central olfactory projections from the main
olfactory bulb
The olfactory bulb projects directly to the amygdala, hypothesised to mediate
emotions and hence the ease at which odours can elicit an emotional response. The
olfactory bulb also projects to the piriform and entorhinal cortices. Whilst the former
projects to the mediodorsal (MD) and submedial (SM) nuclei, then ventro-lateral
orbital (VLO) and lateral orbital (LO) cortices, the latter projects to the hippocampus
(HC). Alzheimer's disease pathology occurs early in the entorhinal cortex, perhaps
mediating the olfactory deficits observed and representing an early marker of the




4.2.1 Animal maintenance and genotyping
Three separate groups of human caspase-3 transgenic mice (Tg; C57BL/6J-
Tg(C4£P3)F18Fine, Kerr et ai, 2004) and wild type littermates (WT) were used in
the final three sections (section 4.3.1, WT n = 6, Tg n = 5, backcrossed onto a
C57B16/J background for 6 generations; section 4.3.2, WT n = 5, Tg = 5,
backcrossed onto a C57B16/J background for 8 generations; section 4.3.3, WT n = 5,
Tg n = 9, backcrossed onto a C57B16/J background for 10 generations). The average
age ofmice in section 4.3.1 was 9 mth (range 8 to 10.5 mth, weight range 25.7 - 32.9
g) at start of training and 10.5 mth when tested. The average age of mice in section
4.3.2 was 4.5 mth (range 3 to 5 mth, weight range 23.7 - 30.7 g) at start of training
and asymptotic performance was assessed at 6, 12 (weight range 27.5 - 35.4 g) and
18 (weight range 27.9 - 39.3 g) mth. The average age ofmice in section 4.3.3 was
3.5 mth (range 3-4 mth, weight range 20.2 and 26.8 g). All studies are listed in
table 4.1. The mice were all trained in the OST in accordance with section 2.3 (pp.
60). C57B1/6J male mice were used in section 4.3.4 (n = 12; Charles River, Margate,
UK). The mice weighed between 25.2 and 29.6 g at the start of the study. The mice
in section 4.3.5 comprised of a group of 5 a7 nAChR KO (B6.12957 - Chrna7tmlbay;
Jackson Laboratories, Bar Habor, U.S.A.), and 5 age-matched littermates (subset
from section 3.3.7, pp. 94; age range 17-18 mth; backcrossed onto a C57B16/J











Acquisition 9-10 6 5
Asymptote 10.5 6 5
4.3.2
Acquisition 4-5.5 5 5
Asymptote 6 5 5
Asymptote 12 5 5
Asymptote 18 5 5
4.3.3 Asymptote 5 5 9








Acquisition 17-18.5 5 5
Asymptote 19 5 5
Table 4.1: List of behavioural studies
The studies performed in this chapter are listed above. The standard 12 odour OST




4.3.1 Human caspase-3 over-expressing mice exhibit impaired working memory
The first study was conducted to assess whether mice could be trained in the
olfactory working memory task. Human caspase-3 over-expressing mice (Tg, n = 6)
and their age-matched littermates (WT, n = 5) were trained to a stable baseline
performance and the span of odours remembered (span length, number of correct
spans prior to the first error) by Tg mice was significantly shorter than the WT
(T=554.5; p < 0.05; Fig. 4.3a). Both groups were however perfect in their ability to
distinguish between only two odours (T=490; p = 0.992). Furthermore both the WT
and Tg mice completed nearly all 11 spans, with no significant difference between
groups (T=517; y? = 0.115; Fig. 4.3b). Thus whilst the Tg mice had the opportunity
to record a similar span length to the WT mice, they made their first error earlier.
The Tg mice erred significantly more often than the WT mice (T=36; p < 0.05; Fig.
4.3c), with more than one incorrect dig per session, as opposed to the WT mice
erring once every three sessions. Whilst the speed of response (mean span latency)
of the Tg mice appeared slower than that of the WT mice, it was not significant
(F(l,27) = 0.33, p = 0.58; Fig. 4.3d), and nor was there an interaction between the
two factors as measured by mean span latency (F(3,27) = 0.431, p = 0.733). To
address any possibly confounding effects such as impoverished locomotor
capabilities, the spontaneous locomotor activity counts of the two groups were
assessed and compared. Whilst the counts for the Tg were lower than that of the WT








Figure 4.3: Impaired OST performance of human caspase-3 over-expressing mice
(10.5 mth)
Performance of a group of 8 - 10.5 month old caspase-3 transgenic mice (Tg, n = 5)
and their age-matched wild type littermates (WT, n = 6) was assessed in the odour
span task. The mice were trained until a stable baseline performance had been
attained. Their performance over four days (Tuesday - Friday) was compared first
by day (no effect) then by genotype. Performance was measured by span length (a),
spans completed (b), errors per session (c), and mean span latency (d). Tg mice
exhibited a reduced span length and a significant increase in errors compared to the
WT mice. There was no difference in spans completed or mean span latency.
Neither was there a difference in spontaneous locomotor count (e). Data presented
as mean + s.e.m. (* denotes p < 0.05 when compared to WT controls).
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4.3.2 Human caspase-3 over-expressing mice exhibit impaired acquisition and
longitudinal performance of the OST
A second group of human caspase-3 over-expressing mice (Tg, n = 5) and their age-
matched littermates (WT, n = 5) mice were used to assess longitudinal task
performance. Mice were trained at 4 mth and performance assessed at 6, 12, and 18
months. The acquisition of the two groups is shown in Fig. 4.4a with the mean span
length of each group increasing as the session numbers increased. However when
the number of days to attain criteria (span length > 5 for two consecutive sessions) by
each mouse was grouped by genotype and compared, it was discovered that the Tg
mice took significantly longer than WT mice (F(l,9) = 7.827, p < 0.05; Fig. 4.4b).
In agreement with data obtained in the previous section, the span of odours attained
by the Tg mice was significantly lower than that of the WT at 6 (T=557.5; p < 0.05,
Fig. 4.5a), 12 (T=562 p < 0.05, Fig. 4.5b) and 18 mth (T=307; p < 0.005, Fig. 4.5c),
with no age-related impairment in span length evident in either group (Fig. 4.5d).
There were no significant differences in the performance of the two groups when
required to discriminate between two odours at 6 (T=450; p = 0.99), 12 (T=410; p =
0.989) or 18 mth (T=240; p = 0.768). Despite the Tg mice appearing to complete
significantly fewer spans than the WT mice at every age tested, there were no
significant differences of genotype, at 6 (T=410; p = 0.989; Fig. 4.6a), 12 (T=451; p
= 0.27; Fig. 4.6b) or 18 mth (T=479.5; p — 0.06; Fig. 4.6c). At 6 mth the increased
number of errors per session of the Tg mice in comparison to the WT mice was not
significant (T=380.5; p — 0.103; Fig. 4.7a). However by 12 mth there was a
significant genotypic difference, with the Tg mice making more errors per session
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than the WT mice (T=320; p < 0.05; Fig. 4.7b). This difference was still apparent at
18 mth, with the Tg mice producing significantly more errors than WT mice (T=177;
p < 0.05; Fig. 4.7c). Analysis of mean time taken to complete a span (mean span
latency) found no significant difference between the two genotypes at any age
(F( 1,16) = 0.272; p = 0.616; Fig. 4.8). In contrast, a significant effect of age was
detected (F(l,16) = 9.171; p < 0.005; Fig. 4.8), with post hoc analysis revealing that
mean span latency at 12 and 18 mth was significantly slower than at 6 mth (p <
0.05). Although time taken to engage in the task appeared longer when assessed at
12 and 18 mth when compared to performance at 6 mth, this apparent difference was
not significant (F(2,16) = 0.513, p = 0.608). Similarly no significant genotypic
effects were found when time taken to engage in the task was compared (F(l,16) =
0.509, p = 0.496; Fig. 4.9). Nor was there any significant interactions between day
and genotype in mean span latency (F(2,16) = 0.826, p = 0.456) or in the time taken
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Figure 4.4: Impaired OST acquisition of human caspase-3 over-expressing mice (4 -
5.5 mth)
Acquisition of the OST by a group of caspase-3 transgenic mice (Tg, n =5) and their
age-matched wild type littermates (WT, n = 5; mean age during acquisition = 4 - 5.5
mth). Acquisition of the task was set at a span length (number of correct spans prior
to error) of 5 for two consecutive days. The acquisition curve of each group is
shown in (a) as span length by session number. The Tg mice appeared to take longer
to reach a span length of 5 on two consecutive days in comparison with the WT
mice. This difference was statistically significant as with the Tg mice taking longer
to attain criteria than the WT mice (b). Data presented as mean + s.e.m. (* denotes p
< 0.05 when compared with WT mice).
129
Chapter 4
Figure 4.5: Span length measures from mice in study 2 in standard and extended
odour span task.
Longitudinal performance (mean ages 6, 12, and 18 months) of a group of caspase-3
transgenic mice (Tg, n = 5) and their age-matched littermates (WT n = 5) in the
odour span task as measured by span length. At each age, performance was
measured over four consecutive days (Tuesday - Friday). Span length was measured
at 6 (a), 12 (b) and at 18 months (c). Performance in the standard task at each age is
presented together (d). The Tg mice exhibited a significantly reduced span length
when compared with the WT mice at every age tested. Data presented as mean ±




























Figure 4.6: Spans completed data from mice in study 2 in the standard odour span
task
Longitudinal performance of a group of caspase-3 transgenic mice (Tg, n = 5) and
their age-matched wild type littermates (WT, n = 5) in the odour span task as
measured by spans completed. Performance was measured over four consecutive
days (Tuesday - Friday) at 6 (a), 12 (b), and 18 months (c). No effects of genotype
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Figure 4.7: Errors per session data from mice in study 2 in standard odour span task
Longitudinal performance of a group of caspase-3 transgenic mice (Tg, n = 5) and
their age-matched wild type littermates (WT, n = 5) in the odour span task as
measured by errors made per session. Performance was measured over four
consecutive days (Tuesday - Friday) at 6 (a), 12 (b) and 18 months (c). At 6 months
of age there was no significant difference in errors made. However when reassessed
at 12 and 18 months the Tg mice made significantly more errors per session than did





Figure 4.8: Mean correct latency from longitudinal odour span task study.
Longitudinal performance (mean ages 6, 12, and 18 months) of caspase-3 transgenic
mice (Tg, n = 5) and their age-matched wild type littermates (WT, n = 5) in mean
span latency. At each age tested, performance was measured over four consecutive
days (Tuesday - Friday). While no effect of genotype was observed, there was a
significant effect of age with latency at 12 and 18 months significantly slower than at




Figure 4.9: Time taken to engage in the task from longitudinal odour span task study.
Longitudinal performance (mean ages 6, 12, and 18 months) of caspase-3 transgenic
mice (Tg, n = 5) and their age-matched wild type littermates (WT, n = 5) in mean
time taken to first response. At each age tested, performance was measured over
four consecutive days (Tuesday - Friday). No effect of genotype or age was
observed. Data presented as mean + s.e.m..
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4.3.3 (-)Nicotine improves OST performance of human caspase-3 over-expressing
mice
The previous studies identified a consistent OST deficit as measured by a reduced
span length in mice over-expressing human caspase-3. A group of human caspase-3
over-expressing mice (Tg, n = 9) and their age-matched littermates (WT, n = 5) were
trained to perform the OST. The performance of the two groups was compared over
a four day period (Tuesday - Friday) once the two groups had attained a stable level
of performance. As had previously been observed, the Tg mice exhibited a
significantly lower span length than the WT mice (T=566,p < 0.05; Fig. 4.10a), with
no significant differences in the number of spans the two groups completed (T=459,
p = 0.875; Fig. 4.10b). There was no significant difference in the ability of the Tg
mice when compared to the WT mice in their ability to discriminate between two
odours (T=592, p = 771). The Tg mice again erred significantly more per session
than the WT mice (T=4475,/> < 0.05; Fig. 4.10c). As observed previously when the
two groups were assessed on their performance speed, no significant differences
were observed in mean span latency (F(l,35) = 2.235, p = 0.153; Fig. 4.10d).
Interestingly the time taken by the Tg mice to engage in the task was significantly
less than the WT mice (F(l,35) = 18.039, p < 0.01; Fig. 4.10e). This however
appeared to reflect three mice in the WT group taking longer than the other WT
mice. Once these mice engaged in the task, they performed similarly to the other
WT mice. No reason for their increased time was discovered.
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Figure 4.10: Human caspase-3 over-expressing mice exhibit a deficit in performance
in the OST
A group of human caspase-3 over-expressing mice (Tg, n = 9) and their age-matched
littermates (WT, n = 5) were trained to perform the OST. Once at asymptote the
performance of the two groups was compared over four consecutive days (Tuesday -
Friday). As observed previously, the Tg mice exhibited a significant impairment in
the task as measured by span length (a). No effect of genotype was observed in
spans completed (b). The Tg group did err significantly more often than the WT
mice (c). No significant differences in mean span latency (d) were observed, but the
Tg mice took significantly less time to engage in the task than the WT mice (e).
Data presented as mean + s.e.m. (* denotes p < 0.05 when compared to WT mice).
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The ability of nicotine to normalise the working memory performance of the Tg mice
was then assessed. The following week every mouse was injected (s.c.) with saline
for three days (Thursday, Friday, and Monday). The Tg mice were then split into 2
groups in a counter-balanced design. One group were administered saline (s.c.), as
were the WT mice, whilst the other Tg group was administered (s.c.) (-)nicotine (3
/xg/kg) on the following four days (Tuesday - Friday). The impaired performance of
mice over-expressing human caspase-3 was again observed in this study. A
significant difference of working memory capacity (span length) was observed
between the three groups (H = 15.9; p < 0.001; Fig. 4.11a), and a multiple
comparison procedure (Dunn's Method) was used to isolate the groups that differed.
The Tg mice administered saline exhibited a significantly lower span length than the
control (WT + saline) mice {p < 0.05). However, the Tg mice administered (-
)nicotine (3 ptg/kg) did not significantly differ from the control mice (p > 0.05).
There were no differences in spans completed as all three groups completed all 11
spans within the time limit (H = 0, p = 1.0; Fig. 4.1 lb). The Tg mice administered
saline made significantly more errors than both the WT mice and the Tg mice
administered (-)nicotine (H = 23.2, p < 0.001; Fig. 4.1 lc). No significant differences
were observed in mean span latency (F(2,33) = 3.338; p = 0.074; Fig. 4.1 Id) and
despite both Tg groups apparently starting the task faster than the WT mice, there
was no significant difference in time taken to first sample (F(2,33) = 1.346; p = 0.3;
Fig. 4.1 le). Nor were there significant interactions between day and drug for mean
span latency (F(2,16) = 1.594,p = 0.158) or mean time to engage in the task (F(3,35)
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Figure 4.11: (-)Nicotine improves performance of human caspase-3 over-expressing
mice in the OST
A group of human caspase-3 over-expressing mice (Tg, n = 9) and their age-matched
littermates (WT, n = 5) were trained to perform the OST. Once at asymptote the
mice were split into three groups, both the WT and one Tg group received saline,
whilst the other Tg group received nicotine (3 /rg/kg; Tg + N) in a counter-balanced
design. Mice were administered saline (s.c.) for three consecutive days (Thursday,
Friday and Monday), then their allocated dose for four consecutive days (Tuesday -
Friday). As observed previously, the Tg mice exhibited a significant impairment in
the task as measured by span length (a). However the Tg + N mice did not differ
significantly from the WT mice. No effect of nicotine or genotype was observed in
spans completed (b). The Tg group did err significantly more often than the WT
mice, whereas the Tg + N mice did not (c). No significant differences in
performance were observed in any other measure including mean span latency (d) or
mean time taken to engage in the task (e). Data presented as mean + s.e.m. (*
denotes p < 0.05 when compared to WT mice).
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A group of C57B1/6J mice (n = 12) were trained to perform the odour span task
(OST). They advanced through training rapidly and very quickly attained criteria of
a span length of 5 for two consecutive days. Training continued until a stable level
of performance was reached and the mice were split into three groups in a counter¬
balanced design. All three groups were then administered saline (s.c.) for three days
(Thursday, Friday and Monday). Despite relatively slow response times in
comparison to other studies (see section 4.3.1, 4.3.2, 4.3.3), the majority of the mice
completed a full session within the time limit, with their span length performance
near perfect (8.7 ± 0.7) and spans completed almost maximal (10.0 ± 0.4). Taking
cognisance of the ceiling effects observed during testing in the 5-CSR task, the
difficulty of the task was increased by increasing the odour number from 12 to 22 for
the following four testing days (Tuesday - Friday) during saline or (-)nicotine (3 or
300 /rg/kg) administration. Analysis of span length over this period revealed no
significant effect of drug dose on span length (H=2.573, p = 0.276; Fig. 4.12a),
despite an apparent increased span length of mice given 3 jUg/kg (-)nicotine when
compared to saline. There was however a significant main effect of drug on spans
completed (H=12.634, p < 0.05; Fig. 4.12b). Dunn's method for post hoc
comparison identified that both the 3 and 300 /rg/kg dose of nicotine increased the
total number of spans completed in comparison to the saline group. There appeared
to be a differential effect of the two doses of nicotine on the number of errors made,
with the 3 /rg/kg dose reducing, and the 300 /rg/kg increasing the number of errors in
comparison to the saline group. Flowever this effect was not significant (H=2.496, p
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= 0.287; Fig. 4.12c). The ability of the three groups to discriminate between two
odours also did not differ (H=2, p = 0.368). The two groups (3 and 300 /xg/kg)
receiving (-)nicotine were faster per span than the saline group, although this drug
effect was not significant (F(2,17) = 3.878, p = 0.082; Fig. 4.12d). The increase in
speed of performance was also apparent with the 3 /xg/kg group, but not the 300
/xg/kg group, compared to saline, when the time taken to engage in the task was
assessed, but again this was not significant (F(2,17) = 0.828, p = 0.481; Fig. 4.12e).
Nor was there a significant interaction between the two factors in mean span latency
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Figure 4.12: (-)Nicotine altered the performance of C7B1/6J mice in the 22-OST
A group of C57B1/6J mice (n = 12) were trained in the OST until a stable level of
performance was attained. The mice were split into three groups, saline and (-
)nicotine (3 and 300 /xg/kg) in a counter-balanced design. Saline was administered
three days (Thursday, Friday and Monday) prior to testing, after which the allocated
dose was administered for four consecutive days (Tuesday - Friday). Neither dose
of nicotine had any effect on span length (a). However, both the 3 and 300 pg/kg
dose of (-)nicotine increased the number of spans completed, (b). No effect of either
dose was observed in any other measure including mean number of errors per session
(c), mean span latency (d) or mean time to first sample (e). Data presented as mean
+ s.e.m. (* denotes p < 0.05 when compared to saline group).
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4.3.5 a7 nAChR knockout mice exhibit poor working memory
A group of a7 nAChR knockout (KO) mice and their age-matched littermates (WT)
were trained to perform the OST (mean age = 17 mth). Their acquisition (number of
days to criteria) and asymptotic performance (assessed over four consecutive days;
Tuesday - Friday) in the task was compared. a7 nAChR KO mice exhibited a lower
span length across session days of training when compared to the WT mice (Fig.
4.13a). The number of days the individual mice took to reach criteria (span length >
5 for two consecutive days) was grouped according to genotype and compared and
the number of days taken by the a7 nAChR KO mice was significantly longer than
the WT mice (t = 2.571, p < 0.05; Fig. 4.13b). During asymptotic performance (19
mth) the a7 nAChR KO mice exhibited a significantly lower span length (T=540.5, p
< 0.001; Fig. 4.14a) and number of spans completed (T=556.5,/? < 0.001; Fig. 4.14b)
than the WT mice. The number of errors made did not differ significantly between
the two groups (T=432.5, p = 0.55; Fig. 4.14c), nor did their ability to discriminate
between two odours (T=410, P = 0.989). The a7 nAChR KO mice exhibited a
significantly longer mean span latency (F(l,24) = 5.989; p < 0.05, Fig. 4.14d), and
whilst this difference in latency was apparently reflected in the time they took to
engage in the task, this was not significant (F(l,24) = 4.105; p = 0.077; Fig. 4.14e).
There was also no significant interactions between the two factors as measured by
mean span latency (F(3,24) = 2.935, p = 0.054) or time taken to engage in the task
(F(3,24) = 1.163,^ = 0.344).
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Hence the a7 nAChR KO mice appeared simply to be taking longer to complete the
task than the WT mice. They may have been less motivated to perform the task than
the WT mice, although they did not exhibit differences in motivation (as measured
by mean reward latency) whilst performing the 5-CSR task (data not shown). Also,
when assessed on their latency to retrieve 10 pellets in a simpler environment (in a
clear cage on the table; training days 3-6; see chapter 2.3.3, pp. 62), the time taken
by the a7 nAChR KO mice to retrieve all 10 pellets did not differ from the WT mice
(T=19, p = 0.095; Fig 4.14f). Whilst it would have been beneficial to assess
nicotine's effects on performance of the a7 nAChR KO and WT mice, it was deemed
that the group sizes were too small and as such the study would have been
statistically underpowered. The mice were therefore killed as a part of the














Figure 4.13: a7 nAChR knockout mice exhibit impaired acquisition of the OST
A group of cc7 nAChR knockout (KO, n = 5) and age-matched littermate (WT, n = 5)
mice were trained to perform the OST. Shown in (a) is the mean span length of each
group across the session days they were trained. As can be seen by the graph the KO
mice appeared to take longer to learn the task. The number of days taken by the KO
mice to attain criteria (span length > 5 for 2 consecutive days; dotted line) was
significantly more than the WT mice (b). Data presented as mean +sem (* denotes p
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Figure 4.14: a7 nAChR KO mice exhibit impaired working memory
Once the a7 nAChR knockout (KO, n = 5) mice and their age-matched littermates
(WT, n = 5) had attained asymptote, their performance over four consecutive days
(Tuesday to Friday) was compared. The KO mice exhibited a significantly reduced
span length when compared with the WT mice (a) and they also completed
significantly fewer spans in total (b). However the KO mice did not make
significantly more errors per session than the WT mice (c). There was a significant
increase in mean span latency in the KO mice when compared to the WT mice (d).
The time taken by the KO mice to engage in the task to obtain the first pellet reward
did not differ from the WT mice (e), nor did the length of time they took to retrieve
ten pellets in a simplified environment (f). Data presented as mean + s.e.m. (*




Mice can acquire this adapted odour span task (OST). Furthermore the data show
that the task can be used to assess both pharmacological and genetic manipulation.
Moreover the results also demonstrate the synergy between working memory and
attentional performance in mice, and provide additional evidence that an awareness
of the attentional load employed in a task is essential.
The olfactory working memory span observed for mice was comparable to that of
rats (Dudchenko et al., 2000). In the original publication, the possibility that the rats
could smell the reinforcement through the digging medium (sand) was discounted
when tested in a non-baited probe session. Hence the use of sand appeared to be
successful in masking the rewards' scent. Initial attempts to train the mice to dig in
sand were unsuccessful. However, although not systematically examined, similar
observations in non-baited probes for mice suggested the use of woodchip (with
crushed pellet rewards) was a viable alternative to sand as a digging medium for
mice, sufficiently masking the smell of the reinforcement. Also randomly removing
every third bowl on the table ensured that the mice could not scent mark the bowls
they had already visited. The excellent level of performance of rodents (mice and
rats; Dudchenko et al., 2000) in this task was expected as rodents exhibit preferential
attendance to olfactory, as opposed to visual cues (Jennings and Keefer, 1969). Also,
previous research demonstrates that rats trained to olfactory stimuli acquire a
learning set as rapidly as primates in response to visual stimuli (Slotnick and Katz,
1974; Lu et al., 1993).
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4.4.1 Nicotine and working memory in human caspase-3 over-expressing mice
Whilst it is evident that mice can readily acquire the odour span task, the over-
expression of human caspase-3 appears to be detrimental to performance in this task.
In the initial study (section 4.3.1, pp. 132) the littermate mice exhibited a span length
(number of correct spans prior to an error) of ~ 10, whilst the human caspsase-3
over-expressing mice could only reach ~ 7 (Fig. 4.3a, pp. 126). This was not simply
attributable to the human caspsase-3 over-expressing mice completing significantly
fewer spans than their littermates due to time constraints, as there were no
differences in the spans completed (~ 11 vs. ~ 10 respectively; Fig. 4.3b, pp. 126).
Such a genotypic difference in span length could therefore only be accounted for by
the human caspsase-3 over-expressing mice erring earlier in a session than their
littermates. In accordance, the human caspsase-3 over-expressing mice also erred
significantly more often (Fig. 4.3c, pp. 126). The difference observed in mean span
latency (Fig. 4.3d, pp. 126) was not significant, thus combined with the lack of
locomotor count differences between the two groups (Fig. 4.3e, pp. 126) suggest that
any differences observed between the two groups are not due to motoric confounds.
Finally, despite the preferential expression of caspase-3 in the olfactory system
(Cowan et al., 2001) and its importance for cell turnover which has been shown to be
important for odour discrimination (Gheusi et al, 2000), the over-expressing mice
could discriminate between two odours as readily as their age-matched littermates,




The results from section 4.3.2 (pp. 134) support the findings that human caspase-3
over-expressing mice can discriminate between two odours as readily as their
littermates. They also provide support that the performance deficit observed in the
human caspase-3 over-expressing mice is reproducible and apparently age-unrelated
(Fig. 4.5, pp. 130). Whilst the biology of this impairment is still being established,
this deficit can be attenuated by nicotine administration at doses that enhance
sustained attention (3 /xg/kg, chapter 3.3.3, pp. 86). The human caspase-3 over-
expressing mice given nicotine exhibited fewer errors and an improved span length
equivalent to that of their age-matched littermates administered saline (Fig. 4.11, pp.
138). This clearly shows that nicotine can improve working memory deficit
observed in human capsease-3 over-expressing mice who have no known cholinergic
dysfunction, therefore providing a new tool for assessment of putative cognitive
enhancers. Nicotine-induced improvements in working memory have been observed
in a variety of species including mice (Maviel and Durkin, 2003), rats (Levin et al.,
1993), monkeys (Buccafusco et al., 2003) and man (Phillips and Fox, 1998).
Observing consistent improvements in humans has proven arduous. Whilst
beneficial effects on working memory have been observed in some studies
(Newhouse et al., 1988; Sahakian et al., 1989; Levin et al., 1996; Philips and Fox,
1998; Smith et al., 2002) others report no effect, (Heishman and Henningfield, 2000;
Ernst et al., 2001; Min et al., 2001), or performance deficits (Park et al., 2000).
Procedural differences have been cited as possible confounding effects when
comparing studies (Phillips and Fox, 1998; Park et al., 2000), with impairments
generally reflecting the degree of proactive interference in the task (Dunnett and
Martel, 1990; Levin et al., 1997; Park et al., 2000) and improvements only occurring
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if the task had a sufficiently high degree of attentional load placed upon the subjects
(Phillips and Fox, 1998). Therefore there is considerable evidence that supports the
hypothesis that the main cognitive effect of nicotine is to enhance attention (Rusted
and Eaton-Williams, 1991; Mancuso et al., 1999; Newhouse et al., 2004; Fig. 4.1,
pp. 118). Levin and colleagues that the main cognitive effect of nicotine in humans
is that of enhanced attention in spite of their excellent reports on the effects of
nicotine on rat working memory performance in the RAM (see reviews Levin and
Simon, 1998; Rezvani and Levin, 2001; Levin 2002). However the high attentional
load employed in the RAM may provide evidence that suggests that nicotine-induced
improvement in attention in rats. The OST places a high attentional component on
the subjects performing the task. Thus the improvement seen with nicotine in the
human caspase-3 over-expressing mice may reflect an enhanced ability of these mice
to attend to the task, for the duration of the session. Interestingly human caspase-3
over-expressing mice did not exhibit impaired sustained attention in the 5-CSR task
(Kerr et al., 2004). However, they were not subject to any task challenges (Dr. C.
Spratt personal communication). Therefore their apparent lack of impaired
performance in the 5-CSR task may have been a consequence of ceiling effects (see
chapter 3.3.1, pp. 81). Hence, an attentional component cannot yet be ruled out in
the impaired performance of mice over-expressing human caspase-3 in the OST and
in the improvements observed with nicotine. Human caspase-3 over-expressing mice
in the OST could therefore be used to assess nAChR selective compounds, as and
when they become available, to identify the nAChR(s) underlying the beneficial
effects observed.
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In cognisance of the ceiling effects of the C57B1/6J mice discussed and observed
previously (Vorhees, 1991; chapter 3.3.1 to 3.3.4, pp. 81 to 88) the difficulty of the
task was increased during testing. Nicotine (3 and 300 /xg/kg) significantly enhanced
the number of spans completed when compared to the control mice, suggesting the
low spans completed was not as a result of using the same time limit as that in the
12-OST. Nor was it due to an increased number of errors, as those observed (~ 1)
were comparable to other studies (~ 1, chapter 5.3.3, pp. 184). The increased
number of spans completed could have been as a result of the trend for nicotine at
both doses to reduce mean span latency (p = 0.082). Whilst hyperlocomotion has
been observed at higher doses of nicotine (125 and 250 /xg/kg, Nordberg and Bergh,
1985) no effect has been observed other than that of enhanced sustained attention
(see chapter 3.3.3, pp. 86). The 300 /xg/kg dose of nicotine may have increased
speed, facilitating an increase in spans completed. The 3 /xg/kg dose appears to have
exerted a different effect as there was a trend for increased span length, reduced
errors, and a faster time to engage in the task. This could reflect enhanced
attentiveness to the task and thus the more rapid progression through the task when
compared to mice administered saline. If so it would provide further evidence that
nicotine might enhance cognitive performance by enhancing attentive processing
(Mancuso etal., 1999; Newhouse et al., 2004; Fig. 4.1, pp. 118).
The performance of a7 nAChR KO mice in the OST appear to provide further
support for this hypothesis, as the pattern of deficit does not appear to simply reflect
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an impairment in working memory capacity. There appeared to be a general slowing
of response, resulting in a working memory span deficiency, possibly as a result of
task cessation due to the time limit imposed upon the subjects. Their impairment in
sustained attention (chapters 3.3.6 and 3.3.7, pp. 92 and 94) could be responsible for
the increased mean span latency and thus reduced span length and total spans
completed exhibited. Overall the a7 nAChR KO mice appeared as active as their
littermates, but simply did not select a bowl to dig in as readily as the WT mice
(personal observations). Verification of the foraging paths taken by the a7 nAChR
KO mice would possibly corroborate such an hypothesis. Etho-Vision equipment
that monitors the paths taken by rodents performing the Morris Water Maze should
perhaps be included in any future OST studies. Future studies could include a
longitudinal assessment of OST performance in these mice, corroborating the deficit
observed here. Ideally larger group sizes would be preferred, for nicotine could be
administered to half of the a7 nAChR KO group to assess whether it could improve
performance in mice lacking the a7 nAChR. This was not possible in the present
study due to low group sizes and mice being required for histopathological analysis.
al nAChR transgenic mice exhibit low fertility rates (Orr-Urtreger et al., 1997) and
this combined with the detrimental effects of building work severely affected the
breeding program, curtailing the possibility of retraining a new group of al nAChR
transgenic mice.
No weight differences between the KO and WT mice were observed (data not
shown), nor were there any differences in their latencies to collect the reward in the
5-CSR task (data not shown), a putative index of motivation (Robbins, 2002).
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Moreover, the time taken by the two groups to retrieve 10 pellets in a simplified
version of the task (Fig. 4.14f, pp. 145) did not differ significantly, suggesting that in
a simpler environment the a.7 nAChR KO mice do not take longer to complete a
similar task. However it would also be interesting to assess the motivation of these
mice to collect a reward using a fixed ratio breakpoint study, which can be
established in the 5-CSR task equipment. This would provide further information on
whether the slowing of response and thus impaired performance observed was due to
different motivational levels
Impairment in attention does however fit the model of nicotinic receptor stimulation
proposed by Newhouse and colleagues (2004), whereby a baseline loss of
stimulation may impair attention, filtering down to impaired working memory (Fig.
4.1, pp. 124). This would also be consistent with the nAChR loss observed in
patients with Alzheimer's disease (see chapter 1.2.2, pp. 13) whom also exhibit a
reduced working memory span when the attentional load in the task is increased
(Bayles, 2003). The concomitant improvements observed following nicotine
administration may therefore reflect enhancement of that attention (Phillips and Fox,
1998; Newhouse et al., 2004).
Levin and colleagues have utilised the radial arm maze (RAM - a task with a high
attentional load, see chapter 1.4.4.4, pp. 45) plus a variety of nAChR
agonist/antagonist and lesion studies in an attempt to delineate the nAChR that
mediates nicotine-induced improvement in cognition (Levin et al., 1993; Kim and
Levin, 1996; Felix and Levin, 1997; Levin et al., 1999; Bancroft and Levin, 2000;
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Bettany and Levin, 2001; Levin et al., 2002, Addy et al., 2003). Ceiling effects
complicating rat performance in the RAM requiring baseline performance to be
artificially impaired (Levin, 2002). Levin's group have shown that blockade of both
the a7 and a4[32 nAChR (MLA and DH[3E, respectively) produces working memory
impairment in the RAM (Felix and Levin, 1997; Bancroft and Levin, 2000; Bettany
and Levin, 2001). Furthermore, in the presence of MLA, nicotine does not improve
working memory, but in the presence of DHpE, nicotine did improve working
memory in the RAM (Bancroft and Levin, 2000; Bettany and Levin, 2001). Thus
suggesting that it is the al nAChR. that mediates the nicotine-induced performance
observed in this task. However, as mentioned previously (see chapter 3.1, pp. 76),
the administration of cholinergic drugs may be confounded by the lack of receptor
subtype selectivity, as MLA also inhibits the 5HT3 and P2X3 receptors (Papke et al.,
2004; Lalo et al., 2004).
Agonist studies also provide support for the al nAChR in nicotine-induced
improvements in working memory. Kitagawa and colleagues (2003) administered 3-
(2,3-dimethoxybenzylidine)anabaseine (DMXBA or GTS-21), an al nAChR partial
agonist (also an a4p2 nAChR antagonist), to healthy human male volunteers and
found it improved working memory, attention and episodic memory. Previously,
Arendash and colleagues (1995a) found that whilst DMXBA did not improve
working memory in aged (22 months) rats in a 17-arm RAM due to ceiling effects
(-90% correct), it did improve learning and reference memory. These results were
similar to the effects observed with chronic nicotine administration (Arendash et al.,
1995a,b). Administration of AR-R17779, a full al nAChR agonist (Mullen et al.,
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1995), was shown to improve learning in the 8-arm RAM (Levin et al., 1999).
Similarly to nicotine in the 8-arm RAM, AR-R17779 administration also reversed
the working memory deficit induced by fimbra-fornix lesion (Levin et al., 1993;





In conclusion, the OST, a test of non-spatial olfactory working memory capacity was
established in mice and can therefore be used to assess both pharmacological and
genetic manipulations in mice. Nicotine administration improved working memory
performance in human caspase-3 over-expressing mice, who exhibit a deficit in this
task, and in C57B16/J mice. The dose (3 /xg/kg) used to improve working memory
performance was identical to a dose that enhanced sustained attention (chapter 3.3.3,
pp. 86). The impaired performance working memory performance of a7 nAChR KO
mice in the OST, may indicate poor sustained attention during the task as opposed to
simply a reduced olfactory working memory capacity. The findings therefore
provide support for the hypothesis that the effects of nAChR manipulation on
working memory may be mediated primarily through their manipulation of attention.
Thus these studies again provide data in support of the hypothesis, that the a7
nAChR may have a role in producing the beneficial effects of nicotine.
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Chapter 5 - Behavioural Phenotyping Tg2576 model of Alzheimer's disease
5.1 Introduction
Alzheimer's disease (AD) is a debilitating neurodegenerative disorder that manifests
as a premature cognitive decline in the elderly (Cummings, 2004). Amyloid-[3 (Ap)
plaque deposition, neurofibrillary tangles (NFTs) and cholinergic degeneration are
the central hallmarks of this disease. Whether the cognitive decline observed is a
result of cholinergic dysfunction, NFTs, Ap deposition, or a combination of any
three is still the subject of much debate. There is now some evidence to suggest that
impaired processing of the amyloid precursor protein (APP) may underlie Ap plaque
deposition, cholinergic dysfunction and NFTs, resulting in cognitive decline (Hardy
and Selkoe, 2002; Cummings, 2004; Selkoe, 2004; chapter 1.2.2 and Fig. 1.1, pp.
16). Support for the 'amyloid hypothesis' of AD stems in some part from genetic
analysis of patients with familial AD (which accounts for 5 - 10% of all cases of
AD; Tanzi, 1999). Mutations in APP, preselinin and apolipoprotein E (ApoE) genes
have been discovered and are all thought to contribute to AP plaque (Goate et al.,
1991; Mullan et al., 1992; Van Broeckhoven et al., 1992; Levy-Lahad et al., 1995;
Sherrington et al., 1995; Selkoe and Hardy, 2002; Rocchi et al., 2003; Gotz et al.,
2004; Selkoe, 2004; see chapter 1.2.2, table 1.1, pp. 19).
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The identification of genetic mutations that produce familial AD has led to the
creation of several transgenic models of the disease, in a variety of species. These
include the fruit fly Drosophila melanogaster (Shulman et al., 2003), the nematode
Caenorhabditis elegans (Anderton, 1999) and mice Mus musculus (table 5.1).
Whilst creating transgenic models in mice is the most challenging, they do however
offer the greatest construct and face validity (Gotz et al., 2004). A large variety of
different AD transgenic mouse models have been created, with each varying in the
degree to which they resemble the cause of the disease (construct validity) and the
appearance of the disease (face validity). The mouse lines generated have been
based upon both the mutations observed in familial AD, such as the London and
Swedish mutations (Goate et al., 1991; Mullan et al., 1992), but also on common risk
factors observed in idiopathic AD such as the ApoE4 gene, and on mutations in tau










Quon et al., (1991);
Moran et al., (1995)
Express A(3; age related impairments in Y-maze






Games et al., (1995);
Chen et al., (2000)
Express A(3 @ 7 mth; presence of age related and unrelated
impairments in spatial memory and learning as measured by





Hsiao et al., (1996);
Chapman et al.,
1999) King et al.,
(1999)
Express A(3 @ 6-8 mth; presence of age related and
unrelated impairments in spatial memory; no neuronal loss;









Express A3 @ 6 mth; plaques immunoreactive for
hyperphosphorylated tau, reminiscent of an early tau





Janus et al., (2000);
Chishti et al., (2001)
Impaired spatial reference learning and memory at 3 mth.
R406W Tau mutant Tatebayashi et al.,
(2002)
Development of forebrain NFTs by 18 mth with poor
associative learning by 16-23 m; little cognitive testing
performed; do not develop A3 deposition.
P301S Tau mutant Allen et al., (2002)
Develop NFTs in the spinal cord by 5-6 mth, and exhibit
severe paraparesis, thus no cognitive testing performed; do
not develop A3 deposition.
P301L Tau mutant
Fewis et al., (2000);
Arendash et al.,
(2004)
Develop widespread NFTs (spinal cord, brainstem &
forebrain) by 6.5 mth leading to progressive motoric
impairments and death, thus no cognitive testing performed;




Development of NFTs within the hippocampus by 10
months; no A3 deposition or cognitive impairment.
TAPP Tg2756X
P301L cross
Lewis et al., (2001)
Expresses A3 and NFT; A3 similarly to Tg2576; NFT
intensified in comparison to P301L; exhibit retinal
degeneration severely limiting possibilities for cognitive
assessment.
Table 5.1: Common transgenic mouse models of Alzheimer's disease
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It was only a little over ten years ago that Quon and colleagues (1991), developed the
first APP transgenic mice (NSE:P-APP751) that exhibited Ap deposition. In 1995,
Games and colleagues successfully expressed high levels of the V717F mutant form
of APP, under control of the platelet derived growth factor (PDGF) mini-promoter.
These 'PDAPP' mice exhibited a number of the characteristics of AD including Ap
deposition in the hippocampus that spread into cortical areas. Impairment in spatial
learning in the MWM appeared to be age-independent, occurring in both young (pre-
Ap deposition) and older (post-Ap deposition) mice (Games et al., 1995).
Subsequent modifications of the task that increased subtlety, identified an age-related
impairment (Chen et al., 2000). Hsiao et al., (1996) developed mice that expressed
the Swedish mutation (Mullan et al., 1992) by inserting it into a hamster prion
protein cosmid vector. The resulting Tg2576 line exhibited Ap plaque deposition,
with age-dependent impairments in spatial learning and memory, assessed in the Y-
maze and the MWM which corresponded to a 14-fold increase in Ap plaque
deposition (Hsiao et al., 1996). However, no tau pathology or neuronal loss is
evident in either PDAPP or Tg2576 mice. In 1997 Sturchler-Pierat and colleagues,
created APP23 mice that had a seven-fold increase in APP expression with plaques
appearing at 6 months of age. These plaques were immunoreactive for
hyperphosphorylated tau, reminiscent of an early tau pathology (Boincrisstiano et al.,
2002). Unlike the Tg2576 and PDAPP lines, the APP23 mice exhibit neuronal loss,
with a 14% reduction in CA1 pyramidal neurons (Dickson, 2004). Schmitz and
colleagues (2004) developed an APP/PS1 double-transgenic mouse line (Swedish
and London mutations crossed with PS1 transgenics), which have AP deposition and
neuronal loss, although they have yet to be behaviourally phenotyped. Other
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transgenic mice with altered APP processing also include such as the TGCRND8 and
J20 mice (Janus et al., 2000; Mucke et al., 2000). Initial attempts to produce
preselinin 1 (PS1) knockout mice resulted in lethality that could be rescued by the
expression of the mutated PS1 A246E (Shen et al., 1997). Preselinin 2 (PS2) KO
mice were viable however there are minor complications such as mild pulmonary
fibrosis (Herreman et al., 1999). Although combined mutations of APP and
preselinin genes have not yet been identified in any Alzheimer's disease patients,
APP and PS1 bigenic mice have been created by crossing Tg2576 mice with the PS1
mutant A264E, resulting in elevated Ap deposition levels and a more rapid
deposition rate (Borchelt et al., 1996; 1997). Expression of mutant APP on an
ApoE4 KO background did not effect the age of Ap deposition onset, but did reduce
the number of diffuse Ap plaques (Bales et al., 1997). APP V717F mutant mice on a
null ApoE background developed Ap plaque deposits by 9 months, but at lower
levels (Holtzman et al., 1999). On a human ApoE3 and ApoE4 background, these
mice did not deposit Ap until 15 months, with a 10 fold greater deposition level was
observed in the ApoE4 mice (Holtzman et al., 1999).
When ApoE4 was expressed in neurons of transgenic mice they exhibited tau
hyperphosphorylation but unfortunately had motor problems, muscle loss and
premature death (Tesseur et al., 2000). Tau transgenics that express NFTs have also
been created such as the P301L, P301S and R406W mutants and exhibit varying
degrees of cognitive and motoric impairment but no Ap plaque deposition (Lewis et
al., 2000; Allen et al., 2002; Tatebayashi et al., 2002). Crossing the Tg2576 APP
mutant mice with the P301L tau mutant mice created a line (TAPP mice) that
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exhibited both Ap plaque deposition and neurofibrillary tangles (Lewis et al., 2001).
However, these mice show reduce viability and exhibit both retinal and motoric
degeneration making cognitive assessment extremely complex (Lewis et al., 2001;
Arendash et al., 2004).
It is clear that all these mice have different limitations, however the transgenic line
used will be governed by the research goals. Any attempt to identify a vaccine that
will modify the histopathological hallmarks of AD, requires the use of a mouse
transgenic line that most closely mimic those hallmarks, such as the TAPP line
(Lewis et al., 2001). However, the physiological impairments suffered by these mice
make them extremely difficult to behaviourally phenotype. Using the TAPP mice to
model the cognitive aspects ofAD in the search for a cognitive enhancing compound
could prove fruitless. In contrast the Tg2576 transgenic mouse line developed by
Hsiao and colleagues (1996), has been extensively behaviourally phenotyped and
histopathologically assessed. However, cognitive testing has largely been within the
domain of spatial learning and memory (Hsiao et al., 1996; Chapman et al., 1999;
King et al., 1999; Arendash et al., 2001; King and Arendash, 2002). Whilst
Alzheimer's disease patients do exhibit cognitive impairments within these domains
(spatial learning and memory), the predominant and earliest impairments observed
appear to be in either episodic memory (memory for events in life) or attentional
function (Baddeley et al., 1991; Becker et al., 1992; Binetti et al., 1996a,b; Reid et
al., 1996; Perry and Hodges, 2000; see chapter 1.3, pp. 20). Though not all
components of attention are affected at the same stages in AD, it has been proposed
that the early attentional and processing speed deficits in AD patients may contribute
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to performance reductions in other cognitive domains such as memory and executive
function (Simone et al., 1997; Perry and Hodges, 1999; Perry et al., 2000; Rizzo et
al., 2000). Lawrence and Sahakian (1995), suggest it may be a core feature ofAD.
It has also been suggested that olfactory capabilities and memory impairments may
represent an early marker for AD (Devanand et al., 2000). This is supported by the
findings that the earliest pathological hallmarks in AD occur in the entorhinal cortex,
part of the main olfactory system (Fig. 4.2, pp. 122), and an area highly sensitive to
Ap deposition induced loss of nAChRs (Braak and Braak, 1995; Perry et al., 1995;
Mufson et al., 1999). Ap deposition is also high in the entorhinal cortex of patients
with mild cognitive impairment (MCI), and, if accompanied by olfactory
impairments, these patients have a high risk of being diagnosed with AD later in life
(Mufson et al., 1999; Devanand et al., 2000). Likewise the highest region of Ap
deposition in the Tg2576 mouse model of AD is in the olfactory tract (Nordberg et
al., 2002).
However to my knowledge the Tg2576 mice have not been assessed in any of these
cognitive and olfactory domains. Assessing episodic memory in rodents has proven
problematic due to the difficulty in rodents relaying information regarding previous
events. A recent behavioural paradigm developed locally by Professor Morris' group
in the University of Edinburgh to assess episodic memory in rats shows some
promise (Day et al., 2003). However an analogous task for use in mice has not yet
been developed. Assessing attentional and olfactory memory capabilities in mice is
however possible (see chapters 3.3 and 4.3, pp. 81 and 125). Knowledge of the
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cognitive abilities of the Tg2576 mice within these domains (attention, olfaction and
memory) would prove advantageous when assessing the possible efficacy of a novel
nicotinic-based cognitive enhancing compound to treat AD patients.
Therefore the Tg2576 mice (the creation ofwhich is detailed in Appendix I, pp. 156)
were trained and their performance assessed in sustained attention (5-CSR task) and
olfactory working memory (OST). It was hypothesised that these mice would exhibit
both age-related attentional and olfactory working memory impairments that may be
related to Ap deposition. More interestingly these models may detect a deficit in
attention or olfaction prior to Ap deposition, and allow us to examine the effect of
drugs at an earlier stage (MCI) in AD progression. An assessment of their
exploratory behaviour was also conducted using spontaneous alternation on the T-
maze, as exploratory behaviour might decrease with increasing AD pathology as
curiosity levels are reported to decrease in AD patients. Wang and colleagues
(2001), postulated that the a7 nAChR may be pivotal to the deposition of Ap.
Therefore we established a breeding programme to generate mice over-expressing
Ap on an a7 nAChR null background, with an aim to biochemically and
behaviourally phenotype these animals for comparison with both Tg2576 and a7
nAChR KO mice. Moreover the ability of nicotine to reduce Ap accumulation in




5.2.1 Animal maintenance and genotyping
Mice over-expressing the Swedish amyloid precursor protein (APP) mutation,
Tg(HuAPP695.K70N-M671L)2576 and their age-matched littermates were
purchased from Taconic (New York, U.S.A.). The mice were quarantined and
initially group housed according to vetinary guidelines, but due to high levels of
aggression observed (Moechars et al., 1996; 1998), they were subsequently
individually housed. The mice were purchased for the following studies.
Longitudinal assessment of performance in sustained attention, olfactory working
memory and exploratory behaviour at 6, 12, and 18 mth in the 5-CSR task, 7, 13, and
19 mth in the OST, and at 6.5, 12.5 and 18.5 mth in the T-maze. At 6 and 12 mth, 2
mice from each group were to be removed for Af3 measurements (ELISA) and plaque
deposition, with the remaining mice assessed at 19 mth.
Unfortunately due to a reduced survival rate in the Tg2576 (Tg) mice; consistent
with previous observations (Lalonde et al., 2003) and other unexpected difficulties
(section 5.2.2, pp. 169), no mice were removed for assessment of Ap levels and the
ages of training and testing could not correspond with original plans. Hence a
second group of mice were brought in for inclusion in the studies. Training and
testing took place as follows: 5-CSR task at ~ 10 (section 5.3.1) and 16 (section
5.3.2) months; OST at ~ 4 (section 5.3.3), ~ 12 (section 5.3.4) and ~ 18 (section
5.3.5) months; T-CAT at 4.5 (section 5.3.6) and 16.5 (section 5.3.7) months
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(summarised in table 5.2). The variations in the group numbers shown were due to
mice dying, not acquiring the task, or losing stability during testing (see below).
A breeding programme was established to generate Tg2576 mice on an a7 nAChR
null background. Initially Tg2576 male mice were bred with a7 nAChR knockout
(KO) females from the in-house a7 nAChR colony. The resulting F1 progeny would
therefore express either the Tg2576 gene (APP+) and be an a7 nAChR heterozygote
(HT), or not express the Tg2576 gene (APP-) and be an a7 nAChR HT. The former
mice in the F1 progeny would then be bred with a7 nAChR HT mice from the in-
house a7 nAChR colony. The resulting F2 progeny would then be one of six
different genotypes: APP+ X a7 nAChR KO (desired genotype); APP+ X a7
nAChR HT; APP+ X a7 nAChR wildtype (WT; desired control genotype); APP- X
a7 nAChR KO; APP- X a7 nAChR HT; APP- X a7 nAChR WT. Due to Mendelian
genetics, there would be a 1 in 4 chance of the F2 progeny being of the desired
genotype. However as only males were desired for behavioural assessment, the
chance of the F2 progeny being the desired genotype and gender was 1 in 8
(summarised in Fig. 5.1).
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Group Section Cognitive Task Performance Measured Age (m) Group sizes
number WT
1 5.3.1 5-CSR task Acquisition
4.5 - 10 9 5
Asymptote 10.5 9 5
Asymptote 16 5 4
1 5.3.2 5-CSR task
Extended session 16 5 4
Noise distraction (lOOdB) 16.5 5 4
Noise distraction (1 lOdB) 17 5 4
Acquisition 3-4 6 8
2 5.3.3 OST Asymptote 4.5 6 8
22 odour challenge 4.5 6 8
Acquisition 10.5-11.5 4 5
1 5.3.4 OST Asymptote 12 4 5
22 odour challenge 12 4 5
1 5.3.5 OST Asymptote 19.5 3 4
2 5.3.6 T-CAT Spontaneous exploration 4.5 6 6
1 5.3.7 T-CAT Spontaneous exploration 18 7 9
1 5.3.8 None Ap plaques post nicotine 20 10 8
Both 5.3.8 None Weight differences observed 3-20 3-10 4-10
Table 5.2: Studies performed using the Tg2576 mice
The studies performed using the Tg2576 (Tg) mice and their age-matched littermates
(WT). Due to behavioural difficulties some studies originally planned (group 1) had
to be performed by a second group of mice (group 2). Extended session and noise
distraction challenges for the 5-CSR task were not performed at 10.5 months as these
protocols were not in place at that time. Assessment of whether 10-day nicotine
administration could reduce Ap plaque levels (section 5.3.8, pp. 204) was performed
on the remaining mice from group 1. Weight comparisons (section 5.3.9, pp. 207)




Figure 5.1: Breeding programme to assess the effects of Tg2576 expression on an a7
nAChR null background
The following breeding programme was designed to generate mice that were Tg2756
positive (APP+) and oc7 nAChR knockouts (-/-), and compare their levels of A(3
deposition to APP+ and al wildtype (+/+) age-matched littermates. Male (c?)
Tg2576 mice from the first group brought in (represented by ), bred with a
female ($) al-l- from the in-house colony (colony mice represented by C^). The
resulting APP+,a7+/- F1 progeny were then crossed with an al heterozygote (+/-)
from the in-house colony. Any progeny that did not express the A3 deposition
genotype (APP-) were not used for further breeding. There were six possible
genotypic progeny from the F1 cross. The desired genotypes in the F2 generation
were APP+,a7-/- and APP-,a7+/+ (represented by Therefore there was a 1 in
4 chance of obtaining a S or $ with a desired genotype in the F2 progeny.
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Finally, the effects of nicotine on amyloid processing/deposition were assessed in
aged Tg2576 mice when A(3 plaque levels were high (20 months old; WT n = 8; Tg n
= 10). The mice were subdivided into four groups receiving either saline or nicotine
(WT nicotine = 4, WT saline = 4, Tg nicotine = 5, Tg saline = 5) in a counter¬
balanced design according genotype, age and the level of previous behavioural
training (OST and 5-CSR task; section 5.3.8). Previous behavioural training was
considered, as it has been reported that increased cognitive activity can delay the
onset ofAlzheimer's disease in humans, and also that rats performing the 5-CSR task
exhibit increased levels of endogenous acetylcholine in the prefrontal cortex, which
may in itself be neuroprotective (Passsetti et al., 2000; 2001). The mice were
administered (s.c.) their allotted drug (either saline or (-)nicotine) twice a day (09:30
and 15:30 hrs), over a 10-day period exactly as described by Court and colleagues
(2004). The mice receiving (-)nicotine were administered 0.25 mg/kg on day 1, 0.35
mg/kg on day 2, then 0.45 mg/kg for the following 8 days. The brains of each mouse
was removed and levels of soluble and insoluble Ap (1-40 and 1-42) in each group




5.2.2 Behavioural problems encountered in the Tg2576 mice
The 48 mice were purchased (3 mth, n = 24 per group). Several difficulties were
encountered prior to the initiation of training in the 5-CSR task. Initial group sizes
were to be 14 from each group. After assessment in the 5-CSR task at 6 and 12 mth,
2 mice from each group were to be removed for Ap measurements (ELISA) and
plaque deposition, with remaining mice assessed at 19 mth. As training in the 5-CSR
task usually requires 3 months, training was to begin at 3 mth. However training was
delayed as two Tg mice were still under 20 g in weight and as such could not be food
restricted. Another two Tg mice also required Dermisol treatment, twice daily, for a
skin infection. Training commenced when the mice were 4.5 mth old. Several mice
also exhibited signs of stereotypy behaviour, complicating the selection of 14 mice
from each group. The stereotypy behaviour including spinning round in a circle and
jumping against a side-wall, which has been observed in other transgenic mouse
models of AD and likened to myoclonus observed in AD patients (Caviness, 2003;
Lalonde et al., 2003). Further complications arose after training began when
genotyping of the mice became possible and was discovered that Taconic had
incorrectly labelled three of the mice. Therefore final group sizes were 13 Tg and 15
WT mice. Training these two groups proved more arduous than any other in this
thesis. On several occasions upon attaining criteria, performance would deteriorate,
requiring that subject to be moved one or several stage/s back. Also 7 Tg mice died
during training, now recognised as common in this transgenic line (King et al., 1999;
















Figure 5.2: Survivability plot of the Tg2576 mice
Tg2576 (Tg) mice have a reduced survival rate when compared to their age-matched
littermates. In 2002, King and Arendash identified the survival rate of the Tg mice




5.3.1 Normal performance of Tg2576 mice (4.5 - 10.5 m) in the 5-CSR task
Of the 48 mice imported to the MFAA quarantine facilities at FINE, 4 were dead on
arrival, 1 died within 5 days, then 7 more died during 5-CSR task training. All
deaths were in the Tg2576 (Tg) group (final numbers = 9 WT and 5 Tg). Other
problems occurred during 5-CSR task training, including large weight alterations in
the Tg mice (to maintain 85% of free-feeding weight, two were fed within their cage
and one only consumed powdered diet). This weight variation may have contributed
to the variability in performance during training of the Tg mice, requiring some mice
moved back stages. Hence training took longer than any other study. Final group
numbers eventually consisted of 9 WT and 5 Tg mice.
Despite the difficulties, mice exhibited stable acquisition curves of proportion correct
over increasing session days (Fig. 5.3a). Each subject's A50 (score indicating half
way to acquisition) was calculated (as per chapter 3.3.5, pp. 90) and the values of the
two groups compared using a one-way ANOVA. No significant differences between
groups were observed (F(l,12) = 0.0362, p - 0.852; see Fig. 5.3b). Training
continued until a stable level of performance had been attained (10.5 mth) then
assessed over a four day period (Tuesday - Friday) using a 2-Way Repeated
Measures ANOVA, with genotype and day as between subject factors and subject
identity as the within subject factor. No significant main effects were observed for
any measure (table 5.3, pp. 182). There was no significant main effect of genotype
on % omissions (F(l,32) = 0.0003, p = 0.985; Fig. 5.3c), or proportion correct
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(F(l,32) = 2.63, p = 0.131; Fig. 5.3d), nor was there an effect on mean correct
latency (F(l,32) = 0.13, p = 0.725; Fig. 5.3e). Nor was there any significant
interactions between day and genotype on % omissions (F(3,32) = 0.033,/? = 0.992),










Figure 5.3: Normal acquisition and asymptotic performance of Tg2576 mice (4.5 -
10.5 mth) in the 5-CSR task
Tg2576 mice (Tg, n = 5) and their age-matched littermates (WT, n = 9) were trained
(4.5 - 9.5 mth) to perform the 5-CSR task (wide array format). The acquisition of
the 5-CSR task for one representative subject from each group with data shown as
proportion correct across session days (a). The Tg mice acquired the task as readily
as the WT mice as measured by the mean time taken by each group to reach halfway
to asymptote (A50; b). The asymptotic performance of the mice (10.5 mth) was
measured over four consecutive days (Tuesday - Friday), with no significant
differences observed between the two groups for every measure, including %





































































5.3.2 Tg2576 mouse (16 - 17 m) performance of the 5-CSR task
The mice used in the previous study (section 5.3.1) were retrained in the 5-CSR task.
The stable baseline performance of the Tg and WT mice was compared as were their
responses to several challenges, including extending the session length (see chapter
3.3.7, pp. 94) and noise distracters at 100 and 110 dB.
5.3.2.1 Tg2576 mouse (16 m) performance at asymptote
Analysis of asymptotic performance in the 5-CSR task of Tg (n = 4) and WT (n = 5)
mice (16 mth) again revealed no significant genotypic effects at any measure tested.
The two groups did not differ significantly in levels of % omissions (F(l,20) =
0.0004, p = 0.985; Fig. 5.4a), proportion correct (F(l,20) = 0.005, p = 0.943; Fig.
5.4b), or mean correct latency (F(l,20) = 0.7, p = 0.443; Fig. 5.4c). Nor was there
any significant interactions between the two factors, as measured by % omissions
(F(3,20) = 1.561, p = 0.230), proportion correct (F(3,20) = 0.658, p = 0.587), or



















Figure 5.4: Normal asymptotic performance of Tg2576 mice (16 m) in the 5-CSR
task
Tg2576 mice (Tg, n = 4) and their age-matched littermates (WT, n = 5) were trained
(16 mth) were assessed in their asymptotic performance of the 5-CSR task (wide
array format). The Tg and WT mice from section 5.3.1 were retrained in the 5-CSR
task. Stable baseline was measured over 4 days (Tuesday - Friday). As at 10
months of age, the asymptotic performance of the Tg mice did not differ from that of
the WT mice as measured by % omissions (a), proportion correct (b) and mean
correct latency (c). Data presented as mean + s.e.m..
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5.3.2.2 Normal 5-CSR task performance of Tg2576 mice (16 mth) when
session length was extended
After assessment of baseline performance, the ability of these mice to sustain
attention for a longer period of time was examined (40 min, with an unlimited trial
number compared to the standard 25 min, and 120 trials; see chapters 2.2.5 and 3.3.7,
pp. 58 and 94). The performance of the mice was assessed over a two-day period
(Tuesday and Thursday) interspersed with training days (Monday, Wednesday and
Friday), a schedule commonly used in the literature (Hahn and Stolerman, 2002;
Grottick et al., 2003). Performance was assessed using a 2 Way Repeated Measures
ANOVA with day and genotype as between subject factors and mouse identity as the
within subjects factor. Again no significant effect of day or genotype was found on
any measure assessed, including proportion correct (F(l,6) = 0.314,/? = 0.596; Fig.
5.5a), % omissions (F(l,6) = 1.088, p = 0.337; Fig. 5.5b), mean correct latency
(F(l,6) = 0.0322, p = 0.863; Fig. 5.5c), mean reward latency (F(l,6) = 0.245, p =
0.638; Fig. 5.5d) and total trials (F(l,6) = 0.903,/? = 0.379; Fig. 5.5e). No significant
effects of genotype were observed for any other measure of raw data examined (see
table 5.3, pp. 182). Nor were there any significant interactions between day and
genotype observed as measured by % omissions (F(l,6) = 1.155, p = 0.324),
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Figure 5.5: Normal performance of Tg2576 mice in the extended session 5-CSR task
(16 mth)
The performance of the Tg2576 (Tg, n = 4) mice and their age-matched littermates
(WT, n = 5) (from Fig. 5.4) were then assessed in their ability to perform the
extended session 5-CSR task (wide array format). This task differed in that the
session length was increased by 15 min, and the trial limit removed. Performance
was assessed over two days, interspersed with training days. As before the Tg mice
did not differ from that of the WT mice on any measure, including % omissions (a),
proportion correct (b), mean correct latency (c), mean reward latency (d) and total
trials completed (e). Data presented as mean + s.e.m..
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5.3.2.3 Slowed response of Tg2576 mice (16.5 mth) performing the 5-CSR
task during 100 dB noise distraclers
After a short interlude (0.5 mth), the mice were trained in the standard 5-CSR task
until performance was stable, and then their ability to sustain attention in the
presence of auditory distracters was assessed. Initially attempts to distract the mice
(16.5 mth) utilised 0.5 s 100 dB noise bursts, occurring either at the same time as the
cue stimulus, 1 s prior to cue stimulus onset (halfway through the ITI), or not at all,
in a randomised manner. No significant main effects of genotype was observed on
% omissions (F(l,16) = 1.255, p = 0.295; Fig. 5.6a) or proportion correct (F(l,16) =
0.151, p = 0.707; Fig. 5.6b). However, there was a significant genotypic effect on
mean correct latency (F(l,16) = 6.152,/> < 0.05; Fig. 5.6c). No significant effects of
genotype were observed for any measure of raw data (see table 5.3, pp. 182). No
significant effect of noise onset was observed for any measure, including %
omissions, proportion correct, mean correct latency, total number of correct
responses, and total number of omission errors (data not shown). Nor was there a
significant interaction between noise onset and genotype for % omissions (F(2,16) =
1.292, p = 0.302), proportion correct (F(2,16) = 0.469, p = 0.634) or mean correct














































Figure 5.6: Slowed response of Tg2576 mice in the 5-CSR task during auditory
distracters (16.5 m)
The distractibility of the Tg2576 (Tg, n = 4) and their age-matched littermates (WT,
n = 5) was assessed by interpolating lOOdB bursts (0.5 s) of noise during
performance of the standard 5-CSR task. The presence and timing of the noise
distraction was in one of three randomly selected states. Either no noise was present
during a trial (No noise), the noise would begin 1 s prior to the cue stimulus (Half
ITI), or the noise would begin at the same time as the presentation of the cue
stimulus (On Cue Stim). The performance of the Tg and WT mice was compared.
Performance was measured over two days (Tuesday and Thursday) which were
interspersed with training days (Monday, Wednesday and Friday). Whilst some
trends were apparent there was no significant main effect of genotype on %
omissions (a) or proportion correct (b). However, there was a significant main effect
of genotype on mean correct latency, with the Tg mice performing slower in every
distraction state when compared with the WT mice (c). Data presented as mean
+sem (* denotes p < 0.05 in genotypic comparison).
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5.3.2.4 Increased effect of 110 dB noise distracters slowing response of
Tg2576 mice (17 mth) performing the 5-CSR task
After a short interlude (0.5 mth), 5-CSR task baseline performance was re¬
established, the response of the Tg mice to louder (110 dB) noise distracters was
compared to WT mice. One Tg was removed as performance had become erratic.
The louder noise was used as a transgenic mouse model of AD (TgCRND8 mice,
Janus et al., 2000, see table 5.1, pp. 158) exhibited a startle response at levels greater
than 105 dB (McCool et al., 2003). No effect on % omissions (F(l,14) = 0.466,/? =
0.517; Fig. 5.7a), or proportion correct (F(l,14) = 0.192,/? = 0.674; Fig. 5.7b) was
observed. Again however, a significant genotypic effect on mean correct latency
was present (F(l,14) = 9.941,/? < 0.05; Fig. 5.7c). Although no significant genotypic
effect was observed for the raw data (see table 5.3, pp. 182), there were significant
main effects of time of noise onset (at cue stimulus, halfway through ITI, or not at
all). A significant effect of noise onset on % omisisons (F(l,2) = 4.650, p < 0.05;
Fig. 5.7a) was observed with Tukey post hoc test revealing % omissions at noise
halfway through the ITI significantly higher than no noise (/? < 0.05). There was also
a significant effect of noise onset on total correct responses (F(l,2) = 9.651 . P <
0.005; Fig. 5.7e), with Tukey post hoc analysis revealing significantly fewer correct
responses at both noise onsets compared to no noise {p < 0.05). There was also a
significant genotypic/noise onset interaction for total correct responses (F(l,2) =
4.077,/? < 0.05). Whilst there was a trend towards an effect of noise onset on the
total number of omission errors, it was not significant (F(l,2) = 2.841, p = 0.092).
No, effect of noise onset was observed in total trials (F(l,2) = 0.616, p = 0.514), or
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In summary, whilst there was no main effect of genotype on asymptotic performance
of the Tg2576 mice in the 5-CSR task at 10.5 or 16.5 months of age (sections 5.3.1
and 5.3.2.1; Fig. 5.3 and 5.4, pp. 173 and 175). Nor was there a genotypic effect
when the task was extended to 40 min, although there was a trend towards the
Tg2576 mice exhibiting higher % omissions and a lower proportion correct (section
5.3.2.2; Fig. 5.5a and b, pp. 177). There was a significant genotypic effect on mean
correct latency when the mice were subjected to both 100 and 110 dB noise
distracters, with the Tg2576 mice exhibiting significantly slower responses than their
age-matched littermates (sections 5.3.2.3 and 5.3.2.4; Fig. 5.6c and 5.7c, pp. 179 and
181). Also, whilst no effect of time of noise onset was observed for any measure at
100 dB, when 110 dB was employed (at a level known to induce a startle response in
TgCRND8 mice, McCool et al., 2003) the performance of both groups was
significantly worse during trials with auditory distracters as measured by %
omissions and correct responses (section 5.3.2.4; Fig. 5.7, pp. 181). Also there was a
significant genotypic/noise onset interaction on the number of correct responses,
although the source of significance was unidentifiable. However, it appears that
whilst the littermate mice maintained a high level of correct responses at each time of
noise onset, the Tg2576 mice exhibited fewer correct responses as the time of noise
onset drew closer to the cue stimulus (Fig. 5.7e, pp. 181).
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5.3.3 Tg2576 mice (3 - 4.5 mth) exhibit normal acquisition and asymptotic
performance of the 12, but not 22-OST
To date, in the literature there are numerous papers assessing the effects APP over-
expression in mice on spatial working memory (section 5.1, pp. 156). However,
there is little/no information available on the performance of these mice in a non-
spatial working memory task. Olfactory working memory is a form of non-spatial
working memory, and is clearly impaired in patients with AD. It has been suggested
that this impairment may be an early marker with which to diagnose patients with
mild cognitive impairments who are likely to progress to fully blown AD (Devanand
et al., 2000). This hypothesis is supported by the findings that Ap deposition, and
AD pathology occurs first in the entorhinal cortex (Braak and Braak, 1995; Nordberg
et al., 2002). Therefore the performance of a second group of Tg2576 mice and their
age-matched littermates were examined in the OST. A group of young (3-4 mth)
Tg2576 (Tg) mice were trained to perform the OST. Fig 5.8a represents the span
length performance of the two groups over the period of task acquisition. A one-way
ANOVA of the number of days taken by each group to attain criteria (span length >
5 for two consecutive days) revealed no significant genotypic effect (F(l,11) =
0.0589,/? = 0.813; Fig. 5.8b). Once a stable baseline performance had been reached,
the performance of the two groups (at 4.5 mth) was assessed over four consecutive
days (Tuesday - Friday). There were no significant differences between the two
genotypes on every measure examined. The Tg mice did not differ from the WT
mice in span length (T=608, p = 0.144; Fig. 5.9a), spans completed (T=530, p =
0.992; Fig. 5.9b), or in the total number of errors they made (T=460,p = 0.190; Fig.
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5.9c). A 2-Way Repeated Measures ANOVA with genotype and day as between
subject factors, and mouse identity as the within subject factor, revealed no
significant main effects of day or genotype on mean span latency (F( 1,33) = 2.521, p
= 0.141; Fig. 5.9d) or time taken to first sample (F(l,33) = 0.378, p = 0.551; Fig.
5.9e) or ability to discriminate between two odours (T=530, p = 0.992). There was
no significant interaction between day and genotype in mean span latency (F(3,33) =
0.330, p = 0.804) or time taken to engage in the task (F(3,33) = 0.755, p = 0.728).
There did however appear to be a trend towards poorer performance in the Tg mice,
that may have been being masked by ceiling effects in the task. Therefore the two
groups of mice were then assessed in their ability to perform the 22-OST, which
places increased demand on the olfactory working memory of the mice. The
performance of the mice (at 4.5 mth) over two days (Tuesday and Thursday), with
normal training sessions on the intervening days (Monday, Wednesday and Friday),
was grouped and assessed for a genotypic effect. The observation that ceiling effects
appeared to mask the differences in performance between the two groups proved
correct. When assessed in the 22-OST there were significant effects of genotype on
performance of the task. The Tg mice exhibited a significantly shorter span length
than the WT mice (T=l81, p < 0.05; Fig. 5.10a). The Tg mice also completed
significantly fewer spans (T=175, p < 0.05; Fig. 5.10b) and committed more errors
per session (T=102.5,/> < 0.05; Fig. 5.10c). A 2-Way Repeated Measures ANOVA
with genotype and day as between subject factors, and mouse identity as the within
subject factor, revealed a significant main effect of genotype on mean span latency
(F(1,11) = 7.347;p < 0.05; Fig. 5.lOd), but not on time taken to first sample (F(l,l 1)
= 0.156, p = 0.701; Fig. 5.10e). The differences appear to he in the time taken to
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complete individual spans. The Tg group appear slower to complete each individual
span, and the difference was exaggerated when the span number is increased from 12
to 22 (Fig. 5.11). There was no significant interaction between the two actors as
measured by mean span latency (F(l,ll) = 4.842, p = 0.054) or time taken to engage



































Figure 5.8: Normal OST acquisition of Tg2576 mice (3-4 mth)
The acquisition of young (3-4 mth) Tg2576 (Tg, n = 8) mice were compared with
their age-matched littermates (WT, n = 6) in the standard (12 odour) OST. The mean
span length across session days of each group is shown in (a). The average number
of sessions each mouse took to acquire the task was grouped by genotype an
compared. As the two groups attained a span length of 5 on two consecutive days at
relatively the same time, the mean number of days to attain criteria taken by two
groups was not statistically different (b). Data presented as mean + s.e.m..
186
Chapter 5
Figure 5.9: Normal asymptotic performance of Tg2576 mice (4.5 mth) in the OST
The asymptotic performance of young (4.5 mth) Tg2576 (Tg, n = 8) mice were
compared with their age-matched littermates (WT, n = 6) in the standard (12 odour)
OST. The performance of the two groups did not differ on any measure tested.
There was no significant difference in span length (a), spans completed (b), errors
per session (c), mean span latency (d) or time taken to engage in the task (e). Data




Figure 5.10: Impaired performance of Tg2576 mice in the 22-OST (4.5 mth)
The performance of young (4.5 mth) Tg2576 (Tg, n = 8) mice was compared with
their age-matched littermates (WT, n = 6) in the 22 odour OST. Performance was
assessed over two days (Tuesday and Thursday), with normal training on the
intervening days (Monday, Wednesday and Friday). The Tg mice exhibited a
significantly lower span length (a), and total number of spans completed per session
(b) when compared with the WT mice. The Tg mice also committed more errors per
session (c), and had a significantly higher mean span latency (e) than the WT mice.
However, as with the 12 odour task, no significant difference was observed in the
mean time taken by each group to engage in the task (e). Data presented as mean +
s.e.m. (* denotes p < 0.05).
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Figure 5.11: Slowing response of Tg2576 mice (4.5 mth) in the OST when difficulty
increased from 12 to 22 odours
The performance of young (4.5 mth) Tg2576 (Tg, n = 8) mice was compared with
their age-matched littermates (WT, n = 6) in time taken to complete the individual
spans of a session. Their performance in both thel2 and 22 OST was examined. The
data revealed a significant difference in mean span latency in the 22 but not 12 OST
(Fig. 5.9d vs. Fig. 5.10d). The figure above demonstrates the difference between the
12 and 22 OST in time taken to complete the spans. Once beyond the standard 12
spans, the two groups increasingly differ in their time taken to complete each span.
Data presented as mean + s.e.m..
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5.3.4 Impaired acquisition and asymptotic performance of Tg2576 mice (10.5-12
mth) in the OST
After initial assessment of baseline performance in the 5-CSR task the Tg2576 (Tg)
mice and their age-matched littermates (WT) from section 5.3.1 (pp. 171) were
trained to perform the 12 span OST. One Tg mouse was removed from the study as
it had lost its lower teeth, and thus prevented consumption of the pellet rewards.
Final group sizes were, WT n = 6, Tgn = 5. The acquisition of the OST by these
mice is shown in Fig. 5.12a with the mean span length performance of each group
shown across session days. The number of days each mouse took to attain criteria
was grouped by genotype and compared using a one-way ANOVA. The Tg mice
took significantly longer than the WT mice to attain the set criteria (F(l,7) = 7.658,p
< 0.05; Fig. 5.12b). Training continued until a stable level of performance was
attained (12 mth old). Their performance over four consecutive days (Tuesday —
Friday), were grouped and analysed. The Tg mice were found to have a significantly
lower span length than the WT mice (T=416, p < 0.001; Fig. 5.13a). However, the
two groups did not differ in total spans completed (T=296, p = 0.987; Fig. 5.13b), or
in their ability to discriminate between two odours (T=304, p = 0.809). The Tg mice
erred significantly more per session than the WT mice (T=185.5, p < 0.001; Fig.
5.12c). A 2-Way Repeated Measures ANOVA with genotype and day as between
subject factors with mouse identity as the within subjects factor revealed no
significant main effects of day or genotype on mean span latency (F( 1,21) = 3.514, p
= 0.103; Fig. 5.13d), or mean time to first response (F( 1,21) = 1.728, p = 0.23; Fig.
5.13e), with no significant interactions between the two factors on either measure
(F(3,21) = 2.139,p = 0.126 and F(3,21) =1.194,p = 0.336 respectively).
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Figure 5.12: Impaired OST acquisition of Tg2576 mice (10.5 - 11.5 mth)
The acquisition performance of Tg2576 (Tg, n = 5) mice in the OST was compared
with their age-matched littermates (WT, n = 4; 10.5 - 11.5 mth). The acquisition
curve of each group is shown in (a) as mean span length across session number. The
Tg mice appeared to take longer to reach a span length of 5 on two consecutive days
in comparison with the WT mice. Analysis of the number of days the mice took to
attain criteria grouped by genotype revealed that the Tg mice took significantly
longer than the WT mice (b). Data presented as mean + s.e.m. (* denotes p < 0.05




Figure 5.13: Impaired asymptotic performance of Tg2576 mice (12 mth) in the OST
Tg2576 (Tg, n = 5) mice and their age-matched littermates (WT, n = 4; 12 mth) were
compared in their performance of the standard (12 odour) OST. Stable performance
was assessed over four consecutive days (Tuesday - Friday). Unlike data at 4.5 mth,
there was a difference in asymptotic performance of the Tg and WT mice. The Tg
mice exhibited a significantly lower span length (a) than the WT mice. No
differences between the two groups were observed in the total number of spans
completed per session (b) but the Tg group did err significantly more often per
session than the WT mice (c). No differences were observed in the mean span
latency (d) or the mean time taken by each group to engage in the task (e) between
each group. Data presented as mean + s.e.m. (* denotes p < 0.05).
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Although it is unlikely that the differences observed were confounded by ceiling
effects, the number of odours in the task was increased from 12 to 22 on two test
days (Tuesday and Thursday) interspersed with three training (12 odour) days
(Monday, Wednesday and Thursday). No effect of day was observed for any
measure. Again the Tg mice exhibited a significantly lower span length when
compared to the WT mice (T=101.5, p < 0.05; Fig. 5.14a). The total number of
spans completed by the two groups did not differ (T=84, p = 0.497; Fig. 5.14b), nor
did their ability to discriminate between two odours (T=76, p = 0.964). The Tg mice
again erred significantly more times per session than the WT mice (T=49, p < 0.05;
Fig. 5.14c). No effect of day, or genotype on mean span latency (F(l,7) = 0.54, p =
0.486; Fig. 5.14d), or time to first response (F(l,7) = 1.281,/? = 0.295; Fig. 5.14e)
was observed. Nor was there a significant interaction between the two factors as
measured by mean span latency (F(l,7) = 0.016,p — 0.903) or time taken for the first
response (F(l,7) = 4.143,/? = 0.081).
193
Chapter 5
Figure 5.14: Impaired performance of Tg2576 mice in the 22-OST (12 mth)
The performance of Tg2576 (Tg, n = 5) mice was compared with their age-matched
littermates (WT, n = 4; 12 mth) in the increased difficulty (22 odour) OST.
Performance was assessed over two days (Tuesday and Thursday), with normal OST
training on the intervening days (Monday, Wednesday and Friday). The Tg mice
exhibited a significantly lower span length when compared with the WT mice (a).
However the total number of spans completed by the two groups did not differ (b).
The Tg mice made significantly more errors per session than the WT mice (c).
However, no significant differences were observed in mean time taken to complete a
span (d) or mean time taken time to begin the task (e). Data presented as mean +
s.e.m. (* denotes p < 0.05 when compared to WT mice).
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5.3.5 Impaired performance of Tg2576 mice (19.5 mth) in the OST
After exploratory behaviour was assessed on the T-maze (section 5.3.7, pp. 202), the
Tg2576 (Tg) mice and their age-matched littermates (WT; 19.5 mth) from section
5.3.4 (pp. 190) were retrained to a stable baseline performance in the OST. In the
interim period two WT mice had died and one Tg was removed due to diarrhoea
(WT, n = 3 and Tg, n = 4). Their performance over four consecutive days (Tuesday
- Friday) was grouped and analysed. The Tg mice were again found to have a
significantly lower span length than the WT mice (T=223,p < 0.01; Fig. 5.15a), but
did not differ in total spans completed (T=174, p = 0.981; Fig. 5.15b), or in their
ability to discriminate between two odours (T=186, p = 0.809). The number of
errors made by the Tg mice was again significantly greater than the WT mice
(T=l 12.5, p < 0.01; Fig. 5.15c). A 2-Way Repeated Measures ANOVA with
genotype and day as between subject factors, and mouse identity as the within
subjects factor, revealed no significant main effects of genotype on mean span
latency (F(l,15) = 1.867, p = 0.358; Fig. 5.15d) or mean time to initial response
(F(1,15) = 1.023,/? = 0.23; Fig. 5.15e).
However, a significant effect of day was observed for both mean span latency
(F(l,15) = 5.737, p < 0.05), and mean time to first response (F(l,15) = 4.998, p <
0.05). Tukey post hoc comparison indicated that mean span latency and time taken
to engage in the task performance on day 2 (Wednesday) differed from days 1 and 3
(Tuesday and Thursday respectively). This was the first time a day effect was
observed. Attempts to identify the cause proved inconclusive. Analysis assessing
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the effect of day on the remaining measures using a Kruskal Wallis ANOVA on
Ranks identified no significant main effects on any other measure. Thus the span
length (H=3.661, p - 0.3), spans completed (H=0, p = 1.0) and errors per session
(H=0.954, p = 0.812) did not significantly differ between days. Finally there was no
significant interaction between day and genotype on mean span latency (F(3,15) =




Figure 5.15: Impaired asymptotic performance of Tg2576 mice in the OST (19.5
mth)
The performance of Tg2576 (Tg, n = 4) mice was compared with their age-matched
littermates (WT, n = 3; 19.5 mth) in the standard (12 odour) OST. The mice from
section 5.3.5 (pp. 195) were retrained in the task. Asymptotic performance was
assessed over four consecutive days (Tuesday - Friday). The pattern of performance
was akin to that when tested at 12 months. Tg mice again exhibited a significantly
lower span length (a) than the WT mice, but did not differ from the WT mice in the
total number of spans completed per session (b). The Tg group did err significantly
more often per session than the WT mice (c) though no genotypic differences were
observed in the mean span latency (d) or the mean time taken by each group to
engage in the task (e). Data presented as mean + s.e.m. (* denotes p < 0.05).
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In summary, the Tg mice exhibited normal learning and asymptotic performance in
the 12-OST at 3 - 4.5 months of age. However, when assessed in the 22-OST, their
performance was significantly worse than the WT mice. Whilst the mean span
latency of the Tg mice was significantly longer than the WT mice, resulting in their
completion of fewer spans, there was a possible speed/accuracy trade-off, whereby
they performed more slowly to remain as accurate as possible. However, the Tg
mice also erred significantly more often than the WT mice. The lack of olfactory
discriminatory deficit provides support for an impaired olfactory working memory
span in this more arduous task 22 span OST. When assessed at 12 months, the Tg
mice exhibited both impaired acquisition and asymptotic performance in the standard
12-OST. There was a significant age-related effect of acquisition, as older Tg mice
(10.5 - 11.5 mth) took significantly longer to attain criteria than young Tg mice (3 -
4 mth, F(3, 18) = 5.966,p < 0.005). There was also a significant age-related effect of
OST performance in the standard task as measured by span length (H=41.261 \P<
0.001; Fig. 5.16), with Dunn's pairwise comparison identifying that the Tg mice at
4.5 months performed significantly better than when assessed at both 12 and 19.5
months (p < 0.05). Thus with increased age, the olfactory acquisition and working
memory impairment observed in these mice became even more apparent. Moreover,
when performance was reassessed at 19.5 months, the Tg mice remained
















Figure 5.16: Age-related impairment of Tg2576 mice in the OST
The performance of Tg and WT mice in 12-OST is represented across the three ages
tested (4.5, 12 and 19.5 mth). An effect of age was observed with the Tg mice
exhibiting a higher span length at 4.5 mth when compared to 12 and 19.5 mth. Data
presented as mean ± s.e.m. (t denotes p < 0.05 when compared to Tg at 4.5 mth).
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5.3.6 Normal Tg2576 mouse performance in the T-maze (4.5 mth)
After assessment of performance in the 22-OST, the mice from section 5.3.3 (pp.
184) were permitted ad libitum access to food for several days. The exploratory
behaviour of the two groups (WT = 6, Tg = 6; 4.5 mth) was then evaluated by
assessing their rates of spontaneous alternation in the T-maze continuous alternation
task (T-CAT) on a single day. The rate of spontaneous alternation of each group was
compared using a t-test. Despite the WT mice having a higher rate of spontaneous
alternation than the Tg mice, it was not significantly different (t=l.728, p = 0.115;
Fig. 5.17a). Caution is recommended when interpreting the result however as the
study was underpowered due to the low group sizes. A one-sample t-test comparing
the % spontaneous alternation of the WT group with expected chance levels (50%)
suggested that despite alternation rates of ~ 60%, they did not significantly differ
from chance levels (t=T.6592, p = 0.158). Neither did the spontaneous alternation
rate of the Tg (~ 45 %) differ significantly from chance levels (t=0.7251, p =
0.5009). A one-way ANOVA revealed no significant effect of genotype on length of









Figure 5.17: Normal spontaneous alternation of Tg2576 mice (4,5 mth) in the T-
Spontaneous alternation rates of young (4.5 mth) Tg2576 (Tg, n = 6) mice were
compared with their age-matched littermates (WT, n = 6) using the T-maze
continuous alternation task (T-CAT) over one day. The two groups did not differ in
% alternation (a), nor did either group differ significantly from chance (broken line).
Likewise no differences in total time taken by each group to complete the session




5.3.7 Normal spontaneous alternation of Tg2576 mice in the T-maze (18 mth)
After assessment of performance in the 5-CSR task, the mice from section 5.3.2 (pp.
174) were permitted ad libitum access to food for one week. Their exploratory
behaviour was then assessed (WT = 6, Tg = 6, at 18 months of age) by examining
their rates of spontaneous alternation in the T-CAT. Spontaneous alternation rates of
each group were compared using a t-test. The results were similar to those observed
in the 4.5 month old mice. Despite the apparent increase in spontaneous alternation
in the WT mice when compared to the Tg mice, this was not significant (t=2.037,/? =
0.061; Fig. 5.18a). However as before caution is recommended in interpreting a
negative result as the test was underpowered due to low group sizes. Again, despite
alternation rates of ~ 60%, a one-sample t-test comparing the % spontaneous
alternation of the WT group with expected chance levels (50%) revealed a non¬
significant trend toward above chance level performance (t=2.1213, p = 0.0781).
The Tg group (45%) did not differ significantly from chance (t=0.7833, p = 0.456).
A One-way ANOVA with genotype as the between subjects, factor revealed no
significant difference between the Tg and WT mice in time taken to complete the
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Figure 5.18: Normal spontaneous alternation of Tg2576 mice (18 mth) in the T-CAT
Spontaneous alternation rates of Tg2576 (Tg, n = 9) mice were compared with their
age-matched littermates (WT, n = 7; 18 mth) using the T-maze continuous
alternation task (T-CAT) over one day. The two groups did not differ significantly in
their levels of % alternation (a). Nor did each group differ significantly from chance
levels (broken line). Likewise no differences in the mean time taken by each group
to complete the session were observed (b). Data presented as mean + s.e.m..
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5.3.8 Difficulties in breeding the Tg2576 mice on an a7 nAChR null background
The breeding programme was designed such that the behaviour of Tg2576 and a7
nAChR KO mice could be compared with a7 nAChR KO, T2576 and age matched
littermate mice. It was hypothesised that if the a7 nAChR was essential for Ap
deposition, and if the behaviour of the Tg2576 mice was because of their levels of
Ap deposition, then the mice would behave similarly to a7 nAChR KO mice, with
impaired performance in the 5-CSR task when young, and impaired OST due to their
attentional deficits when older. Otherwise, they would behave similarly to both
groups. The programme began by mating four of the first group ofTg2576 mice (not
used in any behavioural study) with a7 nAChR KO females (see Fig. 5.1, pp. 167).
However, due to the low fertility of a7 nAChR KO mice (Orr-Urtreger et al., 1997),
and the high levels of aggression in the Tg2576 mice (discussed section 5.2.1, pp.
164), it was some time (2.5 mth) before litters were produced that survived beyond
weaning. Thus in the F1 mating it was ensured that only female Tg2576 mice were
utilised, further slowing the programme.
Further problems arose with the F1 generation, as several mice died shortly after
weaning, and genetic analysis identified that it was predominantly the mice required
that died (Tg2576 gene and al nAChR HT). Of the 22 mice born with this genotype,
only 27.3% (6 out of 22) survived beyond 2 mth. Moreover, significant weight
differences were apparent when these mice were first weighed at approximately 2
mth. The weights were compared using a one-way ANOVA, with genotype (no
Tg2576 gene, Tg2576 gene with at least one disrupted al nAChR allele, i.e. HT or
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KO, or Tg2576 gene with wildtype a7 nAChr alleles; n = 8, 7, 3 for males and 10, 7,
2 for females, respectively) as the between subject factor. Male and female mice
were compared separately. A significant main effect of genotype was observed in
the male mice (F(2,15) = 28.551, p < 0.001, Fig. 5.19a), with Holm-Sidak pairwise
comparison identifying that the two groups of mice with the Tg2576 genotype were
significantly lighter than mice with no Tg2576 gene {p < 0.001). When the weights
of the female mice were compared, again a significant main effect of genotype was
observed (F(2,16) = 8.535, p < 0.01; Fig. 5.19b), with Holm-Sidak pairwise
comparison identifying that the mice with the Tg2576 gene and disrupted a7 nAChR
alleles were significantly lighter than mice with no Tg2576 gene (p < 0.001),
although the mice with the Tg2576 gene and wildtype a7 nAChR alleles was nearly
significantly different to the mice with no Tg2576 gene (p = 0.058), and lack of
difference was likely to reflect group sizes. These weight differences continued
throughout the life-span of the mice, with many not reaching 20 g in weight even at
3.5 months (10 out of 15 males). Therefore, due to their low weights making early
behavioural assessment impossible, and the difficulties breeding these mice, no
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Figure 5.19: Reduced weights of young mice with the Tg2576 gene
Tg2576 mice were bred onto an a7 nAChR null background. The weights of mice
without the Tg2576 gene on a a7 nAChR HT or WT background (-, +/?) were
compared with mice with the Tg2576 gene and at least one disrupted al nAChR
allele (+, -/?) and mice with the Tg2576 gene with only wildtype al nAChR alleles
(+, +/+). Weights were taken at approximately 2 mth old. It was discovered that
male mice with the Tg2576 gene were significantly lighter than those without the
gene (a). Whereas female mice with the Tg2576 gene only differed from those
without the gene if they also expressed disrupted al nAChR alleles (b). Data




5.3.9 (-)Nicotine administration had no effect on A(3 levels in Tg2576 mice (20
mth)
Recent studies suggest that nicotine administration can reduce the level of soluble
and insoluble A[3 in the brains of Tg2576 mice (Nordberg et al., 2002; Hellstrom-
Lindahl et al. 2004). These studies utilised a 5.5 mth ingestion protocol (Ap levels
assessed at 14.5 mth) and a 10-day injection protocol (AP levels assessed at 9 m)
respectively. As our Tg2576 mice from group 1 were 20 mth of age we followed the
10-day nicotine injection protocol (20mth, WT n = 8, Tg n = 10). Whilst the Tg
mcie exhibited significantly higher levels of soluble AP(i_40) (F(,l,14) = 16.279, p <
0.001; Fig. 5.20a), insoluble Ap(i^o) (F(l,14) = 17.274, p < 0.001; Fig. 5.20a) and
insoluble AP(M2) (F( 1,14) = 68.277, p < 0.001; Fig. 5.20a), when compared to WT
mice, no effect of drug was observed on any measure. Thus nicotine administration
had no effect on levels of soluble AP(mo) (F(,l,14) = 0.143, p = 711; Fig. 5.20b)
insoluble AP(i_40) (F(l,14) = 0.192, p = 0.668; Fig. 5.20b) or insoluble AP(i_42)
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5.3.10 Weight differences of Tg2576 mice in the above sections
As the behavioural tasks used for assessment of cognitive function in the Tg2576
mice utilised food as their motivation, weight differences at the time of testing may
account for the performance differences observed in the tasks. The weights of the
mice in section 5.3.1 (pp. 171) were measured when placed on ad libitum feeding
during 5-CSR acquisition were compared using a 2-Way Repeated Measures
ANOVA with genotype and age as between subject factors, and identity as the within
subject factor. A significant main effect of genotype and age was identified, with Tg
mice significantly lighter than WT mice (F(l,87) = 60.318, p < 0.001). A significant
main effect of age was identified also (F(3,87) — 10.213,/? < 0.001), with Dunnett's
post hoc analysis revealing that mice weights at 7 and 8.5 mth were significantly
heavier than at 4 mth (p < 0.05). When tested for the second time in the 5-CSR task
(section 5.3.2, pp. 174), the weights of the mice when placed on ad libitum feeding
were again compared using a 2-Way Repeated Measures ANOVA with genotype and
age as between subject factors, and mouse identity as the within subject factor.
Again no significant main effect of age was observed (F(2,16) = 1.019, p = 0.383),
but there was a significant main effect of genotype (F( 1,16) = 10.860,/? < 0.01) with
Tg mice again being lighter than WT mice.
Weights taken at the start of each OST study (sections 5.3.3 - 5.3.5, pp. 184 - 198)
were compared for genotypic effects. In the first iteration (3 mth), a Student's t-test
revealed that the Tg mice were significantly lighter than the WT mice (t=-2.294, p <
0.05). The Tg mice at 12 mth was again significantly lower than the WT mice (t=-
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3.111, p < 0.05). In the final iteration of the task at the oldest age examined (19.5
mth), again the Tg mice were significantly lighter than the WT mice (t=-3.325, p <
0.05).
The weights of young mice (4.5 mth) performing the T-maze (section 5.3.6, pp. 200)
were also compared after the group had finished testing in the OST, having been on
ad libitum for one week. A student's t-test revealed a significant difference between
the two groups (t=-3.363, p < 0.01), with the Tg mice being lighter than the WT
mice. This difference in weights was also observed in the older (17.5 mth) mice
performing the T-maze (section 5.3.7, pp. 202). These mice had just finished testing
in the 5-CSR task and were on ad libitum feeding for one week. Again the Tg mice
were significantly lighter than the WT mice as revealed by a student's t-test (t=-
3.983, p < 0.01).
Therefore significant differences were observed in the weights of the Tg mice
compared to the WT mice. However, as these differences occurred in every task, yet
the performance of the Tg2576 mice was normal on several of these tasks (see
sections 5.3.1, pp. 171, 5.3.2.1, pp. 174, 5.3.2.2, pp. 176, 5.3.3, pp. 184) it is unlikely
that the impairments in performance observed was due to weight differences. Graphs
for a comparison of the weights of the WT and Tg mice in each task and at each age




In this chapter I have systematically and comprehensively examined the behavioural
phenotype of the Tg2576 mouse line, the most commonly used model in AD
research (Hsiao et al., 1996). Identification of their impaired sustained attention and
poor olfactory capabilities strengthens their use in AD research. The difficulties in
crossbreeding two different transgenic mouse lines have also been highlighted. Also
the identification that nicotine administration does not reduce levels ofAp deposition
in old mice (20 months of age), guides future research to administering the
compound early in the disease progression.
5.4.1 Sustained attention in Tg2576 mice
Initial attempts to identify impaired sustained attention in the Tg2576 mice proved
inconclusive. Acquisition and asymptotic performance (4.5 - 10.5 months; Fig. 5.3,
pp. 173) clearly showed normal performance of the Tg2576 mice. The asymptotic
performance of the Tg2576 mice was normal again at 16 months of age (Fig. 5.4, pp.
175). Although the numbers in each study were limited due to the high mortality of
the Tg2576 mice (King and Arendash, 2002; Fig. 5.2, pp. 170), which is a
disadvantage when cognitive testing and may mask experimental effects, I do not
believe the group sizes affected the results of the studies. Significant effects of drugs
and genotype have been observed in rodents performing the 5-CSR task with small
group sizes (Hahn and Stolerman, 2002; see chapters 3.3.3, 3.3.4, pp. 86 and 88).
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Modelling impaired sustained attention observed in AD patients in this mouse model
would be advantageous (White and Levin, 1999; Perry and Hodges, 2000). Whilst
the lack of effect observed was unlikely to reflect low group sizes, aforementioned
ceiling effects may mask any group differences (see chapters 3.3.1 and 3.3.2, pp. 81
and 84). Increasing the difficulty of the task could be achieved by extending session
length, a challenge not altering the task protocol, and therefore does not introduce a
learning confound. This challenge simply increased the load placed on the mice
according to theories on taxing sustained attention, and has been utilised in assessing
sustained attention in AD patients (Nebes and Brady, 1993; Brazzelli et al., 1994;
Parasuraman et al., 1998; Grottick et al., 2003; see chapter 3.3.7, pp. 94). Whilst
there was a trend towards a higher % omissions and lower proportion correct in the
Tg2576 mice in this challenge (Fig. 5.5, pp. 177), this was not significant. This
could possibly reflect the low group sizes utilised in these studies. A further increase
in session length (50 or 60 min) may have proven effective in differentiating the
performance of the two groups without needing to increase group numbers, as
increasing session length from 15 to 45 min in a sustained attention task sufficiently
taxed AD patients and lead to a reduction in accuracy (proportion correct; Brazzelli
et al., 1994). However, a further increase was not introduced in order to limit the
possibility of shifts in baseline performance, as observed previously following
repeated challenges (see chapter 3.3.7, pp. 94). The most consistent effect of
increasing session length in Alzheimer's disease patients performing sustained
attention tasks was increased response latencies, suggesting a shift in response
strategy (Nebes and Brady, 1993; Brazzelli et al., 1994), in order to remain as
accurate as possible - known as a speed/accuracy trade-off. This suggests they could
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not sustain attention as equally as their age-matched controls (Busemeyer and
Townsend, 1993).
AD patients are easily distracted when performing a task (Vecera and Rizzo, 2003).
Thus the Tg2576 mice were assessed for their ability to perform the 5-CSR task
whilst subject to noise distractions. Various levels of noise (dB) have been used in
the literature in the 5-CSR task, with 100 dB the more common (Humby et al., 1999;
Hahn and Stolerman, 2002). Initial levels were therefore set at 100 dB and whilst the
noise slowed the performance of the Tg2756 mice in comparison to their age-
matched littermates, there was no effects on % omissions or proportion correct (Fig.
5.4, pp. 175). This slowing of response, yet maintenance of proportion correct, was
akin to the speed/accuracy trade-off observed in Alzheimer's disease patients (Nebes
and Brady, 1993; Brazzelli et al., 1994). To investigate whether noise at a dB level
that elicits a startle response from TgCRND8 mice (McCool et al., 2003) could
separate performance Tg2576 and WT mice any further, noise distractions at 110 dB
were used. Again a speed/accuracy trade-off strategy was observed by the Tg2756
mice (Fig. 5.5c, pp. 177). At this dB level there was a significant effect of the timing
of the noise onset, with the performance of both groups significantly worse during
trials with distracters as measured by % omissions and correct responses (section
5.3.2.4; Fig. 5.5d and e). There was also a significant genotypic/noise onset
interaction, although the source of significance was not clear. However, it appears
that whilst the WT mice maintained a high level of correct at each time of noise
onset, the Tg2576 mice exhibited fewer correct responses the closer the time of noise
onset came to the cue stimulus (Fig. 5.5e). As observed in AD patients, the
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speed/accuracy trade-off could reflect an impoverished ability to sustain attention,
thus switching response strategies to maintain a high degree of accuracy. The medial
and antero-dorsal prefrontal cortices have been implicated in the maintenance of
attention during distracters, and the shifting of response strategies (Muir et al., 1996;
Zaborszky et al., 1997; Gill et al., 1999; Birrell and Brown, 2000; Sarter et al.,
2001). Thus the Tg2576 mice may exhibit pathology in these areas at least at 17
months old.
Whilst it could have been invaluable to assess the effects of noise distractions
similarly at 10 months of age, and therefore identifying whether this impaired ability
was apparent at a younger age, unfortunately I had not developed the programs and
equipment at that time. Hence, whilst the results provide further evidence in support
of the Tg2756 mice as a valid animal model of AD in terms of sustained attention
performance, greater information on the progression of this impairment is still
required. As the 5-CSR task has both selective and divided attentional components
in it (Robbins, 2002), it would also be beneficial to analyse the longitudinal
performance of these mice in tasks specifically assessing selective and divided
attention, possibly providing further face validity for the Tg2576 transgenic mouse
model ofAD.
5.4.2 Working memory in Tg2576 mice
In the literature, the assessment of the attentional performance of Tg2576 mice is
limited. However, the visuo-spatial working memory ability of the mice has been
extensively tested. In the first publication of the cognitive performance of these
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mice, Hsiao and colleagues (1996) identified that Tg2756 mice exhibited age-related
(post Ap deposition) impairment of visuo-spatial working memory as assessed by the
MWM (see chapter 1.4.4.1, pp. 39). This effect was reproduced by Chapman and
colleagues (1999), who also identified an age-related impairment in long-term
potentiation in the dentate gyrus and CA1 regions of the hippocampus, therefore
identifying a neuroanatomical basis for impaired learning and memory. In contrast,
other research groups have had difficulty in reproducing these visuo-spatial working
memory deficits, with King and colleagues (1999) observing impaired performance
in mice as young as 3 months, whereas Westerman and colleagues (2002) did not
observe any impairments until 15 months, 5 months later than the impairments
observed by Hsiao and colleagues (1996). When visuo-spatial learning and working
memory was assessed in a dry land version of the MWM, the Barnes circular
platform test, King and colleagues (1999) observed impaired performance at 3, but
not 9 months, whilst the same group later found no differences at any age tested (5
mth to 8.5 mth; Arendash et al., 2004). These apparently conflicting reports on the
memory capabilities of the Tg2576 mice also occur within other transgenic mouse
models of Alzheimer's disease, such as the PDAPP mice (Games et al., 1995; Chen
et al., 2000). This has generated some debate on the possible source(s) of these
differences. Whilst procedural differences between laboratories could be a factor,
some have suggested that the mice suffer from both age-related and age-unrelated
cognitive impairments, whilst others suggest the tasks used are too insensitive to
detect subtle cognitive deficiencies (Hsiao et al., 2001; Westerman et al., 2002;
Arendash et al., 2004).
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Gerlai and Clayton (1999), and Slonick (2001), both recommend the use of
ethologically relevant stimuli when attempting to identify differences between
groups of rodents, especially in transgenic mice when differences in perofrmance
may be subtle. The OST represents a simple, easy to run task that assesses working
memory capacity by utilising ethologically relevant stimuli. I have already shown
that the task is sensitive enough to detect differences as following both
pharmacological and genetic manipulations (chapters 4.3.2 - 4.3.5, pp. 128 - 142).
Also as the task utilises olfactory stimuli, it might be capable of detecting the effects
of A(3 deposition before many other tasks, as the histopathological changes in both
humans and mice begin to occur first in the entorhinal cortex, part of the main
olfactory cortex (Fig. 4.2, pp. 122), the area of greatest AP(i_42) plaque burden in
Tg2576 mice (Braak and Braak, 1995; Slotnick, 2001; Nordberg et al., 2002). This
hypothesis is supported by the present data. The Tg2576 mice exhibited an age-
related learning impairment in the OST. Young (3-4 month old) Tg2576 mice
acquired the task as readily as their age-matched littermates, whilst older (10.5 - 11.5
month) Tg2576 mice took significantly longer to acquire the task compared to both
their age-matched littermates and the young Tg2576 mice (Figs. 5.8, pp. 186 and
5.12, pp. 191). Such age-related learning impairments have been observed elsewhere
in tasks using spatial cues (Hsiao et al., 1996; Chapman et al., 1999). The Tg2576
mice also exhibited age-related performance deficits of the standard 12-OST. Young
(4.5 months) Tg2576 mice performed as well as their age-matched littermates, and
significantly better than the older Tg2576 counterparts (12 and 19.5 months), whom
performed worse than their age-matched littermates (Fig. 5.16, pp. 199).
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Closer inspection of the Tg2576 mice and their age-matched littermates at 4 months
revealed that there appeared to be a trend towards a reduced span length and an
increased error number for Tg2576 mice in the 12-OST. As both groups of mice
were performing at near optimal levels, the lack of any differences may have been
due to ceiling effects. When the 'ceiling' was raised by increasing the maximum
number of spans to 21, the Tg2576 mice exhibited a significantly reduced span
length and spans completed, increased error number and significantly longer mean
span length than their age-matched littermates (Fig. 5.10, pp. 188). Further analysis
of the time taken to complete individual spans in both tasks identified that whilst the
mean span latency of both groups remained similar at the beginning of the tasks, by
span 11 the mean span latency for each group had begun to separate, and by span 21
the differences were exacerbated, with the Tg2756 mice clearly taking longer to
complete each span than their age-matched littermates (Fig. 5.11, pp. 189). This
slowing with increased task length may be as a result of a speed/accuracy trade-off,
or fatigue due to task length. The performance of the Tg2576 mice in the 5-CSR task
would suggest the former as when the 5-CSR task length was increased to 40 min
(double the time the mice spend performing the OST; see section 5.3.2.2, 173), no
significant differences in latencies or total number of trials completed were observed
(Fig. 5.5, pp. 177). The Tg2576 mice may therefore have been performing more
slowly as the difficulty increased, in an attempt to ensure accuracy of responding.
The search strategy of the two groups did not appear to differ {personal observations
- verification could be obtained through the use of an Etho-Vision tracker as
discussed earlier, chapter 4.3.2, pp. 128), but the Tg2576 mice would often bypass
the correct odour and thus spend more time circling the odours.
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As the Tg2576 mice also made significantly more errors than their age-matched
littermates, they spent more time repeating spans, thus further limiting the time they
appeared on the table. This could account for the lower number of spans completed
by the Tg2576 mice as the time limit of 10 min spent on the table remained in place
for the 22-OST. Although increasing the time limit might allow the Tg2576 mice to
complete the same number of spans as their littermates, the Tg2576 mice also erred
significantly more often. This not only suggests a cognitive component to their
impaired performance, but also that even an increase in the task time limitwould
probably still result in a reduced span length. These differences in performance
between the two groups were also evident when assessed at 12 months. Again the
Tg2576 mice exhibited a reduced span length and an increased error number. No
differences were observed in mean span latency (Fig. 5.15, pp. 197) which could
reflect the general slowing of performance in the task with increased age observed
elsewhere (see chapter 4.3.4, pp. 134). The differences observed in olfactory
working memory performance is unlikely to be due to impoverished olfactory
discriminatory abilities as the performance of both groups when required to choose
the novel odour from a choice of two (span 1) was always near perfect. Whilst the
mice could discriminate between two odours, their ability to identify a specific odour
among many (when the signal to noise ratio is lower, i.e. there are an increasing
number of non-target stimuli) may have been impaired (Marston, 1996). Requiring




The consistently reduced weight of the Tg2576 mice was unlikely to have affected
motivational levels (collect a food reward) in the 5-CSR task and OST. No
differences between the two groups were observed in mean reward latency, a
putative measure of motivation (Robbins, 2002), or total trials, during performance
of the 40 min 5-CSR task (Fig. 5.5, pp. 177). However a definitive measure of
motivation to collect a food reward (e.g. a progressive ratio breakpoint study) could
be assessed using the 5-CSR task apparatus. Progressive ratio breakpoint studies
evaluate the willingness of a subject to retrieve a reward by increasing the workload
required to gain that reward after every trial. Assessing the trial at which the mice
will not respond a sufficient number of times to collect the reward identifies their
breakpoint and hence their level of motivation to attain the reward. Identification of
the breakpoint of the Tg2576 mice and their age-matched littermates would be
advantageous in order to ensure altered motivational levels have not confounded the
data obtained (Samson et al., 1998; Grottick et al., 2000).
5.4.3 Exploratory behaviour of Tg2576 mice
In their original work, Hsiao and colleagues (1996) identified an age-related (post A(3
deposition) loss of spontaneous alternation of the Tg2576 mice in the T-maze. This
has been suggested to reflect a diminished desire to explore a novel situation and has
been likened to the loss of curiosity observed in Alzheimer's disease patients
(Daffner et al., 1992; Frisoni et al., 1999; Chung and Cummings, 2000; Lalonde et
al., 2003). Whilst the current studies did not support these findings, there was a
trend for increased spontaneous alternation in the age-matched littermates but not
219
Chapter 5
Tg2576 mice (Figs 5.17; pp. 201 and 5.18; pp. 203). This however was neither
significant nor age-related, although it may reflect the low number of animals used in
this study compared to the number used in the original T-CAT study (n = -10 per
group vs. n = -30 per group respectively; Gerlai, 1998). More recent studies have
however used fewer mice (Spowart-Manning and van der Staay, 2004). The T-CAT
was chosen as opposed to the procedure used in the original study (where the mice
were picked up from their chosen arm and replaced in the start arm) in order to limit
the possible confounding effect of altering anxiety levels, which are known to effect
spontaneous alternation behaviour (Quintero et al., 1985; Belotti et al., 1998;
Lalonde et al., 2003). That the spontaneous alternation rate of the littermate mice
was not significantly above chance levels suggests that there was a lack of statistical
power due to low group sizes, as both age-related and age un-related spontaneous
alternation in these mice have previously been recorded (Chapman et al., 1999; King
et al., 1999; Lalonde et al., 2003).
5.4.4 Nicotinic modulation ofAp deposition in Tg2576 mice
As discussed in section 5.2.1 (pp. 164), Ap deposition (Fig. 5.21) was to be measured
in a subset of animals in parallel to the behavioural studies. Due to the high death
rate of the Tg2576, te number of animals trained in the 5-CSR task was lower than
preferred and prohibited the possibility of removing mice for analysis of Ap
deposition at each stage of cognitive assessment. However, Ap deposition in the
Tg2756 transgenic mouse model of Alzheimer's disease is well characterised (Hsiao
et al., 1996; Kawarabayashi et al., 2001). In their extensive study, Kawarabayashi
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and colleagues (2001) confirmed the observations of Hsiao and colleagues (1996)
with Ap deposition levels increasing from ~ 6 months, with a considerable increase
between 9 (10 pmols/g) and 12 months (500 pmols/g; see Fig. 5.22). This would
suggest that the age-related worsening of performance of the Tg2576 mice in the
odour span task (Fig. 5.16, pp. 199) was not as a result of Ap deposition as impaired
22-odour performance was observed at 4 months of age (Fig. 5.10, pp. 188).
However, as AP levels have been shown to be highest in the main olfactory system in
Alzheimer's disease patients and Tg2576 mice (Braak and Braak, 1995; Nordberg et
al., 2002), subtle changes occurring prior to the formation of plaques may underlie
the deficit in olfactory working memory at 4 months, and that the OST can pick up
such subtle changes. It has been proposed that AP first accumulates intracellularly,
which eventually undergoes lysis, resulting in the local dispersal of their cytoplasmic
contents including Ap (Wang et al., 2000; D'Andrea et al., 2001). Intracellular Ap
has been observed in the CA1 region of the hippocampus in a mouse model of AD at
4 months of age (Shie et al., 2003). Therefore intracellular accumulation would
likely have occurred within the olfactory system as well, disrupting olfactory
working memory performance prior to extracellular Ap deposition (Devanand et al.,
2000; Nagelle et al., 2002; Oddo et al., 2003). Also ultrastructural changes such as
dystrophic neuritis and lipid deposits have been shown to occur in the TAS10
transgenic mouse model of Alzheimer's disease prior to APp-42) plaque deposition
(Richardson et al., 2003). Surprisingly no alterations in choline acetyltransferase and
anticholinesterase activity akin to that observed in Alzheimer's disease patients have
been reported in the Tg2576 mice (Davies and Maloney, 1976; Perry et al., 1978;
Davies, 1979; Shinotoh et al., 2000; Apelt et al., 2002), though they do exhibit
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Impaired synaptic plasticity (Chapman et al., 1999). This may represent a mouse's
natural resistance to A(3(i.42> plaque-induced toxicity and why no neuronal loss has
been observed in Tg2576 mice (Ashe, 2001). However, the cause(s) of the reduced
survival rate of the Tg2576 mice have yet to be determined (King et al., 1999; King








Wild type, age-matched littermates
Figure 5.21: Histopathological differences of Tg2576 mice (12 mth) compared to
their age-matched littermates
Histopathology of 12 mth old Tg2576 mice (panels on left) and their age-matched
littermates (panels on right) was assessed. Unlike the littermate mice, Tg2576 mice
exhibited Ap deposition in the striatum at magnification x 10 (a), magnification x 20
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Figure 5.22: ABn-^ plaque levels in Tg2576 mice (adapted from Kawarabavashi et
al. 2001)
The level of Ap(i_42) plaque levels in ageing Tg2576 mouse brain is depicted. There
was no detectable Ap in mice at 2-5 months old. Deposition does not begin to occur
until 6 months, after which the Ap(i_42) plaque levels increase steadily.
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The a7 nAChR plays a pivotal role in Wang and colleagues' (2000) hypothesis that
Ap(i-42) first accumulates intracellularly. To investigate whether the a7 nAChR plays
a central role in Ap deposition and/or the mediation of the effects of nicotine on Ap
reduction, attempts were made in creating Tg2576 mice on an a7 nAChR null
background (Hellstrom-Lidahl et al. 2004; see section 5.3.8, pp. 204). Difficulties
were encountered due to the high levels of aggression on the Tg2576 males
(Moechers et al., 1996; 1998), low weights (see Appendix II, pp. 257) and reduced
fertility of a7 nAChR null mice (Orr-Urtreger et al., 1997). This study was
subsequently abandoned.
If Tg2576 mice on an al nAChR knockout background were created and did deposit
Ap, they could have been assessed for the ability of nicotine to reduce Ap levels. As
yet we have not shown nicotine to reduce levels of Ap in Tg2576 mice, as has been
observed previously (Nordberg et al., 2002; Hellstrom-Lindahl et al. 2004; section
5.3.9, pp. 207). The lack of effect in these studies could however reflect the age
differences employed in these studies. Hellstrom-Lindahl and colleagues (2004)
examined Ap levels in 9 month old mice after 10-day nicotine administration,
observing a 77 - 85% reduction. Nordberg and colleagues (2002) examined Ap
levels in 15.5 month old mice after chronic nicotine administration, observing a 37 -
56 % reduction. In section 5.3.9 we did not observe any effects of 10-day nicotine
administration on the Ap levels of 20 month old mice (Fig. 5.20b, pp. 208).
It has been proposed that AP(i.42) binds to the al nAChR with picomolar affinity,
preventable in the presence of more selective ligands (Wang et al. 2000a). Thus
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nicotine administration may prevent the AP(j_42) from binding to these receptors and
activating the Janus kinase 2 pathway (Shaw et al., 2002). Whilst the exact
mechanism is unknown, whether advanced age can block the neuroprotective effects
of nicotine can be investigated by completing a similar study to section 5.3.8, but
with mice at 9, 12, 15, and 18 months old. Furthermore, the co-administration of
nAChR selective antagonists to a cohort in this study may establish the nAChR that




In conclusion, Tg2576 mice exhibit impaired attention in the 5-CSR task when the
attentional load is increased by utilising using distracters. Moreover an age-related
deficit in olfactory working memory was observed in the Tg2576 mice when
compared with their age-matched littermates. The OST has therefore proven to be a
valuable tool in assessing the age-related cognitive decline in Tg2576 mouse model
of Alzheimer's disease and could be used to assess the effects of drug administration
designed at improving cognitive functioning in Alzheimer's disease patients.
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Chapter 6 - General Discussion
6.1 The a7 nAChR and nicotine-induced improvements in cognition
This thesis provides further evidence that nicotine can improve cognitive
performance in a variety of domains. Improved sustained attention and olfactory
working memory post nicotine administration have not previously been observed in
mice, and emphasise the ability of nicotine to improve cognition across a variety of
species. The results also provide evidence to support the a7 nAChR as a valid
therapeutic target for the treatment of cognitive impairment, as mice lacking this
receptor exhibited sustained attention and olfactory working memory deficits. Since
the pattern of working memory impairment observed in the a7 nAChR KO mice
could be interpreted as the result of a deficit in sustained attention, the hypothesis
that modulation of attention via nAChRs can impact on all areas of cognition is in
agreement with Newhouse and colleagues (2004; Fig. 4.1, pp. 118). As both
schizophrenic and Alzheimer's disease patients suffer from a wide range of cognitive
deficits, a compound that globally alleviates these deficits would be highly beneficial
(see chapter 1.3, pp. 20). Whilst nicotine has been shown to improve cognition and
symptomatology in a variety of diseases including schizophrenia and Alzheimer's
disease, its side-effect profile discussed previously (chapter 1.3.6 pp. 26) limits its
potential role as a therapeutic agent (Waldum et al., 1996; Levin, 2002; White and
Levin, 2004; Yildiz, 2004). Thus the identification of the pathway/receptor(s)
nicotine acts through to improve cognition, should enhance the possibility of
generating more selective agonists with a limited side-effect profile (Levin, 2002).
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The a7 nAChR has received a great deal of interest as a possible target underlying
the nicotine-induced improvement in cognition, and has led to several companies
developing agonists for this receptor. These compounds include an (E)-N-methyl-5
(2-pyridinal)-4-peten-2-amine at Targacept, a l,4-diaza-bicyclo[3.2.2]nonane-4-
carboxylic acid 4-pyridin-2-yl-phenyl ester at Pfizer, and substituted-heteroaryl-7-
aza[2.2.1]bicycloheptanes at Pharmacia & Upjohn. AR-R17779, a full agonist of the
a7 nAChR, 3-(2,4-dimethoxybenzylidene)-anabaseine (GTS-21 or DMXBA), a
partial agonist of the a7 nAChR (though a weak antagonist of the a4 P2 nAChR) and
ABT-418, an agonist of the a4p2 and a7 nAChR (though affinity is lower in the
latter) have also been developed (Briggs et al., 1995; De Fiebre et al., 1995; Kem et
al., 1996; Gordon et al., 1998; Mullen et al., 2000). The therapeutic interest in this
receptor has arisen for a variety of reasons. Several lines of investigation implicate
the a7 nAChR in the deficiency of schizophrenic patients to 'gate' sensory
information (Adler et al., 1985; Boutros et al., 1991; Cullum et al., 1993; Clementz
et al., 1997). Further to Broadbent's (1958) influential filter theory of attention,
Venables (1992) suggested that this inability to cope with incoming sensory input
might affect schizophrenia patients' perception of the world around them, leading to
the variety of cognitive and perceptual disorders that manifest in this condition.
Certainly this impairment has been associated with poor attention in these patients
(Cullum et al., 1993; Yee et al., 1998). Administration of nicotine to these patients
attenuates their impaired sensory gating, possibly reflecting why such a large
percentage of schizophrenics smoke compared to the general population (Adler et al.,
1992; 1993; Dalack et al., 1998). The levels of smoking in these patients are
hypothesised to be high enough to activate the a7 nAChR (Adler et al., 1993).
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The a.7 nAChR link to this impairment was supported by the discovery that
mecamylamine administration, a non-selective nicotinic antagonist, did not block the
nicotine-induced enhancement of sensory gating in these patients (Freedman et al.,
1994). It was surmised that the doses administered only blocked high affinity
nAChRs such as a4p2 and not the low affinity al nAChRs, suggesting the nicotine-
induced improvement was acting via al nAChRs (Freedman et al., 1994). Further
evidence of an al nAChR involvement in sensory gating appeared in other species.
It was discovered that neither mecamylamine nor scopolamine administration (a non¬
selective muscarinic acetylcholine receptor antagonist) affected the ability of rats to
gate sensory information (measured as the P20-N40 field potential), whereas
administration of a-Bungarotoxin (a-BgTx), a selective al nAChR antagonist,
impaired rat sensory gating (Luntz-Leybman et al., 1992). Also, when Stevens and
colleagues (1996; 1997) were investigating the ability of several strains of mice to
sensory gate using the P20-N40 paradigm, they found that sensory gating
performance negatively correlated with levels of al nAChRs in the CA3 region of
their hippocampus. Thus DBA/2 mice exhibited the lowest levels of hippocampal al
nAChRs and the worst ability to gate sensory information. The sensory gating of
these mice could be improved by both nicotine-administration and treatment with the
al nAChR partial agonist DMXBA, both subcutaneously or orally (Stevens et al.,
1998; Simosky et al., 2003). The fact that relatives of schizophrenic patients
exhibited deficient sensory gating suggested a genetic basis (Waldo et al., 1991).
The impairment has since been linked to chromosome 15ql4 proximal to the locus of
the al nAChR gene (Freedman et al., 1997; Freedman et al., 2001; Liu et al., 2001;
Tsuang et al., 2001).
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Clozapine, an atypical antipsychotic used for the treatment of schizophrenia, is the
most effective treatment for refractory schizophrenia, and unlike other
antipsychotics, has shown efficacy in attenuating the sensory gating deficit of
schizophrenic patients, with paralleled clinical improvement (Kane et al., 1988;
1998; Griffith et al., 1995; Nagamoto et al., 1999; Light et al., 2000). The ability of
clozapine to improve sensory gating has also been demonstrated in DBA/2 mice, an
effect antagonised by a-BgTx co-administration, suggesting clozapine may attenuate
the sensory gating impairment via the al nAChRs (Simosky et al., 2003). However
recent evidence suggests that clozapine blocks the open channel of nAChRs at the
neuromuscular junction (Nguyen and Miledi (2002). Galanthamine is an
acetylcholinesterase inhibitor used in the treatment of Alzheimer's disease (see
chapter 1.2.2, pp. 12). It's ability to interact directly with nAChRs (Dr. K.
Finlayson, personal communication), including the al nAChR, is now being
recognised and touted as the reason why its clinical efficacy is at least equivalent to
that of donepezil and rivastigmine. This is at doses which are unlikely to reach its
IC50 value for cholinesterase inhibition in the human brain (Raskind et al., 2000;
Wilcock et al., 2000; Samchocki et al., 2003). In accordance with these
observations, direct activation of nAChRs by nicotine proved to be more efficacious
in improving cognition than the use of the cholinesterase inhibitor donepezil
(Mumenthaler et al., 2003).
Studies in other cognitive domains provide further support for the al nAChR in
mediating the cognitive enhancing effects of nicotine. Kitagawa and colleagues
(2003) recently administered DMXBA to healthy human male volunteers and found
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it improved working memory, attention and episodic memory above that of baseline
performance. This is akin to the effects observed with nicotine (Levin et al., 1998).
Arendash and colleagues (1995a), found that whilst DMXBA did not improve
working memory in aged rats (22 months old), in a 17-arm RAM due to ceiling
effects (-90% correct), it did improve learning and reference memory, akin to that
observed with chronic nicotine administration (Arendash et al., 1995a,b). DMXBA
also improved eye blink conditioning in rabbits and delayed match to sample
performance in rhesus macaque monkeys (Woodruff-pak et al., 1994; Briggs et al.,
1997). Furthermore DMXBA and AR.-R17779 have proven efficacious in enhancing
learning in rats (Meyer et al., 1997; Levin et al., 1999). AR-R17779, like nicotine,
enhanced long-term social recognition memory and reversed the working memory
deficit induced by fimbra-fornix lesion in the RAM (Levin et al., 1999; van Kampen
et al., 2004). Further support for the a7 nAChR in mediating the nicotine-induced
improvement in RAM performance has also come from Levin and colleagues.
Initially they identified that blockade of both the al and the 0.4(12 nAChR (by MLA
and DHpE administration respectively) led to a working memory impairment in the
RAM (Felix and Levin, 1997; Bancroft and Levin, 2000; Bettany and Levin, 2001).
However, whilst nicotine co-administration could reverse the a4p2 nAChR
antagonist induced impairment, it could not reverse the al nAChR antagonist
induced impairment (Bancroft and Levin, 2000; Bettany and Levin, 2001). Hence
their conclusion that al nAChRs mediate the nicotine-induced performance




As yet however, improvements with nicotine or a nAChR agonist have yet to be
demonstrated in the RAM without the use of a lesion or corresponding antagonist.
The studies conducted within this thesis have identified mice (human caspase-3 over-
expressers) that exhibit a deficit in olfactory working memory (OST performance)
that is reversible upon nicotine administration, providing a model with which to
assess the role of nAChRs, without the use of a surgical lesion or addition of
antagonists (see chapter 4.3.5, pp. 142). This can be investigated by assessing
whether selective nAChR agonists mimic the effects of nicotine, or whether selective
nAChR antagonists can block the effects of nicotine.
As discussed in chapter 4.1 (pp. 118) and 4.4 (pp. 146), nAChRs appear to modulate
cognition by modulating attentional processes (Newhouse et al., 2004; Fig. 4.1, pp.
118). The pattern ofworking memory impairment observed in al nAChR knockout
mice provides further support for this theory. However, a longitudinal measure of
performance in the OST is desirable to ensure reproducibility, and to examine
possible age-related effects. This theory receives support from data in this thesis.
Chapter 3.3.3 (pp. 86) demonstrates the ability of 3 /xg/kg dose if bicotine to improve
attention by increasing accuracy (proportion correct) and reducing errors (%
omissions), whilst 300 /xg/kg dose enhanced accuracy but had no effect of errors.
This patter of the effects of nicotine was also observed in mice performing a working
memory task (OST; chapter 4.3.1, pp. 125), where the 3 /xg/kg dose of nicotine
appeared to enhance accuracy and reduce errors, whilst the 300 /xg/kg dose of
nicotine only appeared to affect responses without effecting errors. This nAChR
modulation of cognition via attention is also observed in the literature as nicotine
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only appears to exert cognitive enhancing effects above baseline performance in
normal humans, when the task utilised is attentionally demanding. This includes the
rapid visual information-processing task, Conner's continuous performance test, n-
back test, or performance in a flight simulator (Wesnes and Warburton, 1984; Foulds
et al., 1996; Levin et al., 1998; Phillips and Fox, 1998; Mumenthaler et al., 2003).
Thus the main effect of nicotine appears an ability to enhance sustained attention (see
chapters 3.3.3, pp. 86 and 3.3.4, pp. 88). Whilst there is a large body of support for
the a7 nAChR mediating the cognitive enhancing effects of nicotine (see above), this
support is limited within the cognitive domain of sustained attention. DMXBA
administration to schizophrenic patients and normal healthy control volunteers
results in improved cognitive functioning in a variety of domains including sustained
attention (Kitagwa et al., 1998; Kem, 2000; Kitagwa et al., 2003). However the
a4p2 nAChR agonist ABT-418 has also been reported to improve the cognitive
performance of Alzheimer's disease patients, although not in healthy aged humans
(Potter et al., 1998). ABT-418 has a similar affinity to nicotine for nAChRs, both
exhibiting a 500-fold greater selectivity for the a4p2 nAChR compared to the a7
nAChR (Damaj et al., 1995). Also as with nicotine, ABT-418 exhibits
neuroprotective properties (Donnelly-Roberts et al., 1996; see chapter 5.4, pp. 211).
However, it was blockade of al nAChRs, not a4[12 nAChRs that antagonised the
neuroprotective effect of ABT-418, suggesting ABT-418 may also act via the al
nAChR, despite its low affinity for this receptor (Donnelly-Roberts et al., 1996).
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Further uncertainty over the nAChR that mediates the effects ofnicotine on sustained
attention comes from investigation of the performance of rats in the 5-CSR task (see
chapter 3.4, pp. 105). Grottick and Higgins, (2000), first described the action of
selective nicotinic agonists and antagonists on rat 5-CSR task performance. They
showed that AR-R17779, unlike the a4p2 agonist SIB 1765F, did not mimic the
nicotine-induced improvement in performance of rats who had not reached task
criteria. However, Grottick and Higgins (2002), also discussed the difficulty they
experienced in producing nicotine-induced improvement in rats that had acquired the
5-CSR task and have consistently been unable to reproduce the ability of nicotine to
improve standard baseline performance, as is observed in humans (Wesnes and
Warburton, 1984; Foulds et al., 1996; Levin et al., 1998; Mumenthaler et al., 2003).
Therefore the effect observed with nicotine in rats might not reflect that of sustained
attention. As the effect was observed in poor performers, the apparently a4|32-
nAChR mediated improvements in sustained attention could reflect improved
learning. However, their use of only one dose of AR-R17779 (20 mg/kg) has led
others to question their conclusions, as van Kampen and colleagues (2004), recently
showed that AR-R17779 to be effective at 1 mg/kg in a social memory task. After
establishing a replicable nicotine-induced delay of the vigilance decrement in aged
(24 months) rats tested in the 5-CSR task for 40 min instead of the standard 30 (as
also used in this thesis, see chapters 3.3.7, pp. 94 and 5.3.2.3, pp. 178), Grottick and
colleagues (2003) again only administered one dose of AR-R17779 (20 mg/kg).
Hahn and colleagues (2003) also showed that AR-R17779 was unable to mimic the
nicotine-induced improvement in performance of rats in the 5-CSR task (Hahn and
Stolerman, 2002; see chapter 3.4, pp. 105). The protocol they developed in order to
235
Chapter 6
consistently observe nicotine-induced improvements in rat 5-CSR task performance,
involved altering the task protocol during drug administration by increasing the inter-
trial interval (ITI) during that session, with a concomitant increase in the session
length (Hahn et al., 2002). Whilst this challenge is based on the attentional theory of
reduced event rate, the rats are still required to modify their performance in order to
respond accurately (Parasuraman et al., 1998). This may confound results whereby
an enhanced adaptability to the new protocol would represent improved performance,
thus any beneficial effect seen with nicotine may occur via its abilities to enhance
learning (Levin et al., 1999; Brown et al., 2000). Differing effects in response to
task challenges as opposed to standard performance has also been observed in lesion
studies, whereby quinolinic acid lesions to the antero-dorsal prefrontal cortex does
not impair baseline performance, but does impair responses to subsequent challenges
(Muir et al., 1996). Finally, the only agonist both groups have used is AR-R17779
(Grottick and Higgins, 2000; Hahn et al., 2003; Grottick et al., 2003). Despite both
AR-R17779 and DMXBA being selective for the a7 nAChR, DMXBA improved
sensory gating in both DBA/2 mice and Sprague dawley rats, whereas AR-R17779
did not (Stevens et al., 1998; Schreiber et al., 2002; Simosky et al., 2003). Also the
chemical stability of AR-R17779 has recently been questioned (Dr. K Finlayson,
personal communication). This has also been reflected in the literature whereby
Hahn and colleagues (2003a) reported a four-fold lower affinity of AR-R17779 to
the al nAChR than its original publication (Mullen et al., 2000).
The protocol developed in this thesis (see chapter 3.3.3, pp. 86 and 3.3.4, pp. 88), for
nicotine-induced improvement in baseline mouse performance of the 5-CSR task,
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may offer greater predictive validity than those developed in the rat, as it more
closely mimics the nicotine-induced improvement observed in human sustained
attention tasks (Wesnes and Warburton, 1984; Foulds et al., 1996; Levin et al., 1998;
Kitagawa et al., 2003; Mumenthaler et al., 2003). Its development also allows the
use of both pharmacological and genetic manipulations concurrently in attempting to
identify the nAChR that mediates the improvements observed with nicotine
(Chapman, 2000; Levin, 2002; Ohno et al., 2002). However, using this new protocol
in combined pharmacological and genetic studies may first require increased
knowledge of the dose range of nicotine, to ensure the optimal dose is used as a
positive control. Identifying the optimal dose would simply require a large group of
mice to be trained in the task and administered nicotine over a lower dose range e.g.
0.1, 0.3, 0.5, 1, 3, 5, and 10 pg/kg. The optimal dose identified could be used in a
repeat of the experiment described in chapter 3.3.6 (pp. 92), to assess whether
nicotine can improve performance of the al nAChR knockout mice as well as their
age-matched controls. Larger groups would again be required for this study to
ensure the administration protocol follows that used in the positive nicotine studies,
and hence both knockout and littermate mice could be split evenly into two groups
receiving both saline and nicotine (chapter 3.3.3, pp. 86 and 3.3.4, pp. 88).
Considering the sensory gating deficit ofDBA/2 mice and its attenuation by nicotine,
training and testing these mice in this established 5-CSR task protocol, and other
mouse strains assessed by Stevens and colleagues (1996; 1997; St/b, C3H, C57/B1,
BALB, BUB/Ibg, DBA/1J and BUB/J mice), may give further insight into how well
sensory gating and sustained attention performance correlate with one another.
Other nAChR transgenic mice could also be trained and tested, providing more
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information as to the identity of the nAChR(s) that mediate the beneficial effects of
nicotine. Whilst testing P2 nAChR subunit knockout mice would prove problematic
due to deficits in the development of their visual system, a4 nAChR subunit
knockout mice could be tested, although again care would need to be taken in
interpreting any results due to their increased anxiety levels, which can impact on
attentional performance (Ross et al., 2000).
While the a4p2 nAChR cannot be discounted in mediating the beneficial effects of
nicotine, it would be therapeutically preferable if it were mediated by the a7 nAChR.
There is evidence suggesting that a4p2 nAChRs, not al nAChRs, mediate many of
the unwanted side-effects of nicotine. For example P2 nAChR subunit knockout
mice do not self-administer nicotine as often as their littermate controls, whereas al
knockout mice do, suggesting the P2 but not the al subunit is required for the
rewarding effects of nicotine (Picciotto et al., 1998; Lena and Changeux, 1999;
Stolerman et al., 2004). Antagonist ligand studies in mice (DHpE and MLA), and
agonist ligand studies in rats (SIB 1765F and AR-R17779) also support a role for the
a4p2, but not the al nAChR, in the rewarding properties of nicotine (Gommans et
al., 2000; Grottick et al., 2000). Van Haaren and colleagues (1999) found that
DMXBA did not substitute for the nicotine cue, providing further support using a
different al nAChR ligand that the al nAChR does not contribute to the nicotine cue
or self-administration (Briggs et al., 1997). Also, it has been suggested that
DMXBA administration did not substitute for, nor did MLA antagonise, the
analgesic and anxiolytic effects of nicotine, suggesting that these responses are not
mediated by the al nAChR (Decker et al., 1995; Rao et al., 1996). Finally DMXBA
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administration does not appear to worsen cardiovascular function (Van Haaren et al.,
1999). Therefore any a4p2 nAChR agonists developed would likely share many of
the adverse side-effects of nicotine that my research is attempting to avoid, whereas
it appears an a7 nAChR agonist would not. The protocols developed in this thesis
provide an opportunity both to identify the nAChR responsible for the beneficial
effects of nicotine, but also to assess putative cognitive enhancing compounds. The
data produced provides further support for the al nAChR as a valid therapeutic
target for the production of cognitive enhancing compounds.
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6.2 Neuro-anatomical pathway of nicotinic-induced improvement
As previously discussed, it has been proposed that nicotine exerts its beneficial effect
on cognitive processing via enhancement of attention (Mancuso et al., 1999;
Lawrence et al., 2002; Newhouse et al., 2004; see chapters 3.1, pp. 76, 4.1, pp. 118
and Fig. 4.1, pp. 119). Mancuso and colleagues (1999) hypothesised that nicotine
improves cognitive function by 'locking the brain into the attentional processing
mode so there are fewer lapses in attention'. The locus and pathway of the
'attentional processing mode' Mancuso and colleagues (1999) speak of has been the
subject of much debate. The neuropsychological model of attention proposed by
Posner and Petersen (1990; Fig. 6.1) has received considerable interest. It has gained
support from various research domains including single-unit recordings in monkeys,
functional imaging, neuropsychological testing of brain lesioned patients, and
lesioned animal performing attentional tasks (Posner et al., 1984; Bickford and
Wear, 1995; Muir et al., 1995; Coull et al., 1996; McGaughy et al., 1996; Muir et al.,
1996; Everritt and Robbins, 1997; Nobre et al., 1997; Cabeza and Nyberg, 2000;
Inglis et al., 2001).
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Attentional orienting Target detection
Figure 6.1: Neuropsychological model of attention
Posner and Petersen (1990) proposed the attentional network could be divided into
two subsystems. The posterior attentional system is involved in the detection of
target stimuli driven by the salient features of the stimulus (bottom-up processing)
such as hearing your name mentioned elsewhere whilst engaged in a separate
conversation. The anterior attentional system is involved in the orientation to visual
locations via knowledge driven mechanisms (top-down processing) such as finding
Waldo in a 'where's Waldo?' cartoon. Arousal state can affect both these systems.
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There is considerable evidence that the cholinergic system influences this model.
For example the ascending cholinergic system (Ch4 in Fig. 6.2) from the basal
forebrain that projects to most of the cortex, has been shown to be essential for
sustaining attention (Muir et al., 1995; McGaughy et al., 1996; Breese et al., 1997;
Everitt and Robbins, 1997). Lesions to the pedunculopontine tegmental nucleus
(cholinergic pathway Ch5 in Fig. 6.2) cause deficits in baseline sustained attention
(Inglis et al., 2001; see chapter 3.3.9, pp. 103). Further evidence for the involvement
of acetylcholine in maintaining attention is the increased endogenous levels observed
in the cortex during performance of a sustained attention task (Himmelherber et al.,
2000; Passetti et al., 2000; Dalley et al., 2000), where distracting stimuli cause
further increases in levels (Himmelherber et al., 2000).
The role of acetylcholine and the cholinergic pathways in the maintenance of
attention is now widely accepted (Baxter and Chiba, 1999; Sarter et al., 2001; Lucas-
Meunier et al., 2003). Nicotine-induced improvements in attention are proposed to
act on one or several of these pathways. However, these pathways can also be
influenced by other neurotransmitter systems. For example glutamatergic
projections on the medial prefrontal cortex have been implicated in the modulation of
the basal forebrain cholinergic projections, possibly acting as a filter for distracters,
changes in task protocols and shifts in attentional sets (Muir et al., 1996; Miner et al.,
1997; Birrell and Brown, 2000; Sarter et al., 2001). This role of the medial
prefrontal cortex in response to a changing environment and rules, also implicates it
in supporting the central executive of Baddeley's (1986) model of working memory




Figure 6.2: Rat cholinergic pathways (from Lucas-Meunier et al., 2003)
Cholinergic nuclei from the septum (Chi) and the vertical limb of the diagonal band
(Ch2) project to the hippocampus. Those from the horizontal limb of the diagonal
band (Ch3) project to the olfactory bulb. Cholinergic cortical innervation is
mediated via the rodent homologue of the human nucleus basalis of Meynert (Ch4),
whilst cholinergic nuclei from the pedunculopontine tegmental nucleus (Ch5) and
laterodorsal tegmental nucleus (Ch6) project on the thalamus.
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Nicotine administration produces a long lasting and near instantaneous enhancement
of glutamatergic transmission, suggesting an alternative route for the improved
performance observed in the rat 5-CSR task discussed above (Radcliffe and Dani,
1998; Turchi and Sarter, 2001; Hahn and Stolerman, 2002). However, a role for
GABAergic transmission in the basal forebrain, in the maintenance of visual signal
detection and inhibition of responses to non-signals (part of the top-down processing
sub-system of Posner and Peterson's (1990), model of attention; see Fig. 6.1) has
been also been supported (Holley et al., 1995; Moore et al., 1995). The activation of
al nAChRs has been shown to enhance the release of GABA from GABAergic
interneurones, via a pre-synaptic calcium dependent mechanism, and may therefore
modulate the role of GABA in top down processing (Albuquerque et al., 1998;
Frazier et al., 1998). As discussed above however, the state of arousal can alter the
level of both top-down and bottom-up attentional processing (Fig. 6.1), and it has
been proposed that nicotine may also exert its effect on attention via this arousal
mechanism. Sarter and colleagues (2001) have addressed the arousal state in the
model of Posner and Peterson (1990; Fig. 6.1). They suggest arousal state affects
attention via the ascending noradrenergic (NA) projection from the locus coeruleus
(Aston-Jones et al., 1991; Smith and Nutt, 1986; Sarter et al., 2001; Fig 6.3).
Nicotine-induced improvements in attention were antagonised by clonidine
administration, a NA agonist that reduces NA transmission (Coull et al., 1997). Thus
nicotine may enhance sustained attention and thus cognition by increasing cortical
arousal via the ascending acetylcholine and NA projections (Lawrence et al., 2002).
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Evidence of the pathway by which nicotine enhances cognition has also been gleaned
from studies in other cognitive domains. For example, lesion to the fimbra-fomix in
rats, disrupting the septohippocampal cholinergic pathway (Chi and diagonal band
of Ch2, see Fig. 6.2), an area of high a7 nAChR density leads to sensory gating and
RAM deficits, that can be attenuated by nicotine and AR-R1779 administration
(Levin et al., 1993; Bickford and Wear, 1995; Beerse et al., 1997; Levin et al.,
1999). Therefore whilst the septohippocampal cholinergic pathway is required for
baseline performance in these two tasks, it is unlikely to mediate the nicotine-
induced improvement in cognition. Also DMXBA improved passive avoidance
learning in rats with lesions of the nucleus basalis magnocellular (cholinergic
pathway Ch4, see Fig. 6.2), suggesting this structure is not part of the pathway by
which nAChR agonists improve performance (Meyer et al., 1994). Whilst Levin and
colleagues demonstrated that the al nAChR mediated the nicotine-induced
improvement in RAM performance (discussed above), they also spent time
attempting to identify the pathway responsible for this improvement. While
septohippocampal lesions impaired RAM performance, they can be attenuated by
nicotine and AR-R17779 administration, suggesting the septohippocampal pathway
may not the critical site of action for nicotinic mediated improvement in performance
(Levin et al., 1993; 1999). Local infusion of DHpE and MLA into the ventral
hippocampus also impaired RAM performance, and whilst the former was attenuated
by nicotine administration, the latter was not (Bancroft and Levin, 2000; Bettany and
Levin, 2001). Therefore both ventral hippocampal a4(32 and al nAChRs are
important for baseline spatial working memory function, but it is the al nAChRs that
are critical for nicotine-induced improvements (Levin, 2002).
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Figure 6.3: Schematic of transmitter systems influencing Posner and Petersons
(1990) network model of attention (adapted from Sarter et al„ 2001)
The schematic represents a merger of ideas, placing the cholinergic pathways as
central to Posner and Peterson's model of attention. The basal forebrain cholinergic
neurones (BF) are proposed to act on the anterior attentional system using the
cholinergic pathways (Chi and Ch4), which modulates top-down the functions of
posterior cortical areas, enhancing and biasing posterior attentional system, sensory
areas and the BF through sensory-associational regions (red curved arrows).
Furthermore, cholinergic inputs (Ch4) also mediate the facilitation of bottom-up
sensory information processing. The ability of arousal-inducing stimuli to trigger
attentional processing is mediated bottom-up largely via noradrenergic (Na)
projections originating in the locus coeruleus (LC) and terminating in the thalamus
(TH) and the BF, although thalamic stimulation from the pedunculopontinus nucleus
(PPTg) via Ch5 is also possible. Medial prefronto-cotical (mPFC) modulation of the
BF via glutamate (Glu) transmission is thought to affect filtering of distracters, or
modifying performance to new protocols. a7 nAChR release of GABA from
GABAergic internuerones acts on the BF to maintain visual signal detection.
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6.3 Use of animal models to assess putative cognitive enhancing compounds
Even with the identification of a therapeutic target (a7 nAChR), coupled with a
known pathway and an observed improvement, preclinical assessment of novel
compounds are still required. Thus the efficacy of any putative therapeutic
compound requires testing in a suitable animal model of the disease. However,
before the compound can be tested, steps must be taken to ensure that the animal
model chosen is suitable. As discussed in chapter 5.1 (pp. 156) the model chosen is
dependant upon the research direction, as treatment directed at the pathology of a
disease clearly requires a model exhibiting that pathology, i.e. face validity.
However, treatments directed at the symptomatology of the disease, such as
cognitive impairment, would be first required to exhibit equivalent symptomatology,
indicative of pathological face validity. The ability of current treatments of the
disease to antagonise the pathology or symptomatology of the animal model would
represent that model's predictive validity. The construct validity of a model is
indicative of the degree with which the origin of the model is responsible for the
disease in man.
The Tg2576 transgenic mouse model of Alzheimer's disease represents the best
characterised model of Alzheimer's disease, offering construct and face validity
(Hsiao et cil., 1996; see chapters 5.1, pp. 156 and 5.4, pp. 211). To the authors
knowledge the predictive validity via treatment with acetylcholinesterase inhibitors,
of these and other transgenic models of Alzheimer's disease, have yet to be
published. Whilst the cause of sporadic Alzheimer's disease is currently unknown,
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some forms of familial Alzheimer's disease is represented by models such as the
Tg2576 mice, thus exhibiting construct validity. Face validity is represented at both
pathological and symptomatological levels, with A|3 plaque deposition and age-
related cognitive impairments. Thus the value of the Tg2576 model lies in the high
degree with which both face and construct validity have been established (Flsiao et
ah, 1996; Chapman et ah, 1999; King et ah, 1999; Kawerabayashi et al., 2001; King
and Arendash, 2002; Nordberg et ah, 2002; see chapter 5.1, pp. 156).
Despite the Tg2576 model being the most established to date however, cognitive
assessment has previously only been within the domains of spatial learning and
memory, and have been plagued by different testing procedures and the use of
cognitive tests that may not subtle enough to delineate differences (Hsiao et ah,
1996; Chapman et ah, 1999; King et ah, 1999; Hsiao-Ashe, 2001, see chapter 5.1,
pp. 156). However, prior to the present studies, there has been little to no published
studies of experiments in non-spatial working meory, attention, olfactory capabilities
and episodic memory, despite the dominance of these cognitive impairments in
Alzheimer's disease patients (discussed in chapters 1.3, pp. 20 and 5.1, pp. 156).
Whilst episodic memory has still not been assessed in these mice owing to testing
difficulties, their attentional, olfactory and non-spatial working memory performance
was assessed.
Despite the initial difficulties in testing these mice, due to health problems,
stereotypic behaviour and reduced survival rate (see chapter 5.2.2, pp. 169),
attentional deficits were observed in mice at 17 months of age (chapter 5.3.2, pp.
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174). Unfortunately noise distracters were not available when the attentional
performance of the mice was first assessed at 10 months, and thus longitudinal
attentional performance has not been addressed. However, now that a greater
phenotypic understanding of these mice is available, many studies could be designed
that would include large group sizes and the assessment of a longitudinal profile of
their attentional capabilities.
The performance of the Tg2576 mice in the odour span task provides further support
for their use in assessing putative therapeutic compounds (see chapters 5.3.3 - 5.3.5,
pp. 184 - 195). The acquisition and performance deficits observed in this task were
age-related (Fig. 5.14, pp. 194). The ethological relevance of the task (utilising
olfactory cues and requiring the mice to dig for their reward), supports claims that
such relevance is required to observe differences in the cognitive performance of
transgenic mice and their littermates, when such differences may be subtle and so
difficult to detect (Gerlai and Clayton, 2000; Hsiao-Ashe, 2001). Further
longitudinal analysis of the youngest group of Tg2576 mice tested in the OST
(chapter 5.3.3, pp. 184) is still possible as they are only presently 7 months old (Oct
'04). Assessment of OST performance of these mice at 8, 12, 16 and 20 months
would test the reproducibility of the age-related decline in performance, and allow
further characterisation of their longitudinal performance in this task. Reversing the
attentional and/or olfactory working memory deficits of these mice with an
acetylcholinesterase inhibitor would provide further evidence in support of the
predictive validity of this model. Attempts to attenuate the deficits observed with
nicotine or a putative cognitive enhancing compound (such as an a7 nAChR agonist)
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could also be made, further establishing this model as one of the best characterised
transgenic mouse models of Alzheimer's disease.
As discussed in chapter 5.4 (pp. 211), the odour span task has a two-fold advantage
when assessing the performance of a transgenic mouse model of Alzheimer's
disease. Firstly it characterises the non-spatial working memory capabilities of the
mice using a task that is ethologically relevant, increasing the possibility of
observing obscure differences in transgenic animals and their littermates (Gerlai and
Clayton, 2000; Hsiao-Ashe, 2001; Slotnick, 2001). Also olfactory impairments have
been postulated as a possible early marker for Alzheimer's disease (Devanand et al.,
2000). Patients that have been diagnosed with mild cognitive impairment (MCI, or
age-associated memory impairment) are at a greater risk of developing Alzheimer's
disease (Celsis, 2000; Devanand et al., 2000). Those suffering from olfactory
impairments have an association with the apolipoprotein E4 genotype, and are even
more likely to be diagnosed with Alzheimer's disease later in life (Devanand et al.,
2000; Wang et al., 2002). This is consistent with the observation that Alzheimer's
disease pathology is present first in the entorhinal cortex, part of the main olfactory
system (Braak and Braak, 1995; Slotnick, 2001; Nordberg et al., 2002; see chapter
5.1, pp. 156, Fig. 4.2, pp. 122). The fact that nicotine attenuated the cognitive
impairments in MCI patients, gives further weight to the work in this thesis that
examined the effects of nicotine in olfactory working memory, combined with
behaviourally phenotyping of the Tg2576 transgenic mouse model of Alzheimer's
disease (White and Levin, 2004; see chapters 3.3, pp. 81, 4.3, pp. 125, 5.3, pp. 171).
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The choice of animal model used in research is mainly determined by the aims of
that research, as discussed above and in chapter 5.1 (pp. 156). The use of an animal
model exhibiting both Ap deposition and neurofibrillary tangles, such as TAPP mice
(Tg2576 mice crossed with P301L mutants; Lewis et ah, 2001; see table 5.1, pp.
158), is possibly more representative of the pathology pf Alzheimer's disease and
therefore may be more effective when assessing ways to modify that pathology.
However, the physiological problems that these mice exhibit make behavioural
phenotyping extremely challenging, and as such translating the results and possible
side effects into human testing possibly more awkward. Unforseen side effects have
already prematurely ended the clinical trials of possible immunotherapy drugs
(ELAN compound AN-1792 - synthetic AP) against Ap plaque deposition (Schenk
et al., 1999; Check, 2002). Other trials have used non-steroidal anti-inflammatories
(in conjunction with COX-2 inhibitors), lithium, P-secretase inhibitors and adeno-
associated viruses (Dominguez et al., 2001; Hoozemans et al., 2003; Phiel et ah,
2003; Zhang et ah, 2003; Coruzzi et ah, 2004). The ELAN immunotherapy trial was
designed to reduce Ap deposition levels in the brains of Alzheimer's disease patients
(Hardy and Selkoe, 2002). In fact although the trial was prematurely terminated, it
did appear that the first patients examined had reduced Ap levels (Nichol et ah,
2003). The reduction of Ap levels in transgenic mice led to a concomitant increase
in cognitive performance (Janus et ah, 2000; Morgan et ah, 2000). In mice, nicotine
administration over a 5.5 month or 10 day period has been shown to reduce Ap in the
Tg2576 mice and the nicotinic component confirmed as the effect was antagonised
by mecamylamine (Hsiao et ah, 1996; Nordberg et ah, 2002; Hellstrom-Lindahl et
ah 2004). The reduction in Ap levels was greater when nicotine was administered
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acutely for 10 days when compared to chronic administration over 5.5 months
(Nordberg et al., 2002; Hellstrom-Lindahl et al. 2004). This however could be due
to Ap levels being assessed at 9 and 14.5 months respectively, where the Ap
concentration is around 200 times greater in the older animals. When in the present
study the assessment was carried out in 20 month old Tg2576 mice, a 10-day acute
administration of nicotine had no effect on Ap levels (chapter 5.3.8; Fig. 5.17b, pp.
201). Hence the mechanism by which nicotine-induced a reduction in Ap levels in
younger mice, but not in old mice, is yet to be determined (Hellstrom-Lindahl et al.
2004). Whilst y secretase levels are increased in Tg2576 mice, nicotine
administration had no effect on this enzyme (Hellstrom-Lindahl et al. 2004). Despite
the increased levels of P secretase in the brains of Alzheimer's disease patients, the
Tg2576 mice do not exhibit increased P secretase levels, and nicotine administration
did not alter its expression in any way (Izzary et al., 2001; Rossner et al., 2001,
Funkomoto et al., 2002; Tyler et al., 2002; Hellstrom-Lindahl et al. 2004).
Galanthamine exhibits neuroprotective effects, and physostigmine administration
reduces Ap plaque levels in the neocortex of guinea pigs (Birch et al., 2001). As
galanthamine, physostigmine and nicotine increase levels of acetylcholine, perhaps
there is a common pathway by which they reduce Ap deposition. This effect may be
mediated by acetylcholine competitively binding to nAChRs and thus inhibiting the
binding of AP(i.42) (De Fiebre et al., 1995; Donnelly-Roberts et al., 1996; Kem,
2000).
In addition, there is a large body of evidence showing that the al nAChR maybe
important in nicotine-induced neuroprotection. The al nAChR whilst widely
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expressed throughout the nervous system is highly expressed in the basal forebrain
cholinergic neurons that project to the hippocampus and the cortex, which is similar
to the expression pattern of AP(M2) plaque deposition in brains of Alzheimer's
disease patients (Breese et al., 1997; Wevers et al., 1999; Guan et al., 2000). It has
been shown that AP(i_42) can directly modulate nAChR channel activity and block the
response of the al nAChR in rat hippocampal slices and neurones (Liu et al., 2001;
Pettit et al., 2001). This blockade of cholinergic neurotransmission has been
presented as the possible 'missing link' between APp-42) plaque deposition and
impaired cognition, i.e. the 'cholinergic' and 'amyloid' hypotheses (Auld et al.,
1998). Wang and colleagues (2000a), showed that AP(i_42) inhibited binding to al
nAChRs. Thus a competitive al nAChR selective agonist may inhibit the
interaction of Ap(M2) with this receptor as well as improve cognition. Nicotine and
ABT-418 inhibited Ap(M2) induced toxicity in vitro, an effect that was blocked by an
al, but not an a4p2 nAChR antagonist (De Fiebre et al., 1995; Donnelly-Roberts et
al., 1996; Kem, 2000). The neuroprotective effect observed following galantamine
administration is also likely to be mediated via its action on al nAChRs (Arias et al.,
2004). In addition, DMXBA is neuroprotective in vitro, against a variety of
neurotoxic insults and AP(M2) toxicity (Akaike et al., 1994; Kihara et al., 1997;
Shimohama et al., 1997; Meyer et al., 1998; Nanri et al., 1998; Li et al., 1999).
Rather than APp-42) directly interacting with the al nAChR, Shaw and colleagues
(2002), presented another pathway that may mediate al nAChR induced
neuroprotection. They proposed that ligands act on the al nAChR, to activate Janus
kinase 2, which in turn inhibits the AP(i_42) induced apoptotic cascade, and thus is
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neuroprotective. In the present study, the generation of Tg2576 mice on an a7
nAChR null background may have assisted in delineating which pathway was
responsible. Unfortunately the breeding programme was terminated due to low
fertility yet high mortality rates, high levels of aggression, and low body weights (see
chapter 5.3.8, pp. 204). Examination of the effects of selective agonists and
antagonists of the a.7 nAChR on amyloid deposition in Tg2576 mice at various ages





In conclusion, the development of the modified 5-CSR task was central in showing a
nicotine-induced improvement in sustained attention in normal mice and impairment
in performance in a7 nAChR knockout and Tg2576 mice. Also, the establishment of
the odour span task in mice identified impaired working memory performance in
human caspase-3 over-expressing mice (attenuated by nicotine administration), a7
nAChR knockout mice and Tg2576 mice (age-related). In summary, these studies
provide newly developed tasks with which to assess putative cognitive enhancing
compounds and the data provides further evidence in support of a role for the a7





Alpha 7 nicotinic acetylcholine receptor (nAChR) knockout (KO) mice
The deletion mutation was introduced into the ABI 2.1 embryonic stem (ES) cell line
and transmitted to the germline as described in Bullard et al., (1996). Chimeric mice
were backcrossed onto the C57B1/6J strain ofmice.
Human Caspase-3 over-expressing mice
YAC 35EB2 containing the human caspase-3 gene was isolated from transformed
yeast as described in Bellis et al., 1989). A total of 840 F1 C57B1/6J X CBA
fertilised eggs were microinjected with a preparation of highly purified YAC DNA
(2ng//xl) yielding 89 live births (10%) ofwhich 10 were found to be transgenic (11%).
These mice were backcrossed onto the C57B1/6J strain ofmice.
Tg2576 mice
First created in 1996 by Hsiao and colleagues and based on the double mutation found
in a large Swedish family with early-onset Alzheimer's disease. These mice were
created by inserting Human APP695 containing the double mutation Lys670 —> Asn,
Met671 —» Leu (K670N,M671L; APP770 numbering) into a hamster prion protein
(PrP) cosmid vector in which the PrP open reading frame (ORE) was replaced with
the variant APP ORF, creating Tg(HuAPP695.K670N-M671L)2576 mice. The
resultant transgenic mice were bred to C57BL/6 mice. The colony was maintained by
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Appendix II
Effects of over-expressing human APP mutation on ad libitum weights
The effects of over-expressing the human APPswe mutation (Tg) on weight were
compared with their age-matched littermates (WT), during ad libitum feeding prior
to and during testing. The weights were compared during 5-CSR task performance
(a,b), with the overall weight difference depicted (I) as well as the weights when on
periods of ad libitum feeding during training (II). The weights prior to the OST
studies were also depicted (b) at each age tested (I - III). The weights were also
compared prior to assessment in the T-CAT (c) at both young (I) and old age (II).
The Tg mice were significantly lighter than the WT mice at every age and in every
test, although the two groups increased in weight at a similar rate. Data presented as
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Nicotine Improves Sustained Attention in Mice: Evidence for
Involvement of the oc7 Nicotinic Acetylcholine Receptor
Jared W Young1, Keith Finlayson*'1, Christopher Spratt', Hugh M Marston1,2, Nicola Crawford1,
John S Kelly1 and John Sharkey1
'Fujisawa Institute of Neuroscience, Division of Neuroscience, University of Edinburgh, Edinburgh, UK
In humans, nicotine has been shown to improve attention in both normal and impaired individuals. Observations in rats reflect some, but
not all aspects of the nicotine-induced improvements in humans. To date these findings have not been replicated in mice. To examine the
effect of nicotine on sustained attention in mice, we have established a version of the 5-choice serial reaction-time (5-CSR) task with
graded levels of difficulty, based upon spatial displacement and a variable intertrial inteival. Using this paradigm, microgram doses of
nicotine produced a consistent reduction in the level of omissions and an improvement in proportion correct in normal mice. This
improvement in sustained attention was made irrespectively ofwhether mice had previously received nicotine. In an attempt to elucidate
which nicotinic acetylcholine receptor (nAChR) subtype(s) mediate this effect, we examined the performance of a7 nAChR knockout
(KO) mice in the 5-CSR task. a7 nAChR KO mice not only acquired the task more slowly than their wild-type littermates, but on
attaining asymptotic performance, they exhibited a higher level of omissions. In conclusion, by increasing the level of task difficulty, the
performance of mice was maintained at sufficiently low levels to allow a demonstrable improvement in performance upon nicotine
administration. Furthermore, as a7 KO mice are clearly impaired in the acquisition and asymptotic performance of this task, the a7
nAChR may be involved in mediating these effects of nicotine.
Neuropsychopharmacology advance online publication, 18 February 2004; doi: 10.1038/sj.npp. 1300393
Keywords: nicotine; mice; attention; receptors; nicotinic (a7); knockout
INTRODUCTION
It has been proposed that attentional dysfunction may
underlie the psychopathology of schizophrenia (Cullum
et al, 1993; Cornblatt and Keilp, 1994). In humans,
attentional performance is generally assessed using the
continuous performance test (CPT), where subjects have to
attend to visual stimuli over a sustained period of time
(Levin et al, 1998; White and Levin, 1999; Shytle et al, 2002).
Nicotine, the predominant psychoactive compound in
tobacco smoke, has been shown to enhance sustained
attention in normal humans by reducing omission levels
(Levin et al, 1998). Moreover, it has been suggested that
nicotine can lock the brain into an attentional processing
mode whereby there are fewer lapses in attention and
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therefore less omissions (Mancuso et al, 1999). These
observations may underlie the ability of nicotine to enhance
attention and improve the symptomatology of various
human diseases including schizophrenia (Yang et al, 2002),
Alzheimer's disease (White and Levin, 1999), attention
deficit hyperactivity disorder (Shytle et al, 2002), Parkin¬
son's disease (O'Neill et al, 2002), and Tourette's syndrome
(Sanberg et al, 1997).
The identity of the nicotinic acetylcholine receptor
(nAChR) subtype(s) mediating the beneficial effects of
nicotine on cognition has yet to be elucidated. Currently,
nine genes have been described that encode neuronal
nAChR subunits in mammals (a2-a7, /?2-/?4), with a9 and
alO subunits also found in mammalian cochlea. The
majority of subunits appear capable of forming heteromeric
channels, with the number of combinations identified in
tissue continually increasing (Le Novere et al, 2002). In
rodent brains, the two most predominant nAChRs appear to
be the heteromeric yA[l2 nAChR, and the homomeric oc7
nAChR, accounting for 85 and 10% of neuronal nAChRs
respectively (Clarke et al, 1985). In rats, the roles that these
receptors play in sustained attention is examined using the
5-choice serial reaction-time (5-CSR) task (Mirza and
Stolerman, 1998; Grottick and Higgins, 2000; Stolerman
et al, 2000; Mirza and Bright, 2001; Hahn et al, 2002,
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2003a, b; Terry et al, 2002; Grottick et al, 2003). While
nicotine-induced improvements in sustained attention have
been reported in the rat literature, these studies have
generally required the additional complexities afforded by
brain lesions, poorly performing subjects, or task challenges
(Muir et al, 1995; Grottick and Higgins, 2000; Hahn et al,
2002). Indeed, no consistent improvements have been
reported in unimpaired rats (Mirza and Bright, 2001; Terry
et al, 2002). Clear identification of the receptor subtypes
underlying the beneficial effects of nicotine is made more
onerous (Shoaib et al, 2002) by the current lack of truly
selective compounds and the difficulties associated with
producing nAChR subtype selective drugs (Gotti et al, 2000;
Broad et al, 2002). It has therefore been suggested that a
combined approach of pharmacological interventions and
transgenic animals may help delineate the nAChR subtypes
involved (Gotti et al, 2000; Chapman, 2002).
Since its first description by Carli et al (1983), the 5-CSR
task has been extensively used in rat studies. In contrast, the
task has received only limited, and comparatively recent
attention in mice (Humby et al, 1999; Marston et al, 2001).
Hitherto, no reports addressing the effects of nicotine on
the performance of mice in the 5-CSR task have been
published. In the present study, we describe the develop¬
ment and use of a version of the 5-CSR task to examine the
hypothesis that nicotine can improve attentional function in
mice by primarily reducing omission levels and secondarily
by increasing proportion correct. In addition, the role that
the a7 nAChR plays in attention was examined by using a7
knockout (KO; B6.12957-Chrna7tmlbay, Orr-Urtreger et al,
1997) mice in the task, who should conversely exhibit a
deficit as measured by increased omission levels and a lower
proportion correct score. Some of the current findings have
previously been presented in abstract form (Young et al,
2003).
MATERIALS AND METHODS
Animal Maintenance and Genotyping
Two groups ofC57 B1/6J male mice (study 1 ,n = 16; study 2,
n = 25, Charles River, Margate, UK), weighing between 22
and 26 g at the start of the studies, were used in the
behavioral paradigms described. Eight a7 nAChR KO
(B6.12957-Chrna7tmIbay; The Jackson Laboratory, Bar Ha-
bor, USA) and eight age-matched wild-type littermates
(WT; N8F1 and F2), weighing between 22 and 27 g at the
inception of the study, were used in study 3. For
confirmation of genotype, transgenic animals were tail
tipped under halothane/nitrous oxide anesthesia, and DNA
obtained by proteinase K treatment of tail samples
(Promega, Southampton, UK; Sambrook and Russell,
2001). The PCR protocol used was as described on the
Jackson Laboratory website (www.jax.org). All animals were
group housed (where possible) in a temperature controlled
room (21 + 1°C), with a 12 h light/dark cycle (lights on at
0730) and were tested during the light phase of the cycle.
Mice were maintained at 85% of their free-feeding weight
and were permitted free access to water during training and
testing. The animals were given ad libitum access to food
approximately every 5 weeks in order to re-establish a free-
feeding weight. Studies were performed under license by UK
authorities (Scientific Animal Procedures Act, 1986,
http://www.homeoffice.gov.uk), and in accordance with
the Guide for the Care and Use of Laboratory Animals
as adapted and promulgated by the National Institute of
Health.
Tissue Procurement and P2 Synaptosomal Membrane
Preparation
For radioligand binding studies, P2 synaptosomal mem¬
branes were prepared as described previously (Maemoto
et al, 1997). Mice were killed by cervical dislocation, the
brains removed, and immediately placed in ice-cold saline
(0.9% NaCl). The whole brain minus cerebellum (due to the
low density of a7 nAChRs) was used for preparation of
synaptosomal membranes. Brain tissue from each animal
was treated independently in the tx.7 nAChR KO study.
Tissue samples were homogenized in 15 volumes (15 vol) of
ice-cold (4°C) 0.32 M sucrose using a glass/Teflon homo-
genizer, centrifuged at 1000 g for lOmin (4°C), and the
resulting supernatant centrifuged at 17 000 g (20min, 4°C).
The synaptosomal/mitochondrial P2 pellet was lysed in
30 vol of ice-cold (4°C) milliQ H20 for 60min and
centrifuged at 50000g (lOmin, 4°C). The membrane pellet
was then resuspended in 30 vol of ice-cold (4°C) 50 mM
potassium phosphate assay buffer (50 mM potassium
phosphate, 1 mM EDTA, and 0.01% sodium azide, pH
7.4), centrifuged at 50000g for lOmin (4°C) and resus¬
pended in 5 vol (original tissue weight) of assay buffer and
stored at —20°C. On the day of use, frozen membranes were
thawed, diluted to 30 vol with ice-cold (4°C) assay buffer
and the suspension centrifuged at 50 000 g for 10min at 4°C.
The pellet was then resuspended in the appropriate volume
of assay buffer and the protein content determined as
described previously (Finlayson et al, 2001).
Behavioral Apparatus
Training and testing took place in 'nine-hole' operant
chambers (25 x 25 x 25 cm, Cambridge Cognition, Cam¬
bridge, UK). The response holes were used in two
configurations; 'narrow' with holes 3-7 open and 1, 2, 8,
and 9 occluded, or 'wide' with holes 1, 3, 5, 7, and 9 open
and 2, 4, 6, and 8 closed. The mice were required to respond
to a visual stimulus recessed into the holes, with a nose
poke. A response was detected by an infrared beam crossing
the entrance of each hole. Liquid reinforcement in the form
of strawberry milkshake (Yazoo®; UK; 20 pi) was delivered
by a peristaltic pump to a spigot located within the
magazine at the chamber front, on the wall opposite to
the nine-hole array. Entry into the magazine was monitored
by an infrared beam. The house light was set into the roof of
the operant chamber, which was housed within a sound-
attenuating box containing a fan, which provided ventila¬
tion and a constant low background noise. An infrared
camera was installed within each box allowing performance
to be monitored during testing. Each operant chamber
was interfaced to an Acorn computer (RISC OS). The
software required was programmed in house using
the Arachnid extension to BBC Basic (Paul Fray Ltd,
Cambridge, UK).
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Behavioral Handling and Procedures
For the 3 days prior to training, all mice were handled for
approximately lOmin per day. On the day before initiation
of training mice were introduced to the liquid reinforcer.
On training days 1 and 2, mice were placed in the nine-hole
boxes for lOmin, during which liquid reinforcement was
dispensed every 15 s into the well of the magazine, while the
magazine was lit. Entry into the magazine caused the light
to be extinguished until the next reinforcement was
delivered. At the end of this and subsequent sessions, the
wells beneath the spigots were inspected to ensure no liquid
was present. On day 3, in order to obtain reinforcement,
mice were required to nose poke in any of the 5 lit holes at
the rear of the chamber. This process was repeated every
day until all mice were able to make at least 60 responses to
the light cue within a 25 min session.
5-CSR Task
At the beginning of each session the house light was
extinguished and the magazine was lit. A nose poke in the
magazine initiated the trial sequence. An intertrial interval
(ITI) of 2 s preceded one of the five response holes being
illuminated. To record a correct response the mouse had to
respond within a stimulus duration (SD) period of 10 s, or
during the following 2 s limited hold (LH) when the light
was extinguished. The magazine light was then illuminated,
a reinforcement dispensed, with entry in to the magazine
initiating a 4s reward interval (RI). Failure to respond
during the SD + LH resulted in an 'omission' error being
recorded and a 4s time out (TO) initiated. During a TO the
house light was on and all holes were unresponsive, then as
the TO phase ended the house light was extinguished, and
the magazine illuminated. The mouse could then begin a
new trial by responding in the magazine. If, during the
choice phase, the mouse responded in a hole other than the
one that was lit, the response was registered as an incorrect
response and a TO phase began. If the mouse responded
during the ITI, an anticipatory error was recorded and a TO
phase initiated. Each session lasted 25 min, or 120 trials if
completed sooner. The SD was initially set at 10 s and was
only reduced to 8 s following attainment of a mean correct
latency half that of the SD and a minimum of 10 correct
responses per session, maintained for over two consecutive
sessions. The SD was further reduced to 4, 2, and then 1 s
based upon these response latency criteria. Successful
acquisition of the task was defined as attainment of
a 1 s SD, a proportion correct score (correct/correct +
incorrect + anticipatory errors) of > 0.8, and with %
omissions (omissions/correct + incorrect + omissions) of
<40%. In study 3, once every mouse had attained
acquisition criteria, the mice were trained continuously
until asymptotic performance had been established. In
studies 1 and 2, once every mouse had attained acquisition
criteria, a variable (2-10 s) ITI was introduced, and mice
were trained continuously until asymptotic performance
had been established. The mice were allocated to a drug
group in a counter-balanced design. Each mouse received
saline for the three training sessions prior to testing, and
then given their allocated nicotine dose everyday in the four
subsequent test sessions. The effects of subcutaneous
(—)nicotine hydrogen tartrate (Sigma, Poole, UK) on
performance (study 1; 3, 30, and 300pg/kg; study 2; 1, 10,
and lOOpg/kg) were assessed 10min after drug injection,
with nicotine prepared freshly everyday.
[3H]Methyllycaconitine ([3H]MLA) Binding to the i7
nAChR
[3H]MLA (19.8 Ci/mmol; Tocris, Bristol, UK) binding to the
i7 nAChR was carried out as previously described (Davis
et al, 2000). Binding assays were conducted in a total volume
of 250 pi; consisting of 50 or 100 pi (no drug present) of
potassium phosphate assay buffer, 50 pi of test drug, 50 pi of
[3H]MLA (final concentration approximately 2 nM), and
100 pi of membrane suspension. Test compounds (methyl-
lycaconitine and ( + ) epibatidine, Tocris, Bristol, UK;
(—)nicotine hydrogen tartrate and d-tubocurarine chloride,
Sigma, Poole, UK) were prepared by serial dilution in assay
buffer. Nonspecific binding was determined in the presence
of 1 mM d-tubocurarine. Binding was initiated by the
addition of membranes, and samples were incubated for
60min at 25°C. Binding was terminated by filtration onto
glass fiber filters (GF/B, Whatman; presoaked for 3 h in 0.3%
polyethylenimine) using a Brandel cell harvester, followed
by three rapid (1 ml) washes with ice-cold phosphate-
buffered saline (20mM Na2HP04, 5mM KH2P04, 150 mM
NaCl, pH 7.4). Filter disks were transferred to RT30 tubes
(Sterling, UK) and radioactivity determined using a Packard
2500TR liquid scintillation counter.
Data Analysis
The main dependent behavioral variables selected for
analysis were: (a) % omissions, (b) proportion correct,
and (c) mean correct latency (cumulative correct latency/
correct). As the proportion correct in studies 1 and 3 was
not normally distributed, the data were arcsine trans¬
formed. However, in Figures lb and 3d raw data are
presented. Each variable in studies 1 and 2 were compared
to the mean scores obtained with saline using a three-way
ANOVA (dose, day, and ITI time), with Tukey post hoc
analysis. Acquisition performance in study 3 was analyzed
by assessing the increase in proportion correct across
sessions per subject, and the data fitted using a four-
parameter logistic. The number of sessions required to
attain 0.50 proportion correct (A50) was calculated for each
subject, and compared between the groups using a t-test.
Asymptotic performance in study 3 was compared using a
two-way repeated measures ANOVA (genetic make-up and
day). All statistics were performed using Sigma Stat (v. 2.03,
SPSS, USA). For the [3H]MLA binding studies, data were
analyzed using Sigma Plot 8.0 (Jandel, USA) and ligand
affinities (KD/fC;) were calculated as described previously
(Finlayson et al, 2001).
RESULTS
Study 1—The Effect of Nicotine (3, 30, and 300 pg/kg)
on Mouse 5-CSR Task Performance
Initially, a pilot study was conducted in which mice (n = 16)
were trained to perform the 5-CSR task using a less
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Figure I Effects of nicotine on the performance ofmice in the modified 5-CSR task Each mouse in this study had undergone extensive training and had
received nicotine (s.c.) injections 3 weeks prior to testing. The mice were separated into four groups in a counter-balanced design and given saline for three
prior training sessions (Thursday, Friday, and Monday), followed by their allocated dose for 4 consecutive days (Tuesday-Friday). The 3 pg/kg dose of
(—)nicotine significantly reduced % omissions (a) and increased proportion correct (b) without altering mean correct latency (c). In contrast, 300 (tg/kg of
(-)nicotine reduced mean correct latency (c) and increased proportion correct (b), without affecting % omissions (a). The 30 pg/kg dose of (-)nicotine had
no effect on any measure. Doses of nicotine that produced significant effects compared to saline on these measures are marked (*p < 0.05), with data shown
as mean + SEM.
demanding narrow array (holes 3-7), with animals subse¬
quently administered saline or three different doses of
nicotine (3, 30, and 300 (tg/kg). The mice were tested
according to a Latin-square design over a 10-week period.
Each 4-day dosing period was separated by a 10-day
washout period, during which a baseline response to saline
was re-established. No overall statistical difference was seen
with any dose of nicotine examined (data not shown).
However, as the mice had performed at near optimum levels
(proportion correct approximately equal to 0.96), any clear
enhancement in performance would be difficult to detect.
The task was subsequently modified to increase the level of
difficulty by using a wide array (holes 1, 3, 5, 7, and 9) and
by varying the ITI (2-10 s instead of a constant 2 s). Such
modifications have previously been used to increase task
difficulty in human sustained attention tasks (Bates et al,
1995). These modifications differ from the acute challenges
utilized for rats as they are employed in both training and
testing days (Hahn et al, 2002). Following a 3-week washout
period mice were again administered saline or nicotine (3,
30, and 300 pg/kg). As can be seen in Figure la, the 3 pg/kg
dose of nicotine produced a significant reduction in %
omissions and in Figure lb, an increase in proportion
correct when compared to the control group. A three-way
ANOVA with nicotine dose, ITI time, and day as between-
subject factors, yielded significant main effects of: nicotine
dose on % omissions (F(3,36) = 17.4, p< 0.001), proportion
correct (F(3,36) = 8.83, p<0.001), and mean correct latency
(F(3,36) = 5.27, p = 0.004); ITI time on % omissions
(F(3,36) = 28.2, p<0.001), and on mean correct latency
(F(3,36) = 57.8, p<0.001); day on proportion correct
(F(3,36) = 5.15, p = 0.005). Tukey post hoc analysis on
nicotine dose revealed a significant effect of 3 pg/kg nicotine
on % omissions (Figure la) (F(3,36) = 17.4, p<0.001), and
on proportion correct (Figure lb) (F(3,36) = 8.83, p< 0.05).
Nicotine at 300 pg/kg also increased proportion correct
(Figure lb) (F(3,36) = 8.83, p = 0.001), and decreased mean
correct latency (Figure lc) (F(3,36) = 5.27, p<0.005), but
had no significant main effect on % omissions (Figure la).
However, no effect was observed at the intermediate
nicotine dose of 30 pg/kg on any of the parameters
examined.
Study 2—The Effect of Nicotine (1, 10, and 100 pg/kg)
on 5-CSR Task Performance in Drug-Naive Mice
As study 1 was performed in mice that had previously been
exposed to nicotine on a repeated basis, the significant
improvements observed in performance could have been
confounded by factors such as receptor upregulation.
Indeed, our studies suggest that a 1-week washout period
with saline following nicotine administration is not always
sufficient to ensure a return to baseline performance (data
not shown). We therefore examined the cognitive effects of
nicotine using the modified 5-CSR task and drug-naive
mice. As the 3 pg/kg dose of nicotine had produced the most
robust improvement in performance we examined the effect
of nicotine at 1, 10, and 100 pg/kg. All three doses of
nicotine produced a reduction in the levels of % omissions
when compared to the control group (Figure 2a). A three-
way ANOVA with nicotine dose, ITI time, and day as
between-subject factors, yielded significant main effects of:
nicotine dose on % omissions (F(3,36) =212, p<0.001),
proportion correct (F(3,36) = 3.285, p = 0.032), and mean
correct latency (F(3,36) = 13.3, p<0.001); ITI time on %
omissions (F(3,36) = 40.4, p<0.001), proportion correct
(F(3,36) = 3.512, p = 0.016), and on mean correct latency
(F(3,36) = 9.83, p <0.001); day on % omissions
(F(3,36) = 6.58, p = 0.001). Tukey post hoc analysis on
nicotine dose revealed significant effects of 1, 10, and
100pg/kg nicotine on % omissions (F(3,36) = 22.6,p<0.001
for each dose Figure 2a). Moreover the 1 pg/kg dose of
nicotine significantly increased proportion correct
(Figure 2b) and the 10 pg/kg dose significantly altered
mean correct latency (Figure 2c). There were significant
main effects of the 1 pg/kg dose of nicotine on proportion
correct (F(3,36) = 3.29, p = 0.05), and the 10 pg/kg dose
significantly increased mean correct latency (F(3,36) = 13.3,
p< 0.05).
Study 3—The Effect of a7 nAChR KO on Mouse
Performance in the 5-CSR Task
The debate over which nicotinic receptor subtypes are
responsible for the cognitive effects of nicotine is far from
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Figure 2 Effects of nicotine on the performance of drug-naive mice in the modified 5-CSR task. Mice were trained specifically for this study and as such
were nicotine naive. The mice were separated into four groups in a counter-balanced design and given saline for three phor training sessions (Thursday,
Friday, and Monday), followed by their allocated dose for 4 consecutive days (Tuesday-Friday). Every dose of (—)nicotine examined significantly reduced %
omissions (a), with I pg/kg increasing proportion correct (b). The lOpg/kg dose of (—)nicotine produced a significant increase in mean correct latency (c).
















Figure 3 Effects of <*7 nAChR KO on mouse performance of the 5-CSR task. The a7 nAChR KO mice had impaired acquisition as shown in (a), with data
shown as proportion correct across session days for one representative subject from each group, and (b) the mean time taken by each group to reach
halfway to asymptote (A50). a7 nAChR KO mice were also impaired in asymptotic performance of the task, as measured by % omissions (c). Proportion
correct (d), and mean correct latency (e) are also shown but were unaffected by removal of this receptor in the standard task *Significant difference to that
of the controls (p< 0.05), with data shown as mean + SEM.
resolved. As there are no commercially available a7
nAChR selective agonists or totally suitable antagonists
we examined whether ablation of the a7 nAChR would
have any detrimental effects on the performance of
mice in the 5-CSR task. As Figure 3a shows, a7 KO mice
took significantly longer to acquire the task than their
age-matched WT littermates, with the time taken to
reach 50% of asymptotic performance (A50) being approxi¬
mately 5 days longer (Figure 3b) (F(l,12) = 4.763, p = 0.05).
After attaining acquisition criteria and asymptotic
performance, the a7 KO mice exhibited significantly
higher levels of % omissions (Figure 3c). A two-factor
ANOVA for repeated measures with genotype and
day as between-subject factors yielded significant main
effects of genotype on % omissions (F(l,36) = 7.67,
p<0.05) and day on proportion correct (F(l,36) = 4.501,
p — 0.009). There were no significant effects of genotype on
proportion correct (Figure 3d) or mean correct latency
(Figure 3e).
<x7 nAChR Genotyping and [3H]MLA Binding
To validate the behavioral deficits observed for the a7 KO
mice, genotyping was performed, and a radioligand binding
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assay established using the putatively a7 nAChR selective
antagonist [3H]MLA. Genotyping was conducted with a7
nAChR-specific primers that identified WT and disrupted
aheles. These studies confirmed that the mice used were of
the appropriate genotype (data not shown). Verification of
the absence of oe7 nAChRs at the protein level was obtained
by establishing a [3H]MLA binding assay. Using P2
synaptosomal membranes prepared from normal mice and
a range of cholinergic drugs, there was a concentration-
dependent inhibition of [3H]MLA binding, with the
following rank order of potency; MLA > epibatidine > d-
tubocurarine = nicotine (Figure 4a). The affinity (KD) of
MLA was 1.31+0.35nM (nH = 0.81 + 0.02; n = 4), with K,
values of 167+106 nM (nH = 1.46 + 0.14; n — 3) for epiba¬
tidine, 1.80 + 0.07 pM (nH = 1.48 + 0.44; n — 3) for d-tubo-
curarine, and 1.41+0.82 pM (nH = 1.06 + 0.09; n = 3) for
nicotine. For a7 KO mice and their WT littermates, each
brain was treated individually. As Figure 4b clearly shows,
in WT littermates' specific [3H]MLA binding was approxi¬
mately 60% of total binding, whereas no specific binding
was observed for the a7 KO mice.
Log [drug] (M)
b
Figure 4 [3H]MLA binding in P2 synaptosomal brain membranes from
WT and tx7 KO mice, (a) Concentration-dependent inhibition of [3H]MLA
(2 nM) binding to P2 synaptosomal brain membranes fromWT animals by a
range of cholinergic drugs, (b) The level of specific [3H]MLA binding in P2
membranes prepared from individual WT control and transgenic mice
(n = 4 per group) is shown. Clear specific [3H]MLA binding was observed
for WT animals, which is absent in a7 KO mice.
DISCUSSION
This is the first study in normal mice to demonstrate
nicotine-induced improvements in sustained attention.
These results support the hypothesis which suggests that
the nicotine-induced improvement in attention in normal
humans is characterized by a reduction in omission levels,
and by an increase in proportion correct. Moreover, our
demonstration that a7 nAChR KO mice exhibit higher
omission levels in a less demanding version of the task
implicates the a7 nAChR in attentional function.
In humans, the CPT has been routinely used to evaluate
attentional performance (White and Levin, 1999; Shytle et al,
2002). In normal human subjects, nicotine administration
has consistently been shown to enhance attention by
reducing omissions (Levin et al, 1998). This is consistent
with the hypothesis of Mancuso et al (1999), whereby the
nicotine-induced improvement in attention is a conse¬
quence of nicotine acting to 'lock the brain into the
attentional processing mode and so there are fewer lapses in
attention', hence fewer errors of omission might be
expected. However, an improvement in accuracy (propor¬
tion correct) following nicotine administration has also
been observed in subjects displaying impaired attentional
function, associated with schizophrenia, Alzheimer's dis¬
ease, and attention deficit hyperactivity disorder (White and
Levin, 1999; Shytle et al, 2002; Yang et al, 2002). The 5-CSR
task was developed to examine sustained attention in
rodents (Carli et al, 1983) and is regarded as being
analogous to the CPT (Jones and Higgins, 1995). This task
has been used extensively with rats, with nicotine generally
showing an improvement in attention, but only when
lesions or specific task challenges have been introduced to
impair performance (Mirza and Stolerman, 1998; Grottick
and Higgins, 2000; Stolerman et al, 2000; Mirza and Bright,
2001; Hahn et al, 2002, 2003a, b; Grottick et al, 2003). A
consistent demonstration of a nicotine-induced facilitation
of attention in unimpaired rats, unlike observations in
humans (Levin et al, 1998), has proven challenging (Mirza
and Bright, 2001; Terry et al, 2002). While widely used with
rats, the 5-CSR task was only comparatively recently
modified for use in mice (Humby et al, 1999), with no
reports to date, on the effects of nicotine. Our initial studies
indicated that the lack of effect of nicotine in mice may have
been due to a 'ceiling effect' (data not shown), a feature
commonly observed for rats (Grottick and Higgins, 2000;
Hahn et al, 2002). Modification of the task by introducing
the wide array and a variable ITI (this latter alteration
minimizes the possibility of mice using any temporal
mediating strategies), resulted in an increase in % omis¬
sions and a reduction in proportion correct. These data
clearly show that the performance of mice is not impaired
when tested in the larger rat nine-hole operant chambers
and so a reduction in box size, as used by Humby et al
(1999), is not a prerequisite. Four groups of mice,
previously exposed to different doses of nicotine, were
given a 3-week washout period with saline to ensure a
return to prestudy baseline performance. These mice were
then tested in the modified task and given different doses of
nicotine (Figure 1), based upon previous rodent and human
studies (Muir et al, 1995; Grobe et al, 1998; Stolerman et al,
2000; Mirza and Bright, 2001). The 3 pg/kg dose of nicotine
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produced a clear improvement in performance, with a
significant reduction in percent omissions and a concomi¬
tant increase in proportion correct. As nicotine adminis¬
tration is known to alter nAChR density (Gentry and Lukas,
2002), confirmation that the observed improvements in
sustained attention were not merely a consequence of
increased receptor number, required nicotine to be
examined in drug-naive mice. Therefore, a new study was
conducted using a modified dose range that took cogni¬
zance of the improvements seen at 3 fig/kg of nicotine. This
study revealed a significant enhancement in the perfor¬
mance of drug-naive mice that were administered a 1 pg/kg
dose of nicotine. The doses of nicotine that improved
attention in mice in the present studies are consistent with
those reported to improve attention in normal humans
(Levin et al, 1998; Heishman and Henningfield, 2000; Min
et al, 2001). In contrast, studies in rats have generally
required higher doses of nicotine and the inclusion of
lesions or task challenges (Muir et al, 1995; Mirza and
Stolerman, 1998; Stolerman et al, 2000; Hahn et al, 2002,
2003a, b; Grottick et al, 2003). In addition, whereas nicotine
reduced omission levels in ostensibly normal mice in the
current study, and previously in normal human subjects
(Levin et al, 1998), in rats, the most consistent manifesta¬
tion of an improvement in attention was an increase in
accuracy (Mirza and Stolerman, 1998; Hahn et al, 2002).
The reasons underlying these different effects of nicotine on
omissions in rodents have yet to be clearly defined. One
possible explanation is that in rats, the lack of effect of
nicotine on omissions may be due to a floor effect as
baseline omissions are already < 10%, whereas in mice they
are approximately 20% (Inglis et al, 2001; Spratt et al, 2001).
This difference in omission levels cannot be attributed
simply to the fact that mice were tested in apparatus
commonly used for rats, as when the apparatus was scaled
down, omission levels were still about 20% (Humby et al,
1999). Therefore the reduction observed in omissions in
mice is consistent with the nicotine-induced improvement
in attention hypothesis proposed by Mancuso et al (1999).
While it appears that the 1 and 3 pg/kg doses of nicotine
enhance sustained attention, at higher doses the physiolo¬
gical effects become increasingly complex (Picciotto, 2003;
see Figure 5 for schematic representation). Between 10 and
100 pg/kg the overall trend continues to be that of a
reduction in omissions, but with no effect on proportion
correct. In contrast, at 300 pg/kg, nicotine increased
proportion correct without altering % omissions. As this
dose also reduced mean correct latency, this suggests the
increase in accuracy may reflect psychomotor stimulation
(Grottick and Higgins, 2000), with these mice consequently
not attending to the cue array any more than control
subjects. This would be consistent with nicotine being
reported to produce motoric excitation at 125 and 250 pg/kg
in mice (Nordberg and Bergh, 1985). Further increases in
nicotine dose have been shown to lead to motoric inhibition
and hypothermia (Marks et al, 1983; Figure 5).
Despite a plethora of evidence demonstrating nicotine-
induced improvements in attention in different species,
there has been no definitive identification of which nAChR
subtype(s) are responsible. However, several studies in¬
dicate that the oc7 nAChR appears crucial in maintaining
one aspect of attentional function, namely sensory gating
(Stevens et al, 1996, 1998; Simosky et al, 2001). Schizo¬
phrenics have poor sensory gating with a reduction in the
P50 auditory evoked potential (Waldo et al, 1995). This
deficiency has been linked to chromosome 15, in a region
proximal to the a.7 locus (Freedman et al, 1997). Moreover,
the DBA/2 mouse strain, which has a natural reduction in a.7
nAChR density, show sensory gating deficits (Stevens et al,
1996), that can be ameliorated by treatment with the a7
partial agonist DMXBA (GTS-21; Stevens et al, 1998;
Simosky et al, 2001) and atypical antipsychotics (Simosky
et al, 2003). DMXBA also attenuated the sensory gating
deficits observed in rats that were reared in isolation
(O'Neill et al, 2003), an animal neuro-developmental model
of schizophrenia (Geyer et al, 1993). Furthermore, both
DMXBA (Kem, 2000), and the full a7 nAChR agonist AR-
R17779 (Mullen et al, 2000), are able to replicate the
beneficial effects observed with nicotine on working
memory (Felix and Levin, 1997; Levin and Simon, 1998).
In contrast, and perhaps somewhat surprisingly, recent
studies in rats showed that AR-R17779 had no effect on
attention in the 5-CSR task (Grottick and Higgins, 2000;
Grottick et al, 2003; Hahn et al, 2003a). To date,
independent evaluation of these agents is not possible as
these compounds are not commercially available. Similarly,
investigation of the a7 nAChR subtype using the selective
antagonists a-bungarotoxin and methyllycaconitine has
proven difficult as the former is a large peptide which does
not cross the blood-brain barrier, while there is now some
debate over the selectivity of the latter (Mogg et al, 2002).
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Figure 5 Schematic representation of nicotine-induced behavioral effects in mice. Nicotine exerts both cognitive and physiological effects that are largely
dose dependent. The present study suggests that low doses of nicotine (I-3 pg/kg) produce improvements in attention. Higher doses appear to reduce
mean correct latency, suggesting an enhancement ofmotoric capabilities, consistent with previous studies (Nordberg and Bergh, 1985). Doses of nicotine of
500 pg/kg and above inhibit motoric responses, with hypothermic effects observed. A further increase to 5 mg/kg has been shown to induce seizures in mice
(Damaj et al. 1999).
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in attention in mice by studying a7 KO animals (Orr-
Urtreger et al, 1997) in the 5-CSR task. Even in the simple
version of the 5-CSR task, the oc7 KO mice had a clear deficit
in attention, with omission levels significantly increased
when compared to WT littermates. The absence of the oc7
nAChR in the KO mice was verified by genotyping and
radioligand binding studies using [3H]MLA. For WT mice,
the Kd/K; values of the drugs examined in the [3H]MLA
binding assay were consistent with previous studies
(Whiteaker et al, 1999). It is possible that the deficiencies
observed are attributable to developmental problems that
are a consequence of a7 nAChR KO, although these animals
do have an ostensibly normal appearance; with standard
growth, survival, gait, anatomy, and no nervous system
abnormalities (Orr-Urtreger et al, 1997). In addition, Paylor
et al (1998) reported no differences in the behavioral
phenotype of u7 nAChR KO mice and their WT littermates
when subjected to a battery of behavioral tests, including
contextual and auditory fear conditioning, spatial learning
in the Morris water maze, and anxiety tests. However,
unexpectedly it was noted that the mice did not exhibit
sensory gating deficits in the PPI paradigm (Paylor et al,
1998), although this result could have been confounded by
the use female mice. It is conceivable that compensatory
mechanisms, such as alterations in nAChR density,
distribution, and/or receptor subtype, may result in gene
KO studies producing fundamentally different results from
that observed in traditional pharmacological studies.
However, Orr-Urtreger et al (1997) did not detect differ¬
ences in high affinity nicotinic binding sites in these a.7
nAChR KO mice. The development of the modified 5-CSR
task should allow confirmation of the a7 nAChR KO data, if
and when, a7 selective agonists become available and we
can then address whether species differences exist between
rats and mice. In addition, future studies will address
whether nicotine can improve the performance of a7
nAChR KO mice in this modified 5-CSR task and/or
whether a similar effect is observed in a7 nAChR
heterozygous mice.
In conclusion, modifying the 5-CSR task for mice
impaired baseline performance and enabled the demonstra¬
tion of an enhancement in sustained attention following
nicotine administration. Moreover, we have also shown that
a7 nAChR KO mice have a profound deficit in attention that
was observed without increasing task difficulty. Therefore,
it is conceivable that the a.7 nAChR plays a role in nicotine-
induced improvements in sustained attention.
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